Pierre Fenaux

Q: What Schools Are Affiliated With Pierre Fenaux

Pierre Fenaux is affiliated with the following schools: Paris-Saclay University, MD Anderson Cancer Center, University of Limoges, Université Paris Cité, Sorbonne Paris North University, Paris Diderot University, Karolinska Institute

Pierre Fenaux's AcademicInfluence.com Rankings

Pierre Fenaux

Philosophy

#3196

World Rank

#5230

Historical Rank

Logic

#1009

World Rank

#1626

Historical Rank

philosophy Degrees

Download Badge

Philosophy

Pierre Fenaux's Degrees

PhD Biomedical Sciences Université Paris Cité
Doctorate Medicine Université Paris Cité

Why Is Pierre Fenaux Influential?

(Suggest an Edit or Addition)

(See a Problem?)

Pierre Fenaux's Published Works

Number of citations in a given year to any of this author's works

Total number of citations to an author for the works they published in a given year. This highlights publication of the most important work(s) by the author

Published Works

International scoring system for evaluating prognosis in myelodysplastic syndromes. (1997) (4221)
Diagnosis and management of AML in adults: 2017 ELN recommendations from an international expert panel. (2017) (3878)
Diagnosis and management of acute myeloid leukemia in adults: recommendations from an international expert panel, on behalf of the European LeukemiaNet. (2010) (3011)
Revised international prognostic scoring system for myelodysplastic syndromes. (2012) (2285)
Efficacy of azacitidine compared with that of conventional care regimens in the treatment of higher-risk myelodysplastic syndromes: a randomised, open-label, phase III study. (2009) (2236)
All-trans retinoic acid as a differentiation therapy for acute promyelocytic leukemia. I. Clinical results. (1990) (1257)
Management of acute promyelocytic leukemia: recommendations from an expert panel on behalf of the European LeukemiaNet. (2008) (894)
Azacitidine prolongs overall survival compared with conventional care regimens in elderly patients with low bone marrow blast count acute myeloid leukemia. (2010) (878)
Azacitidine and Venetoclax in Previously Untreated Acute Myeloid Leukemia. (2020) (878)
Effect of gemtuzumab ozogamicin on survival of adult patients with de-novo acute myeloid leukaemia (ALFA-0701): a randomised, open-label, phase 3 study (2012) (785)
A randomized comparison of all transretinoic acid (ATRA) followed by chemotherapy and ATRA plus chemotherapy and the role of maintenance therapy in newly diagnosed acute promyelocytic leukemia. The European APL Group. (1999) (749)
Several types of mutations of the Abl gene can be found in chronic myeloid leukemia patients resistant to STI571, and they can pre-exist to the onset of treatment. (2002) (568)
Pegylated interferon-alfa-2a induces complete hematologic and molecular responses with low toxicity in polycythemia vera. (2008) (538)
Diagnosis and treatment of primary myelodysplastic syndromes in adults: recommendations from the European LeukemiaNet. (2013) (535)
Favorable prognostic significance of CEBPA mutations in patients with de novo acute myeloid leukemia: a study from the Acute Leukemia French Association (ALFA). (2002) (529)
Outcome of treatment in adults with acute lymphoblastic leukemia: analysis of the LALA-94 trial. (2004) (512)
Prognostic score including gene mutations in chronic myelomonocytic leukemia. (2013) (467)
Proposal for a new risk model in myelodysplastic syndrome that accounts for events not considered in the original International Prognostic Scoring System (2008) (457)
Effect of all transretinoic acid in newly diagnosed acute promyelocytic leukemia. Results of a multicenter randomized trial. European APL 91 Group (1993) (438)
A randomized phase 3 study of lenalidomide versus placebo in RBC transfusion-dependent patients with Low-/Intermediate-1-risk myelodysplastic syndromes with del5q. (2011) (413)
p53 mutations are associated with resistance to chemotherapy and short survival in hematologic malignancies. (1994) (401)
Cooperating gene mutations in acute myeloid leukemia: a review of the literature (2008) (395)
Outcome of high-risk myelodysplastic syndrome after azacitidine treatment failure. (2011) (387)
Impact of TET2 mutations on response rate to azacitidine in myelodysplastic syndromes and low blast count acute myeloid leukemias (2011) (383)
All-trans-retinoic acid as a differentiating agent in the treatment of acute promyelocytic leukemia. (1995) (375)
All-trans retinoic acid in acute promyelocytic leukemias. II. In vitro studies: structure-function relationship. (1990) (368)
Prognostic factors for response and overall survival in 282 patients with higher-risk myelodysplastic syndromes treated with azacitidine. (2011) (368)
Acute myeloid leukemia and myelodysplastic syndromes following essential thrombocythemia treated with hydroxyurea: high proportion of cases with 17p deletion. (1998) (368)
Methylation of the p15(INK4b) gene in myelodysplastic syndromes is frequent and acquired during disease progression. (1998) (364)
Outcome of treatment in adults with Philadelphia chromosome-positive acute lymphoblastic leukemia--results of the prospective multicenter LALA-94 trial. (2002) (359)
The impact of JAK2 and MPL mutations on diagnosis and prognosis of splanchnic vein thrombosis: a report on 241 cases. (2008) (354)
Cytogenetic analysis has strong independent prognostic value in de novo myelodysplastic syndromes and can be incorporated in a new scoring system: a report on 408 cases. (1993) (325)
B-cell chronic lymphocytic leukemia: present status and future directions. French Cooperative Group on CLL. (1991) (323)
Management of acute promyelocytic leukemia: updated recommendations from an expert panel of the European LeukemiaNet. (2019) (319)
p53 Mutations Are Associated With Resistance to Chemotherapy and Short Survival in Hematologic Malignancies (1994) (319)
A controlled study of recombinant human granulocyte colony-stimulating factor in elderly patients after treatment for acute myelogenous leukemia. AML Cooperative Study Group. (1995) (316)
Clinical course of essential thrombocythemia in 147 cases (1990) (292)
Predictive factors of response and survival in myelodysplastic syndrome treated with erythropoietin and G-CSF: the GFM experience. (2008) (288)
Incidence, Clinical Features, and Outcome of AllTrans-Retinoic Acid Syndrome in 413 Cases of Newly Diagnosed Acute Promyelocytic Leukemia (1998) (280)
Myelodysplastic syndromes are propagated by rare and distinct human cancer stem cells in vivo. (2014) (277)
TET2 mutation is an independent favorable prognostic factor in myelodysplastic syndromes (MDSs). (2009) (277)
Diagnosis and classification of myelodysplastic syndrome: International Working Group on Morphology of myelodysplastic syndrome (IWGM-MDS) consensus proposals for the definition and enumeration of myeloblasts and ring sideroblasts (2008) (276)
Efficacy of amphotericin B encapsulated in liposomes (AmBisome) in the treatment of invasive fungal infections in immunocompromised patients. (1991) (270)
DNA topoisomerase II in therapy-related acute promyelocytic leukemia. (2005) (261)
Very long-term outcome of acute promyelocytic leukemia after treatment with all-trans retinoic acid and chemotherapy: the European APL Group experience. (2009) (250)
Rituximab efficacy and safety in adult splenectomy candidates with chronic immune thrombocytopenic purpura: results of a prospective multicenter phase 2 study. (2008) (249)
High molecular response rate of polycythemia vera patients treated with pegylated interferon alpha-2a. (2006) (239)
Clonal architecture of chronic myelomonocytic leukemias. (2013) (239)
Luspatercept in Patients with Lower-Risk Myelodysplastic Syndromes. (2020) (238)
Author Correction: Implications of TP53 allelic state for genome stability, clinical presentation and outcomes in myelodysplastic syndromes (2019) (237)
V617F mutation in JAK2 is associated with poorer survival in idiopathic myelofibrosis. (2006) (236)
Outcome of treatment after first relapse in adults with acute lymphoblastic leukemia initially treated by the LALA-94 trial (2007) (235)
Allogeneic hematopoietic stem cell transplantation for MDS and CMML: recommendations from an international expert panel. (2017) (234)
High incidence of biallelic point mutations in the Runt domain of the AML1/PEBP2 alpha B gene in Mo acute myeloid leukemia and in myeloid malignancies with acquired trisomy 21. (2000) (233)
TET2 gene mutation is a frequent and adverse event in chronic myelomonocytic leukemia (2009) (232)
Prevalence, clinical profile, and prognosis of NPM mutations in AML with normal karyotype. (2005) (228)
Role of reduced-intensity conditioning allogeneic hematopoietic stem-cell transplantation in older patients with de novo myelodysplastic syndromes: an international collaborative decision analysis. (2013) (226)
Health, economic, and quality-of-life effects of erythropoietin and granulocyte colony-stimulating factor for the treatment of myelodysplastic syndromes: a randomized, controlled trial. (2004) (225)
All-transretinoic acid followed by intensive chemotherapy gives a high complete remission rate and may prolong remissions in newly diagnosed acute promyelocytic leukemia: a pilot study on 26 cases. (1992) (224)
Diagnosis and Management of AML in Adults: 2022 ELN Recommendations from an International Expert Panel. (2022) (218)
Myelodysplastic syndromes and acute myeloid leukemia with 17p deletion. An entity characterized by specific dysgranulopoïesis and a high incidence of P53 mutations. (1995) (210)
Randomized study of intensified anthracycline doses for induction and recombinant interleukin-2 for maintenance in patients with acute myeloid leukemia age 50 to 70 years: results of the ALFA-9801 study. (2010) (208)
P53 gene mutations in acute myeloid leukemia with 17p monosomy. (1991) (208)
Cytogenetics and their prognostic value in de novo acute myeloid leukaemia: a report on 283 cases (1989) (206)
Molecular predictors of response to decitabine in advanced chronic myelomonocytic leukemia: a phase 2 trial. (2011) (203)
Resistance to all-trans retinoic acid (ATRA) therapy in relapsing acute promyelocytic leukemia: study of in vitro ATRA sensitivity and cellular retinoic acid binding protein levels in leukemic cells. (1993) (202)
A white blood cell index as the main prognostic factor in t(8;21) acute myeloid leukemia (AML): a survey of 161 cases from the French AML Intergroup. (2002) (195)
Eprenetapopt (APR-246) and Azacitidine in TP53-Mutant Myelodysplastic Syndromes (2021) (192)
A landscape of germ line mutations in a cohort of inherited bone marrow failure patients. (2018) (190)
Does iron chelation therapy improve survival in regularly transfused lower risk MDS patients? A multicenter study by the GFM (Groupe Francophone des Myélodysplasies). (2010) (190)
CEBPA point mutations in hematological malignancies (2005) (187)
Prognosis of inv(16)/t(16;16) acute myeloid leukemia (AML): a survey of 110 cases from the French AML Intergroup. (2003) (186)
Analysis of p53 antibodies in patients with various cancers define B-cell epitopes of human p53: distribution on primary structure and exposure on protein surface. (1993) (183)
Characteristic repartition of monocyte subsets as a diagnostic signature of chronic myelomonocytic leukemia. (2015) (180)
Continued azacitidine therapy beyond time of first response improves quality of response in patients with higher‐risk myelodysplastic syndromes (2011) (176)
Postremission treatment of elderly patients with acute myeloid leukemia in first complete remission after intensive induction chemotherapy: results of the multicenter randomized Acute Leukemia French Association (ALFA) 9803 trial. (2007) (175)
Deferasirox in iron-overloaded patients with transfusion-dependent myelodysplastic syndromes: Results from the large 1-year EPIC study. (2010) (175)
Mutation allele burden remains unchanged in chronic myelomonocytic leukaemia responding to hypomethylating agents (2016) (175)
Safety and efficacy of romiplostim in patients with lower-risk myelodysplastic syndrome and thrombocytopenia. (2010) (169)
Is cytarabine useful in the treatment of acute promyelocytic leukemia? Results of a randomized trial from the European Acute Promyelocytic Leukemia Group. (2006) (168)
Treatment of newly diagnosed acute promyelocytic leukemia (APL): a comparison of French-Belgian-Swiss and PETHEMA results. (2008) (168)
Hematologic responses to deferasirox therapy in transfusion-dependent patients with myelodysplastic syndromes (2012) (166)
Long-term follow-up confirms the benefit of all-trans retinoic acid in acute promyelocytic leukemia (2000) (163)
Incidence, clinical features, and outcome of all trans-retinoic acid syndrome in 413 cases of newly diagnosed acute promyelocytic leukemia. The European APL Group. (1998) (162)
Mutations of the p53 gene in B-cell chronic lymphocytic leukemia: a report on 39 cases with cytogenetic analysis. (1992) (159)
Prognostic factors in Waldenström's macroglobulinemia: a report of 167 cases. (1993) (156)
Retinoic Acid Syndrome (1998) (156)
Therapy-related acute promyelocytic leukemia. (2003) (155)
Randomized Phase III Study of Lenalidomide Versus Placebo in RBC Transfusion-Dependent Patients With Lower-Risk Non-del(5q) Myelodysplastic Syndromes and Ineligible for or Refractory to Erythropoiesis-Stimulating Agents. (2016) (151)
Efficacy and safety of lenalidomide in intermediate-2 or high-risk myelodysplastic syndromes with 5q deletion: results of a phase 2 study. (2009) (151)
Treatment of progression of Philadelphia-negative myeloproliferative neoplasms to myelodysplastic syndrome or acute myeloid leukemia by azacitidine: a report on 54 cases on the behalf of the Groupe Francophone des Myelodysplasies (GFM). (2010) (149)
Extramedullary relapse in acute promyelocytic leukemia treated with all-trans retinoic acid and chemotherapy (2006) (149)
Re‐evaluation of the role of azathioprine in the treatment of adult chronic idiopathic thrombocytopenic purpura: a report on 53 cases (1990) (148)
p16 gene homozygous deletions in acute lymphoblastic leukemia. (1995) (148)
Prognostic implication of FLT3 and Ras gene mutations in patients with acute promyelocytic leukemia (APL): a retrospective study from the European APL Group (2005) (147)
All-trans retinoic acid and chemotherapy in the treatment of acute promyelocytic leukemia. (2001) (147)
An international consortium proposal of uniform response criteria for myelodysplastic/myeloproliferative neoplasms (MDS/MPN) in adults. (2015) (147)
Systemic inflammatory and autoimmune manifestations associated with myelodysplastic syndromes and chronic myelomonocytic leukaemia: a French multicentre retrospective study. (2016) (147)
Treatment of first relapse in acute promyelocytic leukaemia with all-trans retinoic acid (1990) (146)
A randomized trial of hydroxyurea versus VP16 in adult chronic myelomonocytic leukemia. Groupe Français des Myélodysplasies and European CMML Group. (1996) (146)
Acute promyelocytic leukemia: biology and treatment. (1997) (143)
New mechanisms of AML1 gene alteration in hematological malignancies (2003) (142)
Results of a randomized, double-blind study of romiplostim versus placebo in patients with low/intermediate-1–risk myelodysplastic syndrome and thrombocytopenia (2014) (142)
Nonrandom 4p13 rearrangements of the RhoH/TTF gene, encoding a GTP-binding protein, in non-Hodgkin's lymphoma and multiple myeloma (2000) (141)
TP53 mutation status divides myelodysplastic syndromes with complex karyotypes into distinct prognostic subgroups (2019) (141)
Prognostic factors in adult de novo myelodysplastic syndromes treated by intensive chemotherapy (1991) (140)
Phase 2 clinical trial of 5-azacitidine, valproic acid, and all-trans retinoic acid in patients with high-risk acute myeloid leukemia or myelodysplastic syndrome (2010) (138)
17p Deletion in acute myeloid leukemia and myelodysplastic syndrome. Analysis of breakpoints and deleted segments by fluorescence in situ. (1998) (138)
Targeting NF-κB in hematologic malignancies (2006) (136)
Retinoid differentiation therapy in promyelocytic leukemia (1996) (136)
Prognostic value of TP53 gene mutations in myelodysplastic syndromes and acute myeloid leukemia treated with azacitidine. (2014) (135)
Mutations in the p53 gene in myelodysplastic syndromes. (1991) (135)
Outcome of childhood acute promyelocytic leukemia with all-trans-retinoic acid and chemotherapy. (2004) (135)
Anthracyclines, mitoxantrone, radiotherapy, and granulocyte colony-stimulating factor: risk factors for leukemia and myelodysplastic syndrome after breast cancer. (2007) (135)
Hypomethylating agents and other novel strategies in myelodysplastic syndromes. (2011) (135)
Rigosertib versus best supportive care for patients with high-risk myelodysplastic syndromes after failure of hypomethylating drugs (ONTIME): a randomised, controlled, phase 3 trial. (2016) (134)
Incidence and prognostic value of TET2 alterations in de novo acute myeloid leukemia achieving complete remission. (2010) (133)
Effect of all transretinoic acid in newly diagnosed acute promyelocytic leukemia. Results of a multicenter randomized trial. European APL 91 Group. (1993) (132)
Intensive chemotherapy for poor prognosis myelodysplasia (MDS) and secondary acute myeloid leukemia (sAML) following MDS of more than 6 months duration. A pilot study by the Leukemia Cooperative Group of the European Organisation for Research and Treatment in Cancer (EORTC-LCG). (1995) (131)
Autologous and allogeneic stem-cell transplantation as salvage treatment of acute promyelocytic leukemia initially treated with all-trans-retinoic acid: a retrospective analysis of the European acute promyelocytic leukemia group. (2005) (131)
NF-κB constitutes a potential therapeutic target in high-risk myelodysplastic syndrome (2005) (130)
Mutations of the P53 gene in acute myeloid leukaemia (1992) (129)
Erlotinib exhibits antineoplastic off-target effects in AML and MDS: a preclinical study. (2008) (127)
How we treat lower-risk myelodysplastic syndromes. (2013) (126)
Prognostic value of real-time quantitative PCR (RQ-PCR) in AML with t(8;21) (2005) (125)
Management and supportive care measures for adverse events in patients with myelodysplastic syndromes treated with azacitidine * (2010) (123)
Quantitation of minimal residual disease in acute promyelocytic leukemia patients with t(15;17) translocation using real-time RT-PCR (2000) (122)
Modulation of IL-8, IL-1 beta, and G-CSF secretion by all-trans retinoic acid in acute promyelocytic leukemia. (1994) (122)
High incidence of biallelic point mutations in the Runt domain of the AML1/PEBP2αB gene in Mo acute myeloid leukemia and in myeloid malignancies with acquired trisomy 21 (2000) (122)
Prognostic significance of DNA methyltransferase 3A mutations in cytogenetically normal acute myeloid leukemia: a study by the Acute Leukemia French Association (2011) (121)
Detection of BCR-ABL transcripts in chronic myeloid leukemia (CML) using a ‘real time’ quantitative RT-PCR assay (1999) (121)
Additional chromosomal abnormalities in patients with acute promyelocytic leukaemia (APL) do not confer poor prognosis: results of APL 93 trial (2000) (121)
Time-dependent changes in mortality and transformation risk in MDS. (2016) (120)
Prognostic factors in adult chronic myelomonocytic leukemia: an analysis of 107 cases. (1988) (120)
Cytogenetic studies and their prognostic significance in agnogenic myeloid metaplasia: a report on 47 cases. (1988) (118)
Eprenetapopt Plus Azacitidine in TP53-Mutated Myelodysplastic Syndromes and Acute Myeloid Leukemia: A Phase II Study by the Groupe Francophone des Myélodysplasies (GFM) (2021) (118)
A multivariate analysis of the relationship between response and survival among patients with higher-risk myelodysplastic syndromes treated within azacitidine or conventional care regimens in the randomized AZA-001 trial (2013) (117)
Prognostic significance of FLT3 internal tandem repeat in patients with de novo acute myeloid leukemia treated with reinforced courses of chemotherapy (2002) (117)
Molecular characterization of the idiopathic hypereosinophilic syndrome (HES) in 35 French patients with normal conventional cytogenetics (2005) (117)
p53 protein expression independently predicts outcome in patients with lower-risk myelodysplastic syndromes with del(5q) (2014) (116)
Effects of azacitidine compared with conventional care regimens in elderly (≥ 75 years) patients with higher-risk myelodysplastic syndromes. (2010) (116)
Chromosome and Molecular Abnormalities in Myelodysplastic Syndromes (2001) (116)
Occupational exposure to pesticides and lymphoid neoplasms among men: results of a French case-control study (2008) (116)
THE CLINICAL SIGNIFICANCE OF MUTATIONS OF THE P52 TUMOUR SUPPRESSOR GENE IN HAEMATOLOGICAL MALIGNANCIES (1997) (115)
Survival, prognostic factors and rates of leukemic transformation in 381 untreated patients with MDS and del(5q): A multicenter study (2012) (114)
Cytolytic function and survival of natural killer cells are severely altered in myelodysplastic syndromes (2006) (114)
Prognosis and treatment of lymphoblastic lymphoma in adults: a report on 80 patients. (1992) (113)
Eltrombopag versus placebo for low-risk myelodysplastic syndromes with thrombocytopenia (EQoL-MDS): phase 1 results of a single-blind, randomised, controlled, phase 2 superiority trial. (2017) (112)
Myelodysplastic syndromes: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. (2014) (111)
Retinoic acid and arsenic trioxide trigger degradation of mutated NPM1, resulting in apoptosis of AML cells. (2015) (109)
Real-World Validation of Molecular International Prognostic Scoring System for Myelodysplastic Syndromes. (2022) (109)
Predictive factors of response and survival among chronic myelomonocytic leukemia patients treated with azacitidine. (2013) (109)
Timed sequential chemotherapy for previously treated patients with acute myeloid leukemia: long-term follow-up of the etoposide, mitoxantrone, and cytarabine-86 trial. (1995) (109)
Validation of WHO classification-based Prognostic Scoring System (WPSS) for myelodysplastic syndromes and comparison with the revised International Prognostic Scoring System (IPSS-R). A study of the International Working Group for Prognosis in Myelodysplasia (IWG-PM) (2015) (108)
Transcription intermediary factor 1γ is a tumor suppressor in mouse and human chronic myelomonocytic leukemia. (2011) (108)
Myelodysplastic syndromes (2014) (108)
Cytogenetics of myelodysplastic syndromes. (1996) (106)
A multicenter phase 2 study of the farnesyltransferase inhibitor tipifarnib in intermediate- to high-risk myelodysplastic syndrome. (2007) (106)
An international data set for CMML validates prognostic scoring systems and demonstrates a need for novel prognostication strategies (2015) (106)
The retinoic acid receptor alpha gene is rearranged in retinoic acid-sensitive promyelocytic leukemias. (1990) (102)
Interferon-α therapy in bcr-abl-negative myeloproliferative neoplasms (2008) (102)
Lenalidomide with or without erythropoietin in transfusion-dependent erythropoiesis-stimulating agent-refractory lower-risk MDS without 5q deletion (2016) (102)
High‐dose darbepoetin alpha in the treatment of anaemia of lower risk myelodysplastic syndrome results of a phase II study (2006) (101)
Early locoregional high-dose radiotherapy is associated with long-term disease control in localized primary angiocentric lymphoma of the nose and nasopharynx (2001) (101)
Treatment of relapsing acute promyelocytic leukemia by all-trans retinoic acid therapy followed by timed sequential chemotherapy and stem cell transplantation (2000) (101)
Azacitidine (AZA) Treatment Prolongs Overall Survival (OS) in Higher-Risk MDS Patients Compared with Conventional Care Regimens (CCR): Results of the AZA-001 Phase III Study. (2007) (100)
Detection of minimal residual disease in chronic myeloid leukemia patients after bone marrow transplantation by polymerase chain reaction. (1990) (99)
Hypomethylating agents in relapsed and refractory AML: outcomes and their predictors in a large international patient cohort. (2018) (99)
Germline DDX41 mutations define a significant entity within adult MDS/AML patients. (2019) (98)
Sotatercept with long-term extension for the treatment of anaemia in patients with lower-risk myelodysplastic syndromes: a phase 2, dose-ranging trial. (2018) (98)
SF3B1-mutant MDS as a distinct disease subtype: a proposal from the International Working Group for the Prognosis of MDS (2020) (98)
Occupational and environmental risk factors of the myelodysplastic syndromes in the North of France (2001) (97)
Detection of p53 mutations in hematological malignancies: comparison between immunocytochemistry and DNA analysis. (1994) (96)
Diagnosis, classification, and cytogenetics of myelodysplastic syndromes. (1998) (96)
The JAK2 V617F mutation identifies a subgroup of MDS patients with isolated deletion 5q and a proliferative bone marrow (2006) (95)
Somatic Mutations in MDS Patients Are Associated with Clinical Features and Predict Prognosis Independent of the IPSS-R: Analysis of Combined Datasets from the International Working Group for Prognosis in MDS-Molecular Committee (2015) (95)
Therapy-related myelodysplastic syndrome and acute myeloid leukemia with 17p deletion. A report on 25 cases (1999) (95)
Azacitidine in untreated acute myeloid leukemia: A report on 149 patients (2014) (93)
Primary breast lymphoma: a report of 20 cases (2001) (91)
Epigenetics of myelodysplastic syndromes (2014) (91)
Randomized comparison of double induction and timed-sequential induction to a "3 + 7" induction in adults with AML: long-term analysis of the Acute Leukemia French Association (ALFA) 9000 study. (2004) (90)
A Randomized Trial of Hydroxyurea Versus VP 16 in Adult Chronic Myelomonocytic Leukemia (90)
Long-term incidence of hematological evolution in three French prospective studies of hydroxyurea and pipobroman in polycythemia vera and essential thrombocythemia. (2006) (90)
Prognostic significance of the balanced t(1;19) and unbalanced der(19)t(1;19) translocations in acute lymphoblastic leukemia. (1992) (89)
Good correlation between RT-PCR analysis and relapse in Philadelphia (Ph1)-positive acute lymphoblastic leukemia (ALL) (1997) (87)
Is apoptosis a massive process in myelodysplastic syndromes? (1996) (86)
p16(INK4a) and p15(INK4b) gene methylations in plasma cells from monoclonal gammopathy of undetermined significance. (2001) (85)
An International MDS/MPN Working Group’s perspective and recommendations on molecular pathogenesis, diagnosis and clinical characterization of myelodysplastic/myeloproliferative neoplasms (2015) (85)
Long‐term follow‐up of chronic autoimmune thrombocytopenic purpura refractory to splenectomy: a prospective analysis (2003) (84)
A phase 2 study of the oral farnesyltransferase inhibitor tipifarnib in patients with refractory or relapsed acute myeloid leukemia. (2007) (84)
The use of immunosuppressive therapy in MDS: clinical outcomes and their predictors in a large international patient cohort. (2018) (83)
NF-kappaB constitutes a potential therapeutic target in high-risk myelodysplastic syndrome. (2006) (82)
Synergistic effects of PRIMA-1Met (APR-246) and 5-azacitidine in TP53-mutated myelodysplastic syndromes and acute myeloid leukemia (2019) (82)
Infections in myelodysplastic syndromes (2012) (82)
Chronic and subacute myelomonocytic leukaemia in the adult: a report of 60 cases with special reference to prognostic factors (1987) (81)
Efficacy of Azacitidine in autoimmune and inflammatory disorders associated with myelodysplastic syndromes and chronic myelomonocytic leukemia. (2016) (81)
Arsenic trioxide in patients with myelodysplastic syndromes: a phase II multicenter study. (2006) (81)
Rare occurrence of P53 gene mutations in multiple myeloma (1992) (81)
Myelodysplastic syndromes: From pathogenesis and prognosis to treatment. (2004) (80)
An exploratory phase 2 study of investigational Aurora A kinase inhibitor alisertib (MLN8237) in acute myelogenous leukemia and myelodysplastic syndromes (2014) (80)
A phase 3 randomized, placebo-controlled study assessing the efficacy and safety of epoetin-α in anemic patients with low-risk MDS (2018) (80)
Treatment of acute promyelocytic leukaemia. (2001) (80)
A randomized, double-blind, placebo-controlled study with pegylated recombinant human megakaryocyte growth and development factor (PEG-rHuMGDF) as an adjunct to chemotherapy for adults with de novo acute myeloid leukemia (1999) (79)
Evaluation of minimal residual disease using reverse-transcription polymerase chain reaction in t(8;21) acute myeloid leukemia: a multicenter study of 51 patients. (2000) (79)
Burkitt cell acute leukaemia (L3 ALL) in adults: a report of 18 cases (1989) (79)
Targeting NF-kappaB in hematologic malignancies. (2006) (78)
Positive Impact of Iron Chelation Therapy (CT) on Survival in Regularly Transfused MDS Patients. A Prospective Analysis by the GFM. (2007) (78)
Effect of priming with granulocyte–macrophage colony-stimulating factor in younger adults with newly diagnosed acute myeloid leukemia: a trial by the Acute Leukemia French Association (ALFA) Group (2007) (77)
Practical recommendations on the use of lenalidomide in the management of myelodysplastic syndromes (2008) (76)
Mesenchymal cells generated from patients with myelodysplastic syndromes are devoid of chromosomal clonal markers and support short- and long-term hematopoiesis in vitro (2005) (76)
Long‐term follow‐up of de novo myelodysplastic syndromes treated with intensive chemotherapy: incidence of long‐term survivors and outcome of partial responders (1997) (76)
Granulocyte–macrophage colony-stimulating factor (GM-CSF) to increase efficacy of intensive sequential chemotherapy with etoposide, mitoxantrone and cytarabine (EMA) in previously treated acute myeloid leukemia: a multicenter randomized placebo-controlled trial (EMA91 Trial) (1999) (76)
Inhibitors of DNA methylation: beyond myelodysplastic syndromes (2005) (75)
Allogeneic hematopoietic cell transplantation in patients age 60-70 years with de novo high-risk myelodysplastic syndrome or secondary acute myelogenous leukemia: comparison with patients lacking donors who received azacitidine. (2012) (75)
Myelodysplastic syndrome after acute promyelocytic leukemia: the European APL group experience (2003) (74)
Proposals for revised IWG 2018 hematological response criteria in patients with MDS included in clinical trials. (2019) (74)
ATM mediates constitutive NF-κB activation in high-risk myelodysplastic syndrome and acute myeloid leukemia (2009) (74)
Arsenic trioxide in the treatment of acute promyelocytic leukemia. A review of current evidence. (2005) (74)
Intensive sequential chemotherapy with mitoxantrone and continuous infusion etoposide and cytarabine for previously treated acute myelogenous leukemia. (1991) (74)
M0 AML, clinical and biologic features of the disease, including AML1 gene mutations: a report of 59 cases by the Groupe Français d'Hématologie Cellulaire (GFHC) and the Groupe Français de Cytogénétique Hématologique (GFCH). (2003) (73)
Incidence of 17p deletions and TP53 mutation in myelodysplastic syndrome and acute myeloid leukemia with 5q deletion (2012) (73)
Accessory spleen in recurrent chronic immune thrombocytopenic purpura (1992) (72)
Mutations of the p53 gene in B-cell lymphoblastic acute leukemia: a report on 60 cases. (1992) (71)
Further characterization of clinical and laboratory features in VEXAS syndrome: large‐scale analysis of a multicentre case series of 116 French patients * (2021) (71)
Treatment of myelodysplastic syndromes with 5q deletion before the lenalidomide era; the GFM experience with EPO and thalidomide. (2008) (71)
Prolonged survival with improved tolerability in higher‐risk myelodysplastic syndromes: azacitidine compared with low dose ara‐C (2010) (70)
Reevaluation of the prognostic factors for splenectomy in chronic idiopathic thrombocytopenic purpura (ITP): A report on 181 cases (1989) (70)
Additional chromosomal abnormalities in patients with acute promyelocytic leukaemia (APL) do not confer poor prognosis: results of APL 93 trial. (2000) (70)
Early onset of chemotherapy can reduce the incidence of ATRA syndrome in newly diagnosed acute promyelocytic leukemia (APL) with low white blood cell counts: results from APL 93 trial (2003) (70)
In vivo thrombin and plasmin activities in patients with acute promyelocytic leukemia (APL): effect of all-trans retinoic acid (ATRA) therapy. (1995) (69)
Phase 2 Results of APR-246 and Azacitidine (AZA) in Patients with TP53 mutant Myelodysplastic Syndromes (MDS) and Oligoblastic Acute Myeloid Leukemia (AML) (2019) (69)
Outcome of acute promyelocytic leukemia treated with all trans retinoic acid and chemotherapy in elderly patients: the European group experience (2005) (69)
SF3B1-mutant myelodysplastic syndrome as a distinct disease subtype - A Proposal of the International Working Group for the Prognosis of Myelodysplastic Syndromes (IWG-PM). (2020) (68)
Treatment of acute promyelocytic leukemia by retinoids. (2007) (68)
Allogeneic stem cell transplantation for chronic myelomonocytic leukemia: a report from the Societe Francaise de Greffe de Moelle et de Therapie Cellulaire (2013) (68)
Differentiation therapy for acute promyelocytic leukemia. (1997) (68)
Myelodysplastic Syndromes (MDS) and autoimmune disorders (AD): cause or consequence? (2013) (68)
Treatment of Acute Promyelocytic Leukemia: A Report of 70 Cases. (1991) (67)
Luspatercept for the treatment of anemia in myelodysplastic syndromes and primary myelofibrosis. (2019) (67)
Over‐expression of the MDM2 gene is found in some cases of haematological malignancies (1994) (67)
BCL-2 and mutant NRAS interact physically and functionally in a mouse model of progressive myelodysplasia. (2007) (67)
MDM2 gene amplification in human breast cancer. (1994) (67)
Superior long-term outcome with idarubicin compared with high-dose daunorubicin in patients with acute myeloid leukemia age 50 years and older. (2013) (67)
Rationale for the clinical application of flow cytometry in patients with myelodysplastic syndromes: position paper of an International Consortium and the European LeukemiaNet Working Group (2012) (67)
Lenalidomide does not increase AML progression risk in RBC transfusion-dependent patients with Low- or Intermediate-1-risk MDS with del(5q): a comparative analysis (2012) (66)
Improved outcome of acute promyelocytic leukemia with high WBC counts over the last 15 years: the European APL Group experience. (2009) (66)
Classification and Personalized Prognostic Assessment on the Basis of Clinical and Genomic Features in Myelodysplastic Syndromes (2021) (66)
PROGNOSTIC CLASSIFICATION OF MYELOFIBROSIS WITH MYELOID METAPLASIA (1989) (65)
APR-246 Combined with Azacitidine (AZA) in TP53 Mutated Myelodysplastic Syndrome (MDS) and Acute Myeloid Leukemia (AML). a Phase 2 Study By the Groupe Francophone Des Myélodysplasies (GFM) (2019) (65)
Arsenic trioxide-based therapy of relapsed acute promyelocytic leukemia: registry results from the European LeukemiaNet (2015) (65)
Recommended Guidelines for Validation, Quality Control, and Reporting of TP53 Variants in Clinical Practice. (2017) (64)
γ‐Ray irradiation induces B7.1 expression in myeloid leukaemic cells (2000) (64)
Long-term follow-up for up to 5 years on the risk of leukaemic progression in thrombocytopenic patients with lower-risk myelodysplastic syndromes treated with romiplostim or placebo in a randomised double-blind trial. (2018) (64)
Mediastinal Diffuse Large Cell Lymphoma with Sclerosis (1989) (64)
Association of myelodysplastic syndrome and relapsing polychondritis: further evidence. (1995) (64)
Can the revised IPSS predict response to erythropoietic-stimulating agents in patients with classical IPSS low or intermediate-1 MDS? (2013) (63)
Subcutaneous or intravenous administration of romiplostim in thrombocytopenic patients with lower risk myelodysplastic syndromes (2011) (63)
Azacitidine with or without eltrombopag for first-line treatment of intermediate- or high-risk MDS with thrombocytopenia. (2018) (63)
All trans retinoic acid treatment for patients with acute promyelocytic leukemia. (1992) (63)
Outcome of Lower-Risk Patients With Myelodysplastic Syndromes Without 5q Deletion After Failure of Erythropoiesis-Stimulating Agents. (2017) (63)
Validation of the revised international prognostic scoring system (IPSS‐R) in patients with lower‐risk myelodysplastic syndromes: a report from the prospective European LeukaemiaNet MDS (EUMDS) registry (2015) (62)
Chronic myelomonocytic leukemia: from biology to therapy. (1997) (61)
Androgen therapy in myelodysplastic syndromes with thrombocytopenia: a report on 20 cases (1994) (60)
Suppression of the DNA damage response in acute myeloid leukemia versus myelodysplastic syndrome (2009) (60)
Azacitidine for the treatment of relapsed and refractory AML in older patients. (2015) (60)
Increased gene transfer in acute myeloid leukemic cells by an adenovirus vector containing a modified fiber protein (1999) (60)
De novo myelodysplastic syndrome (MDS) with deletion of the long arm of chromosome 20: a subtype of MDS with distinct hematological and prognostic features? (1993) (60)
Antineoplastic activity of ouabain and pyrithione zinc in acute myeloid leukemia (2012) (60)
Expression level and differential JAK2-V617F-binding of the adaptor protein Lnk regulates JAK2-mediated signals in myeloproliferative neoplasms. (2010) (59)
Essential thrombocythemias without V617F JAK2 mutation are clonal hematopoietic stem cell disorders (2006) (59)
A randomized trial of amsacrine and rubidazone in 39 patients with acute promyelocytic leukemia. (1991) (59)
Granulocyte-macrophage colony-stimulating factor in association to timed-sequential chemotherapy with mitoxantrone, etoposide, and cytarabine for refractory acute myelogenous leukemia. (1993) (58)
Surveillance of Aspergillus galactomannan antigenemia for invasive aspergillosis by enzyme-linked immunosorbent assay in neutropenic patients treated for hematological malignancies. (2000) (58)
Pulsed high‐dose dexamethasone in refractory chronic idiopathic thrombocytopenic purpura: a report on 10 cases (1995) (57)
Exposure to occupational and environmental factors in myelodysplastic syndromes. Preliminary results of a case-control study. (1995) (57)
Phase 1b/2 Combination Study of APR-246 and Azacitidine (AZA) in Patients with TP53 mutant Myelodysplastic Syndromes (MDS) and Acute Myeloid Leukemia (AML) (2018) (57)
Prognostic factors in myelodysplastic syndromes: critical analysis of the impact of age and gender and failure to identify a very‐low‐risk group using standard mortality ratio techniques (1996) (57)
Autologous stem-cell transplantation for non-Hodgkin's lymphomas: the role of graft purging and radiotherapy posttransplantation--results of a retrospective analysis on 120 patients autografted in a single institution. (1998) (56)
Special considerations in the management of adult patients with acute leukaemias and myeloid neoplasms in the COVID-19 era: recommendations from a panel of international experts (2020) (55)
Autoimmune manifestations associated with myelodysplastic syndromes (2018) (55)
NF-κB inhibition sensitizes to starvation-induced cell death in high-risk myelodysplastic syndrome and acute myeloid leukemia (2007) (55)
A randomized trial comparing vinblastine in slow infusion and by bolus i.v. injection in idiopathic thrombocytopenic purpura: a report on 42 patients (1994) (55)
Differential efficacy of adenoviral mediated gene transfer into cells from hematological cell lines and fresh hematological malignancies. (1996) (54)
Long-term outcome of anemic lower-risk myelodysplastic syndromes without 5q deletion refractory to or relapsing after erythropoiesis-stimulating agents (2013) (54)
Role of early splenectomy in malignant lymphomas with prominent splenic involvement (primary lymphomas of the spleen). A study of 59 cases (1993) (54)
Prognostic Role of Gene Mutations in Chronic Myelomonocytic Leukemia Patients Treated With Hypomethylating Agents (2018) (54)
Comparison of high-dose cytarabine and timed-sequential chemotherapy as consolidation for younger adults with AML in first remission: the ALFA-9802 study. (2011) (53)
Classification of myeloproliferative disorders in the JAK2 era: is there a role for red cell mass? (2008) (53)
The Medalist Trial: Results of a Phase 3, Randomized, Double-Blind, Placebo-Controlled Study of Luspatercept to Treat Anemia in Patients with Very Low-, Low-, or Intermediate-Risk Myelodysplastic Syndromes (MDS) with Ring Sideroblasts (RS) Who Require Red Blood Cell (RBC) Transfusions (2018) (53)
Biology and prognostic impact of clonal plasmacytoid dendritic cells in chronic myelomonocytic leukemia (2019) (53)
Early introduction of ESA in low risk MDS patients may delay the need for RBC transfusion: a retrospective analysis on 112 patients. (2010) (53)
Long-term outcome of treatment of anemia in MDS with erythropoietin and G-CSF. Commentary (2005) (52)
[The 5q- syndrome]. (2010) (52)
Health-related quality of life in lower-risk MDS patients compared with age- and sex-matched reference populations: a European LeukemiaNet study (2018) (52)
Practical use of azacitidine in higher-risk myelodysplastic syndromes: an expert panel opinion. (2010) (52)
A novel effect of DNA methyltransferase and histone deacetylase inhibitors : NFκB inhibition in malignant myeloblasts (2008) (51)
Inhibition of NEMO, the regulatory subunit of the IKK complex, induces apoptosis in high-risk myelodysplastic syndrome and acute myeloid leukemia (2007) (51)
Effect of azacitidine (AZA) on overall survival in higher-risk myelodysplastic syndromes (MDS) without complete remission (2008) (51)
Gene transfer of CD154 and IL12 cDNA induces an anti-leukemic immunity in a murine model of acute leukemia (2002) (51)
Alpha-defensins secreted by dysplastic granulocytes inhibit the differentiation of monocytes in chronic myelomonocytic leukemia. (2010) (51)
The complex genetic landscape of familial MDS and AML reveals pathogenic germline variants (2020) (51)
Erlotinib antagonizes ABC transporters in acute myeloid leukemia (2012) (51)
How we manage adults with myelodysplastic syndrome (2020) (50)
Azacitidine frontline therapy for unfit acute myeloid leukemia patients: clinical use and outcome prediction. (2015) (50)
Long-term follow-up confirms the benefit of all-trans retinoic acid in acute promyelocytic leukemia. European APL group. (2000) (50)
NF-kappaB inhibition sensitizes to starvation-induced cell death in high-risk myelodysplastic syndrome and acute myeloid leukemia. (2007) (50)
Tretinoin with chemotherapy in newly diagnosed acute promyelocytic leukaemia (1994) (50)
Infectious complications in adult acute myeloid leukemia: analysis of the Acute Leukemia French Association-9802 prospective multicenter clinical trial (2012) (50)
Inflammatory Arthritis in Patients With Myelodysplastic Syndromes (2014) (50)
Outcome of acute myeloid leukaemia following myelodysplastic syndrome after azacitidine treatment failure (2012) (50)
HLA-matched allogeneic stem cell transplantation improves outcome of higher risk myelodysplastic syndrome A prospective study on behalf of SFGM-TC and GFM (2015) (49)
Azacitidine in the treatment of therapy related myelodysplastic syndrome and acute myeloid leukemia (tMDS/AML): a report on 54 patients by the Groupe Francophone Des Myelodysplasies (GFM). (2013) (49)
A randomized phase II trial of azacitidine +/− epoetin-β in lower-risk myelodysplastic syndromes resistant to erythropoietic stimulating agents (2016) (49)
Detection of chromosome 20q deletions in bone marrow metaphases but not peripheral blood granulocytes in patients with myeloproliferative disorders or myelodysplastic syndromes. (1996) (49)
Imetelstat Achieves Meaningful and Durable Transfusion Independence in High Transfusion-Burden Patients With Lower-Risk Myelodysplastic Syndromes in a Phase II Study. (2020) (49)
The revised IPSS is a powerful tool to evaluate the outcome of MDS patients treated with azacitidine: the GFM experience. (2012) (48)
Review of azacitidine trials in Intermediate-2-and High-risk myelodysplastic syndromes. (2009) (48)
BCL-2 inhibition with ABT-737 prolongs survival in an NRAS/BCL-2 mouse model of AML by targeting primitive LSK and progenitor cells. (2013) (48)
P15INK4b gene methylation and myelodysplastic syndromes. (1999) (48)
Accumulation of classical monocytes defines a subgroup of MDS that frequently evolves into CMML. (2017) (48)
Expression of the multidrug resistance P glycoprotein in newly diagnosed adult acute lymphoblastic leukemia: absence of correlation with response to treatment. (1995) (48)
A prospective study of autologous bone marrow or peripheral blood stem cell transplantation after intensive chemotherapy in myelodysplastic syndromes (1999) (48)
Phase 1/2 Study of AMG 531 in Thrombocytopenic Patients (pts) with Low-Risk Myelodysplastic Syndrome (MDS): Update Including Extended Treatment. (2007) (47)
MIRROS: a randomized, placebo-controlled, Phase III trial of cytarabine ± idasanutlin in relapsed or refractory acute myeloid leukemia. (2020) (47)
Favorable cytogenetic abnormalities in secondary leukemia (1989) (47)
Use of arsenic trioxide in haematological malignancies: insight into the clinical development of a novel agent (2005) (46)
Glutathione S transferase theta 1 gene defects in myelodysplastic syndromes and their correlation with karyotype and exposure to potential carcinogens (1997) (46)
A phase 1b/2b multicenter study of oral panobinostat plus azacitidine in adults with MDS, CMML or AML with ⩽30% blasts (2017) (46)
Fluorescence in situ hybridization improves the detection of monosomy 7 in myelodysplastic syndromes. (1994) (46)
Outcome of older patients with acute myeloid leukemia in first relapse (2013) (45)
Diagnosis and Treatment of Chronic Myelomonocytic Leukemias in Adults (2018) (45)
Valuation of transfusion-free living in MDS: results of health utility interviews with patients (2009) (45)
Strongyloidiasis in Man 75 Years after Initial Exposure (2011) (45)
Transduction of bone marrow cells by the AdZ.F(pK7) modified adenovirus demonstrates preferential gene transfer in myeloma cells. (1999) (45)
Azacytidine and erlotinib exert synergistic effects against acute myeloid leukemia (2013) (45)
Elevated serum levels of soluble interleukin-2 receptor: a marker of disease activity in the hypereosinophilic syndrome. (1991) (45)
Myelodysplastic syndromes: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. (2020) (45)
Early death in acute promyelocytic leukemia (APL) in French centers: a multicenter study in 399 patients (2014) (45)
Azacitidine for patients with Vacuoles, E1 Enzyme, X‐linked, Autoinflammatory, Somatic syndrome (VEXAS) and myelodysplastic syndrome: data from the French VEXAS registry (2021) (44)
Upfront allogeneic stem cell transplantation after reduced-intensity/nonmyeloablative conditioning for patients with myelodysplastic syndrome: a study by the Société Française de Greffe de Moelle et de Thérapie Cellulaire. (2014) (44)
A non‐randomised dose‐escalating phase II study of thalidomide for the treatment of patients with low‐risk myelodysplastic syndromes: the Thal‐SMD‐2000 trial of the Groupe Français des Myélodysplasies (2005) (44)
Appelbaum FR, Rowe JM, Radich J, Dick JE. Acute Myeloid Leukemia. Hematology Am Soc Hematol Educ Program. 2001:62-86. PMID: 11722979 (2008) (44)
Acute Myeloid Leukemia and Myelodysplastic Syndromes Following Essential Thrombocythemia Treated With Hydroxyurea : High Proportion of Cases With 17 p Deletion (1998) (44)
Molecular remission as a therapeutic objective in acute promyelocytic leukemia (2018) (44)
Established practice in the treatment of patients with acute promyleocytic leukemia and the introduction of arsenic trioxide as a novel therapy. (2002) (43)
Lenalidomide as a disease-modifying agent in patients with del(5q) myelodysplastic syndromes: linking mechanism of action to clinical outcomes (2013) (43)
Hematopoietic growth factor expression and ATRA sensitivity in acute promyelocytic blast cells. (1994) (43)
In vitro all-trans retinoic acid sensitivity of acute promyelocytic leukemia blasts: a novel indicator of poor patient outcome. (2001) (42)
Gene transfer of GM-CSF, CD80 and CD154 cDNA enhances survival in a murine model of acute leukemia with persistence of a minimal residual disease (2000) (42)
Outcome of patients with high risk Myelodysplastic Syndrome (MDS) and advanced Chronic Myelomonocytic Leukemia (CMML) treated with decitabine after azacitidine failure. (2015) (41)
Expression of the multidrug resistance P-glycoprotein and its relationship to hematological characteristics and response to treatment in myelodysplastic syndromes. (1994) (41)
Role of splenectomy in the treatment of myelodysplastic syndromes with peripheral thrombocytopenia: a report on six cases (2001) (41)
Quinine improves results of intensive chemotherapy (IC) in myelodysplastic syndromes (MDS) expressing P-glycoprotein (PGP). Updated results of a randomized study. Groupe Français des Myélodysplasies (GFM) and Groupe GOELAMS. (1999) (41)
Cytogenetics and their prognostic value in childhood and adult acute lymphoblastic leukemia (ALL) excluding L3 (1989) (41)
High risk of myelodysplastic syndrome and acute myeloid leukemia after 177Lu-octreotate PRRT in NET patients heavily pretreated with alkylating chemotherapy. (2016) (41)
Azacitidine in adult patients with acute myeloid leukemia. (2017) (41)
High response rate and improved exercise capacity and quality of life with a new regimen of darbepoetin alfa with or without filgrastim in lower-risk myelodysplastic syndromes: a phase II study by the GFM (2013) (41)
EGFR inhibitors exacerbate differentiation and cell cycle arrest induced by retinoic acid and vitamin D3 in acute myeloid leukemia cells (2013) (41)
Farnesyltransferase inhibitors and their potential role in therapy for myelodysplastic syndromes and acute myeloid leukaemia (2008) (41)
Hypomethylating agents reactivate FOXO3A in acute myeloid leukemia (2011) (40)
Effect of lenalidomide treatment on clonal architecture of myelodysplastic syndromes without 5q deletion. (2016) (40)
Characteristics and outcome of myelodysplastic syndromes (MDS) with isolated 20q deletion: a report on 62 cases. (2011) (40)
Autoimmune and inflammatory diseases associated with chronic myelomonocytic leukemia: A series of 26 cases and literature review. (2016) (39)
Matched unrelated or matched sibling donors result in comparable outcomes after non-myeloablative HSCT in patients with AML or MDS (2013) (39)
Outcome of acute promyelocytic leukemia (APL) in children and adolescents: an analysis in two consecutive trials of the European APL Group. (2012) (39)
Impact of iron overload in myelodysplastic syndromes. (2009) (39)
Prognostic value of c-mpl expression in myelodysplastic syndromes. (1995) (39)
Cigarette smoking, alcohol drinking, and risk of lymphoid neoplasms: results of a French case–control study (2008) (38)
Treatment by Lenalidomide in lower risk myelodysplastic syndrome with 5q deletion--the GFM experience. (2011) (38)
Successful treatment of juvenile rheumatoid arthritis associated haemophagocytic syndrome by cyclosporin A with transient exacerbation by conventional-dose G-CSF. (1997) (38)
Are PU.1 mutations frequent genetic events in acute myeloid leukemia (AML)? (2002) (38)
Romiplostim monotherapy in thrombocytopenic patients with myelodysplastic syndromes: long‐term safety and efficacy (2017) (38)
Activation of cytotoxic T-cell receptor γδ T lymphocytes in response to specific stimulation in myelodysplastic syndromes (2008) (38)
Inactivation of the retinoblastoma gene appears to be very uncommon in myelodysplastic syndromes (1994) (38)
Prognostic value of dysmyelopoietic features in de novo acute myeloid leukaemia: a report on 132 patients. (2008) (38)
Preliminary Data on a Phase 1/2A First in Human Study of the Menin-KMT2A (MLL) Inhibitor KO-539 in Patients with Relapsed or Refractory Acute Myeloid Leukemia (2020) (37)
Prognostic significance of monosomal karyotype in higher risk myelodysplastic syndrome treated with azacitidine (2011) (37)
Analysis of p16 gene deletion and point mutation in breast carcinoma. (1995) (37)
Routine diagnostic procedures of myelodysplastic syndromes: value of a structural blood cell parameter (NEUT‐X) determined by the Sysmex XE‐2100TM (2010) (37)
Treatment with lenalidomide does not appear to increase the risk of progression in lower risk myelodysplastic syndromes with 5q deletion. A comparative analysis by the Groupe Francophone des Myelodysplasies (2012) (37)
Biology and treatment of acute promyelocytic leukemia. (1996) (36)
Tyrosine kinase inhibitors for the treatment of acute myeloid leukemia: delineation of anti-leukemic mechanisms of action. (2011) (36)
Cytogenetic studies in 30 patients with Burkitt's lymphoma or L3 acute lymphoblastic leukemia with special reference to additional chromosome abnormalities. (1989) (36)
Cytopenia levels for aiding establishment of the diagnosis of myelodysplastic syndromes. (2016) (36)
All-trans retinoic acid in adult chronic myelomonocytic leukemia: results of a pilot study. (1996) (36)
UBA1 Variations in Neutrophilic Dermatosis Skin Lesions of Patients With VEXAS Syndrome. (2021) (36)
A randomized, double-blind, placebo-controlled study with pegylated recombinant human megakaryocyte growth and development factor (PEG-rHuMGDF) as an adjunct to chemotherapy for adults with de novo acute myeloid leukemia. (1999) (35)
Erlotinib and gefitinib for the treatment of myelodysplastic syndrome and acute myeloid leukemia: a preclinical comparison. (2008) (35)
Health-related quality of life outcomes of lenalidomide in transfusion-dependent patients with Low- or Intermediate-1-risk myelodysplastic syndromes with a chromosome 5q deletion: results from a randomized clinical trial. (2013) (35)
Acute monocytic leukemia with (8;22)(p11;q13) translocation. Involvement of 8p11 as in classical t(8;16)(p11;p13). (1992) (35)
Single agent talacotuzumab demonstrates limited efficacy but considerable toxicity in elderly high-risk MDS or AML patients failing hypomethylating agents (2019) (35)
A decade of progress in myelodysplastic syndrome with chromosome 5q deletion (2018) (35)
Erlotinib antagonizes constitutive activation of SRC family kinases and mTOR in acute myeloid leukemia (2011) (35)
A Decision Analysis of Reduced-Intensity Conditioning Allogeneic Hematopoietic Stem Cell Transplantation for Older Patients with De-Novo Myelodysplastic Syndrome (MDS): Early Transplantation Offers Survival Benefit in Higher-Risk MDS (2011) (35)
Hematopoietic growth factor expression and ATRA sensitivity in acute promyelocytic blast cells (1994) (35)
Low incidence of specific anti‐platelet antibodies detected by the MAIPA assay in the serum of thrombocytopenic MDS patients and lack of correlation between platelet autoantibodies, platelet lifespan and response to danazol therapy (1996) (35)
High body mass index is an independent predictor of differentiation syndrome in patients with acute promyelocytic leukemia. (2010) (35)
Treatment of newly diagnosed acute promyelocytic leukemia (APL) by all transretinoic acid (ATRA) combined with chemotherapy: The European experience. European APL Group. (1995) (35)
A phase II study of guadecitabine in higher-risk myelodysplastic syndrome and low blast count acute myeloid leukemia after azacitidine failure (2019) (34)
Autologous bone marrow transplantation with marrow purged by mafosfamide in seven patients with myelodysplastic syndromes in transformation (AML-MDS): a pilot study. (1993) (34)
Treatment with the Thrombopoietin (TPO)-Receptor Agonist Romiplostim in Thrombocytopenic Patients (Pts) with Low or Intermediate-1 (int-1) Risk Myelodysplastic Syndrome (MDS): Follow-up AML and Survival Results of a Randomized, Double-Blind, Placebo (PBO)-Controlled Study (2012) (34)
The retinoblastoma gene (RB-1) status in multiple myeloma: a report on 35 cases. (1995) (34)
Lenalidomide in lower‐risk myelodysplastic syndromes with karyotypes other than deletion 5q and refractory to erythropoiesis‐stimulating agents (2012) (34)
Long-term outcome of higher-risk MDS patients treated with azacitidine: an update of the GFM compassionate program cohort. (2012) (34)
The Effects of Continued Azacitidine (AZA) Treatment Cycles on Response in Higher-Risk Patients (Pts) with Myelodysplastic Syndromes (MDS) (2008) (34)
Aggressive chemotherapy in adult primary myelodysplastic syndromes. A report on 29 cases. (1988) (33)
The INSERM expert review on glycol ethers: findings and recommendations. (2005) (33)
Prolonged follow-up confirms that all-trans retinoic acid followed by chemotherapy reduces the risk of relapse in newly diagnosed acute promyelocytic leukemia. The French APL Group [letter] (1994) (33)
Assessment of ASC specks as a putative biomarker of pyroptosis in myelodysplastic syndromes: an observational cohort study. (2018) (32)
Flt3 receptor inhibition reduces constitutive NFκB activation in high-risk myelodysplastic syndrome and acute myeloid leukemia (2008) (32)
Fractionated Doses of Gemtuzumab Ozogamicin (GO) Combined to Standard Chemotherapy (CT) Improve Event-Free and Overall Survival in Newly-Diagnosed De Novo AML Patients Aged 50–70 Years Old: A Prospective Randomized Phase 3 Trial From the Acute Leukemia French Association (ALFA) (2011) (32)
Phase III, Randomized, Placebo-Controlled Trial of CC-486 (Oral Azacitidine) in Patients With Lower-Risk Myelodysplastic Syndromes (2021) (32)
Are somatic mutations predictive of response to erythropoiesis stimulating agents in lower risk myelodysplastic syndromes? (2016) (32)
de novo myelodysplastic syndromes in adults aged 50 or less. A report on 37 cases. (1990) (32)
Long‐term follow‐up of European APL 2000 trial, evaluating the role of cytarabine combined with ATRA and Daunorubicin in the treatment of nonelderly APL patients (2013) (32)
Relationship between p53 gene mutations and multidrug resistance (mdr1) gene expression in myelodysplastic syndromes. (1993) (32)
Combined immunophenotyping and in situ hybridization (FICTION): a rapid method to study cell lineage involvement in myelodysplastic syndromes (1995) (31)
Translocations (5;17) and (7;17) in patients with de novo or therapy-related myelodysplastic syndromes or acute nonlymphocytic leukemia. A possible association with acquired pseudo-Pelger-Huët anomaly and small vacuolated granulocytes. (1990) (31)
Effi cacy of azacitidine compared with that of conventional care regimens in the treatment of higher-risk myelodysplastic syndromes : a randomised , open-label , phase III study (2012) (31)
Fas/APO-1 (CD95) expression in myelodysplastic syndromes. (1998) (31)
Somatic mutations and epigenetic abnormalities in myelodysplastic syndromes. (2013) (31)
bcl-2 expression in myelodysplastic syndromes and its correlation with hematological features, p53 mutations and prognosis. (1995) (31)
Manifestations systémiques et auto-immunes des syndromes myélodysplasiques (2011) (31)
Preliminary Results from a Phase Ib Study Evaluating BCL-2 Inhibitor Venetoclax in Combination with MEK Inhibitor Cobimetinib or MDM2 Inhibitor Idasanutlin in Patients with Relapsed or Refractory (R/R) AML (2017) (31)
Feasibility of autologous bone marrow transplantation for early consolidation of follicular non‐Hodgkin's lymphoma (1991) (30)
A G polymorphism in the CRBN gene acts as a biomarker of response to treatment with lenalidomide in low/int-1 risk MDS without del(5q) (2013) (30)
Prognostic value of GST-π expression in diffuse large B-cell lymphomas (2003) (30)
Superiority of an arsenic trioxide-based regimen over a historic control combining all-trans retinoic acid plus intensive chemotherapy in the treatment of relapsed acute promyelocytic leukemia. (2006) (30)
Is there a role for all-trans retinoic acid in combination with recombinant erythropoetin in myelodysplastic syndromes? A report on 59 cases (2009) (30)
The role of lenalidomide in the management of myelodysplasia with del 5q (2008) (30)
Preclinical modeling of myelodysplastic syndromes (2017) (30)
Updated Results from the Venetoclax (Ven) in Combination with Idasanutlin (Idasa) Arm of a Phase 1b Trial in Elderly Patients (Pts) with Relapsed or Refractory (R/R) AML Ineligible for Cytotoxic Chemotherapy (2019) (30)
[Systemic and autoimmune manifestations in myelodysplastic syndromes]. (2011) (30)
UV radiation exposure, skin type and lymphoid malignancies: results of a French case–control study (2008) (30)
All-trans retinoic acid pharmacokinetics and bioavailability in acute promyelocytic leukemia: intracellular concentrations and biologic response relationship. (1995) (30)
Efficacy and safety of darbepoetin alpha in patients with myelodysplastic syndromes: a systematic review and meta‐analysis (2016) (29)
Outcomes in RBC transfusion-dependent patients with Low-/Intermediate-1-risk myelodysplastic syndromes with isolated deletion 5q treated with lenalidomide: a subset analysis from the MDS-004 study (2014) (29)
Transfer of p16inka/CDKN2 gene in leukaemic cell lines inhibits cell proliferation (1996) (29)
RBC Transfusion Independence and Safety Profile of Lenalidomide 5 or 10 mg in Pts with Low- or Int-1-Risk MDS with Del5q: Results From a Randomized Phase III Trial (MDS-004). (2009) (29)
Clinical effectiveness and safety of erythropoietin‐stimulating agents for the treatment of low‐ and intermediate‐1−risk myelodysplastic syndrome: a systematic literature review (2018) (29)
Role of multiplex FISH in identifying chromosome involvement in myelodysplastic syndromes and acute myeloid leukemias with complex karyotypes: a report on 28 cases. (2005) (29)
Trisomy 6 as the sole chromosome abnormality in myeloid disorders. (1994) (29)
14 Revised International Prognostic Scoring System (IPSS-R), developed by the International Prognostic Working Group for Prognosis in MDS (IWG-PM) (2011) (29)
Scoring system for the prediction of successful peripheral blood stem cell (PBSC) collection in non-Hodgkin's lymphoma (NHL): application in clinical practice (2000) (29)
Outcome of patients with low-risk myelodysplasia after azacitidine treatment failure (2013) (28)
Inv(16) may be one of the only 'favorable' factors in acute myeloid leukemia: a report on 19 cases with prolonged follow-up. (1994) (28)
Impact of treatment with iron chelation therapy in patients with lower-risk myelodysplastic syndromes participating in the European MDS registry (2019) (28)
Allogeneic stem cell transplantation in second rather than first complete remission in selected patients with good-risk acute myeloid leukemia (2005) (28)
The cystic fibrosis ΔF508 gene mutation and cancer (1997) (28)
Treatment with very low-dose GM-CSF in myelodysplastic syndromes with neutropenia. A report on 28 cases. (1994) (28)
Dual origin of relapses in retinoic-acid resistant acute promyelocytic leukemia (2018) (28)
Expression of the multidrug resistance‐associated protein in myelodysplastic syndromes (2000) (28)
Vincristine efficacy and safety in treating immune thrombocytopenia: a retrospective study of 35 patients (2016) (27)
Mutations in exon 12 of JAK2 are mainly found in JAK2 V617F‐negative polycythaemia vera patients (2008) (27)
Acute lymphocytic leukemia with 9p anomalies. A report of four additional cases and review of the literature. (1988) (27)
Detection of serum anti p53 antibodies and their correlation with p53 mutations in myelodysplastic syndromes and acute myeloid leukemia. (1994) (27)
An Open-Label, Phase 2, Dose-Finding Study of Sotatercept (ACE-011) in Patients with Low or Intermediate-1 (Int-1)-Risk Myelodysplastic Syndromes (MDS) or Non-Proliferative Chronic Myelomonocytic Leukemia (CMML) and Anemia Requiring Transfusion (2014) (27)
Absence of amplification of MDM2 gene, a regulator of p53 function, in myelodysplastic syndromes. (1993) (27)
Ruxolitinib is more effective than other JAK Inhibitors to treat VEXAS Syndrome: a retrospective multi center study. (2022) (27)
Development of luspatercept to treat ineffective erythropoiesis. (2021) (26)
New Role for Granulocyte Colony-Stimulating Factor-Induced Extracellular Signal-Regulated Kinase 1/2 in Histone Modification and Retinoic Acid Receptor α Recruitment to Gene Promoters: Relevance to Acute Promyelocytic Leukemia Cell Differentiation (2011) (26)
p16ink4a gene and hematological malignancies. (1996) (26)
Cardiac iron overload assessed by T2* magnetic resonance imaging and cardiac function in regularly transfused myelodysplastic syndrome patients (2013) (26)
SPOTLIGHT REVIEW Interferon-a therapy in bcr-abl-negative myeloproliferative neoplasms (2008) (26)
Minimizing risk of hypomethylating agent failure in patients with higher-risk MDS and practical management recommendations. (2014) (26)
Rituximab Is an Alternative to Splenectomy in Adults with Chronic Immune Thrombocytopenic Purpura: Results of a Multicenter Prospective Phase 2 Study. (2006) (26)
Timed sequential chemotherapy for advanced acute myeloid leukemia. (1996) (26)
Biologics in myelodysplastic syndrome-related systemic inflammatory and autoimmune diseases: French multicenter retrospective study of 29 patients. (2017) (26)
CYTOGENETIC AND MOLECULAR REMISSION IN A CASE OF ACUTE MYELOID LEUKAEMIA (AML) WITH INVERSION OF CHROMOSOME 16 (Inv(16)) AND PHILADELPHIA CHROMOSOME (Ph) (1992) (25)
Problematic WHO reclassification of myelodysplastic syndromes. Members of the International MDS Study Group. (2000) (25)
Implication of HTLV-I infection, strongyloidiasis, and P53 overexpression in the development, response to treatment, and evolution of non-Hodgkin's lymphomas in an endemic area (Martinique, French West Indies). (1999) (25)
Glomerular injury in chronic myelomonocytic leukemia. (1995) (25)
p16INK4a immunocytochemical analysis is an independent prognostic factor in childhood acute lymphoblastic leukemia (2002) (25)
Treatment with the Thrombopoietin (TPO)-Receptor Agonist Romiplostim in Thrombocytopenic Patients (Pts) with Low or Intermediate-1 (Int-1) Risk Myelodysplastic Syndrome (MDS): Results of a Randomized, Double-Blind, Placebo(PBO)-Controlled Study (2011) (25)
Impact of post-remission therapy in patients aged 65–70 years with de novo acute myeloid leukemia: a comparison of two concomitant randomized ALFA trials with overlapping age inclusion criteria (2011) (25)
Recent advances in the treatment of lower-risk non-del(5q) myelodysplastic syndromes (MDS). (2017) (25)
Lithium chloride antileukemic activity in acute promyelocytic leukemia is GSK-3 and MEK/ERK dependent (2015) (24)
Acute monocytic leukaemia in adults: treatment and prognosis in 99 cases (1990) (24)
Pro-inflammatory proteins S100A9 and tumor necrosis factor-α suppress erythropoietin elaboration in myelodysplastic syndromes (2017) (24)
[Cytogenetics of myelodysplastic syndromes]. (1997) (24)
Phase I study of cinchonine, a multidrug resistance reversing agent, combined with the CHVP regimen in relapsed and refractory lymphoproliferative syndromes (2000) (24)
CSNK1A1 mutations and gene expression analysis in myelodysplastic syndromes with del(5q) (2015) (24)
Impact of red blood cell transfusion dose density on progression-free survival in patients with lower-risk myelodysplastic syndromes (2019) (24)
Immunomodulating drugs in myelodysplastic syndromes. (2011) (24)
Management of acute promyelocytic leukemia (1993) (24)
Azacytidine (AZA) as First Line Therapy in AML: Results of the French ATU Program. (2009) (24)
A phase I/II trial of Erlotinib in higher risk myelodysplastic syndromes and acute myeloid leukemia after azacitidine failure. (2014) (23)
Translocation t(9;11)(p21;q23) with acute myelomonocytic leukemia after chemotherapy for osteosarcoma: good response to antileukemic drugs. (1987) (23)
Evaluation of induction chemotherapies after hypomethylating agent failure in myelodysplastic syndromes and acute myeloid leukemia. (2018) (23)
Reversible renal failure due to specific infiltration in chronic lymphocytic leukemia. (1988) (23)
Quality of Life and Economic Impact of Red Blood Cell (RBC) Transfusions on Patients with Myelodysplastic Syndromes (MDS). (2004) (23)
High-Risk Myelodysplastic Syndrome (MDS): First Results of International Phase 2 Study with Oral Farnesyltransferase Inhibitor R115777 (ZARNESTRATM). (2004) (23)
Equivalent outcomes using reduced intensity or conventional myeloablative conditioning transplantation for patients aged 35 years and over with AML (2015) (23)
Decitabine Versus Hydroxyurea for Advanced Proliferative CMML: Results of the Emsco Randomized Phase 3 Dacota Trial (2020) (23)
SIMULTANEOUS OCCURRENCE OF GREY PLATELET SYNDROME AND IDIOPATHIC PULMONARY FIBROSIS: A ROLE FOR ABNORMAL MEGAKARYOCYTES IN THE PATHOGENESIS OF PULMONARY FIBROSIS? (1990) (23)
Validation of the IPSS-R in lenalidomide-treated, lower-risk myelodysplastic syndrome patients with del(5q) (2014) (23)
Arsenic trioxide is required in the treatment of newly diagnosed acute promyelocytic leukemia. Analysis of a randomized trial (APL 2006) by the French Belgian Swiss APL group (2018) (23)
Promyelocytic blast crisis of Philadelphia-positive thrombocythemia with translocations (9;22) and (15;17). (1987) (23)
Transfusion-Dependency Is the Most Important Prognostic Factor for Survival in 1000 Newly Diagnosed MDS Patients with Low- and Intermediate-1 Risk MDS in the European LeukemiaNet MDS Registry (2011) (23)
Therapy related myelodysplastic syndrome and leukemia with no "unfavourable" cytogenetic findings have a good response to intensive chemotherapy: a report on 15 cases. (1991) (22)
Treatment of acute promyelocytic leukemia with all-trans retinoic acid. (1991) (22)
Erythropoiesis‐stimulating agents significantly delay the onset of a regular transfusion need in nontransfused patients with lower‐risk myelodysplastic syndrome (2016) (22)
Randomized Comparison of Standard Induction with Daunorubicin (DNR) for 3 Days vs Idarubicin (IDA) for 3 or 4 Days in AML pts Aged 50 to 70 and of Maintenance with Interleukin 2. Final Analysis of the ALFA 9801 Study. (2007) (22)
Actinomycin D Targets NPM1c-Primed Mitochondria to Restore PML-Driven Senescence in AML Therapy (2021) (22)
In vitro treatment with retinoids or the topoisomerase inhibitor, VP-16, evidences different functional apoptotic pathways in acute promyelocytic leukemic cells. (1995) (21)
Lenalidomide combined with intensive chemotherapy in acute myeloid leukemia and higher-risk myelodysplastic syndrome with 5q deletion. Results of a phase II study by the Groupe Francophone Des Myélodysplasies (2016) (21)
Cytogenetic follow-up by karyotyping and fluorescence in situ hybridization: implications for monitoring patients with myelodysplastic syndrome and deletion 5q treated with lenalidomide (2011) (21)
Azacitidine treatment for patients with myelodysplastic syndrome and acute myeloid leukemia with chromosome 3q abnormalities (2015) (21)
Prognostic value of minimal residual disease by real-time quantitative PCR in acute myeloid leukemia with CBFB-MYH11 rearrangement: the French experience (2010) (21)
NPM1 mutation is not associated with prolonged complete remission in acute myeloid leukemia patients treated with hypomethylating agents (2018) (21)
Is AraC Required In the Treatment of Standard Risk APL? Long Term Results of a Randomized Trial (APL 2000) From the French Belgian Swiss APL Group (2010) (21)
Time-dependent prognostic scoring system for myelodysplastic syndromes has significant limitations that may influence its reproducibility and practical application. (2008) (21)
Ferritin level at diagnosis is not correlated with poorer survival in non RBC transfusion dependent lower risk de novo MDS. (2011) (21)
Prolonged follow-up confirms that all-trans retinoic acid followed by chemotherapy reduces the risk of relapse in newly diagnosed acute promyelocytic leukemia. The French APL Group. (1994) (21)
An miRNA–DNMT1 Axis Is Involved in Azacitidine Resistance and Predicts Survival in Higher-Risk Myelodysplastic Syndrome and Low Blast Count Acute Myeloid Leukemia (2016) (21)
The role of intensive chemotherapy in myelodysplastic syndromes. (1992) (21)
Genomic landscape of MDS/CMML associated with systemic inflammatory and autoimmune disease (2021) (20)
Late first relapses in APL treated with all-trans-retinoic acid- and anthracycline- based chemotherapy: the European APL group experience (APL 91 and APL 93 trials) (2006) (20)
Association between myelodysplastic syndromes and inflammatory bowel diseases. Report of seven new cases and review of the literature (1997) (20)
Occupation and Lymphoid Malignancies: Results From a French Case-Control Study (2007) (20)
The cystic fibrosis delta F508 gene mutation and cancer. (1997) (20)
FISH analysis with a YAC probe improves detection of LAZ3/BCL6 rearrangement in non-Hodgkin's lymphoma. (2000) (20)
The treatment of adult idiopathic thrombocytopenic purpura (1987) (20)
p190 bcr-abl rearrangement: a secondary cytogenetic event in some chronic myeloid disorders? (1999) (20)
A phase II trial of induction and consolidation therapy of acute myeloid leukemia with weekly oral idarubicin alone in poor risk elderly patients (1999) (20)
Clinical Outcomes of 217 Patients with Acute Erythroleukemia According to Treatment Type and Line: A Retrospective Multinational Study (2017) (20)
Phase 2 Study of MLN8237, An Investigational Aurora A Kinase (AAK) Inhibitor In Patients with Acute Myelogenous Leukemia (AML) or Myelodysplastic Syndromes (MDS) (2010) (20)
Cooperation of activating Ras/rtk signal transduction pathway mutations and inactivating myeloid differentiation gene mutations in M0 AML: a study of 45 patients (2006) (20)
Safety, Efficacy, Pharmacokinetic (PK) and Biomarker Analyses of BCL2 Inhibitor Venetoclax (Ven) Plus MDM2 Inhibitor Idasanutlin (idasa) in Patients (pts) with Relapsed or Refractory (R/R) AML: A Phase Ib, Non-Randomized, Open-Label Study (2018) (20)
Chronic myelomonocytic leukemia: myelodysplastic or myeloproliferative? (2013) (19)
Impact of Treatment with Iron Chelators in Lower-Risk MDS Patients Participating in the European Leukemianet MDS (EUMDS) Registry (2016) (19)
Efficacy of recombinant human erythropoietin in the treatment of refractory anemias without excess of blasts in myelodysplastic syndromes. (1994) (19)
Daily practice management of myelodysplastic syndromes in France: data from 907 patients in a one-week cross-sectional study by the Groupe Francophone des Myélodysplasies (2010) (19)
Functional G-CSF pathways in t(8;21) leukemic cells allow for differentiation induction and degradation of AML1-ETO. (2000) (19)
Allogeneic bone marrow transplantation in patients with follicular lymphoma: a single center study (2002) (19)
The clinical safety of lenalidomide in multiple myeloma and myelodysplastic syndromes (2012) (19)
Safety of lenalidomide (LEN) from a randomized phase III trial (MDS-004) in low-/int-1-risk myelodysplastic syndromes (MDS) with a del(5q) abnormality. (2010) (19)
Splenic irradiation for chronic autoimmune thrombocytopenic purpura in patients with contra‐indications to splenectomy (1995) (19)
Optimizing hypomethylating agents in myelodysplastic syndromes (2012) (19)
Overall Survival and Subgroup Analysis from a Randomized Phase III Study of Intravenous Rigosertib Versus Best Supportive Care (BSC) in Patients (pts) with Higher-Risk Myelodysplastic Syndrome (HR-MDS) after Failure of Hypomethylating Agents (HMAs) (2014) (19)
Does addition of erythropoiesis stimulating agents improve the outcome of higher-risk myelodysplastic syndromes treated with azacitidine? (2012) (19)
Gastrointestinal Behcet’s-like disease with myelodysplastic neoplasms with trisomy 8: a French case series and literature review (2018) (18)
A cost-effectiveness analysis of using azacitidine vs. decitabine in treating patients with myelodysplastic syndromes (2012) (18)
TP53 State Dictates Genome Stability, Clinical Presentation and Outcomes in Myelodysplastic Syndromes (2019) (18)
Treatment of older adults with acute promyelocytic leukaemia. (2003) (18)
A randomized phase-I/II multicenter study of recombinant human granulocyte-macrophage colony-stimulating factor (GM-CSF) therapy for patients with myelodysplastic syndromes and a relatively low risk of acute leukemia (1992) (18)
Absence of rearrangement of the neurofibromatosis 1 (NF1) gene in myelodysplastic syndromes and acute myeloid leukemia. (1994) (18)
Effectiveness and tolerance of low to very low dose thalidomide in low-risk myelodysplastic syndromes. (2009) (18)
Unusual recurrence of chronic myelogenous leukemia following bone marrow transplantation. (1991) (18)
Lenalidomide (LEN) Combined To Intensive Chemotherapy (IC) In AML and Higher Risk MDS With Del 5q. Results Of a Phase I/II Study Of The Groupe Francophone Des Myelodysplasies (GFM) (2010) (18)
Inflammatory disorders associated with trisomy 8‐myelodysplastic syndromes: French retrospective case‐control study (2018) (18)
Development and validation of a model to predict platelet response to romiplostim in patients with lower‐risk myelodysplastic syndromes (2014) (18)
Synchronous FIP1L1–PDGFRA‐positive chronic eosinophilic leukemia and T‐cell lymphoblastic lymphoma: a bilineal clonal malignancy (2007) (18)
Efficacy and safety of lenalidomide in intermediate-2 or high-risk myelodysplastic syndromes with 5 q deletion : results of a phase 2 study (2009) (18)
The role of danazol in the treatment of refractory idiopathic thrombocytopenic purpura. A report of 22 cases. (1990) (18)
Slow infusions of vinblastine in the treatment of adult idiopathic thrombocytopenic purpura: A report on 43 cases (1990) (18)
A new murine aggressive leukemic model. (1999) (18)
History of infections and vaccinations and risk of lymphoid neoplasms: does influenza immunization reduce the risk? (2007) (17)
A new variant t(6;15;17)(q25;q22;q21) in acute promyelocytic leukemia: fluorescence in situ hybridization confirmation. (2005) (17)
Neurological disorders in essential thrombocythemia (2011) (17)
Acquired trisomy 21 and distinct clonal evolution in acute megakaryoblastic leukaemia in young monozygotic twins (2002) (17)
HTLV-I AND MALIGNANT HYPEREOSINOPHILIC SYNDROME (1988) (17)
Early platelet count kinetics has prognostic value in lower-risk myelodysplastic syndromes. (2018) (17)
Disappearance of slan-positive non-classical monocytes for diagnosis of chronic myelomonocytic leukemia with an associated inflammatory state (2020) (17)
Rearrangement and expression of the p53 gene in myelodysplastic syndrome and acute myeloid leukemia. (1990) (17)
Ivosidenib Monotherapy Is Effective in Patients with IDH1 Mutated Myelodysplastic Syndrome (MDS): The Idiome Phase 2 Study By the GFM Group (2021) (17)
Refractory anaemia according to the FAB classification: A report on 69 cases (1988) (17)
Occupational exposure to organic solvents and lymphoid neoplasms in men: results of a French case-control study (2010) (17)
Presence of TET2 Mutation Predicts A Higher Response Rate to Azacitidine In MDS and AML Post MDS (2010) (17)
Efficacy of tocilizumab in rituximab-refractory cryoglobulinemia vasculitis (2011) (17)
Real life experience with frontline azacitidine in a large series of older adults with acute myeloid leukemia stratified by MRC/LRF score: results from the expanded international E-ALMA series (E-ALMA+) (2018) (17)
Cytogenetics are a predictive factor of response to low dose Ara-C in acute myelogenous leukemia (AML) in the elderly. (1990) (16)
Clinical relevance of clonal hematopoiesis in the oldest-old population. (2021) (16)
The STIMULUS Program: Clinical Trials Evaluating Sabatolimab (MBG453) Combination Therapy in Patients (Pts) with Higher-Risk Myelodysplastic Syndromes (HR-MDS) or Acute Myeloid Leukemia (AML) (2020) (16)
Erdheim-Chester disease associated with chronic myelomonocytic leukemia harboring the same clonal mutation (2019) (16)
Validation of response assessment according to international consortium for MDS/MPN criteria in chronic myelomonocytic leukemia treated with hypomethylating agents (2017) (16)
γ-Irradiation enhances transgene expression in leukemic cells (2003) (16)
Iron overload in patients with sideroblastic anaemia is not related to the presence of the haemochromatosis Cys282Tyr and His63Asp mutations (1999) (16)
Is translocation (8;21) a "favorable" cytogenetic rearrangement in acute myeloid leukemia? (1990) (16)
Expression of lung resistance protein and correlation with other drug resistance proteins and outcome in myelodysplastic syndromes. (1998) (16)
Good predictive value of combined cytogenetic and molecular follow up in chronic myelogenous leukemia after non T-cell depleted allogeneic bone marrow transplantation: a report on 38 consecutive cases. (1995) (16)
Successful xenografts of AML3 samples in immunodeficient NOD/shi-SCID IL2Rγ−/− mice (2012) (16)
Maladies systémiques au cours des syndromes myélodysplasiques (1995) (16)
Multicenter validation of the flow measurement of classical monocyte fraction for chronic myelomonocytic leukemia diagnosis (2018) (16)
Occurrence of myelodysplastic syndrome in 2 patients with reticular dysgenesis. (2011) (15)
Validation of a post-hypomethylating agent failure prognostic model in myelodysplastic syndromes patients treated in a randomized controlled phase III trial of rigosertib vs. best supportive care (2017) (15)
Combination of vorinostat and low dose cytarabine for patients with azacitidine-refractory/relapsed high risk myelodysplastic syndromes. (2014) (15)
Differing clinical features between Japanese and Caucasian patients with myelodysplastic syndromes: Analysis from the International Working Group for Prognosis of MDS. (2018) (15)
Erratum to: Flt3 receptor inhibition reduces constitutive NFκB activation in high-risk myelodysplastic syndrome and acute myeloid leukemia (2008) (15)
Question prompt list responds to information needs of myelodysplastic syndromes patients and caregivers. (2015) (15)
Anti-CD123 Targeted Therapy with Talacotuzumab in Advanced MDS and AML after Failing Hypomethylating Agents - Final Results of the Samba Trial (2018) (15)
Prevalence of UBA1 mutations in MDS/CMML patients with systemic inflammatory and auto-immune disease (2021) (15)
Burkitt's acute lymphocytic leukemia (L3ALL) in adults. (2001) (15)
Molecular prognostic factors in acute myeloid leukemia receiving first-line therapy with azacitidine (2016) (15)
Treatment of Acute Promyelocytic Leukemia with High White Cell Blood Counts. (2011) (15)
Treatment of the 5q- syndrome. (2006) (15)
Oxidized mitochondrial DNA released after inflammasome activation is a disease biomarker for myelodysplastic syndromes. (2021) (15)
Long Term Follow-up and Combined Phase 2 Results of Eprenetapopt (APR-246) and Azacitidine (AZA) in Patients with TP53 mutant Myelodysplastic Syndromes (MDS) and Oligoblastic Acute Myeloid Leukemia (AML) (2021) (15)
Impact of baseline cytogenetic findings and cytogenetic response on outcome of high-risk myelodysplastic syndromes and low blast count AML treated with azacitidine. (2017) (15)
Evaluating safety and efficacy of AMG 531 for the treatment of thrombocytopenic patients with myelodysplastic syndrome (MDS): Preliminary results of a phase 1/2 study (2007) (15)
Surcharge martiale et syndromes myélodysplasiques (SMD) (2001) (15)
Outcome of older (≥70 years) APL patients frontline treated with or without arsenic trioxide—an International Collaborative Study (2020) (15)
A randomized phase-I/II multicenter study of recombinant human granulocyte-macrophage colony-stimulating factor (GM-CSF) therapy for patients with myelodysplastic syndromes and a relatively low risk of acute leukemia (1992) (15)
High Response Rate to Darbopoetin Alfa in “Low Risk” MDS : Results of a Phase II Study. (2004) (15)
Mutations of PTPN11 are rare in adult myeloid malignancies. (2005) (15)
Acute myeloblastic leukemia (AML) with inv (16)(p13;q22) and the rare I type CBFβ-MYH11 transcript: report of two new cases (2002) (15)
AML-063: A Randomized, Double-Blind, Placebo-Controlled Study of Venetoclax with Azacitidine Versus Azacitidine in Treatment-Naïve Patients with Acute Myeloid Leukemia Ineligible for Intensive Therapy-Viale-A (2020) (14)
Recurrent in-frame insertion in C/EBPα TAD2 region is a polymorphism without prognostic value in AML (2008) (14)
The role of all-trans-retinoic acid in the treatment of acute promyelocytic leukemia. (1993) (14)
BCL2L10 positive cells in bone marrow are an independent prognostic factor of azacitidine outcome in myelodysplastic syndrome and acute myeloid leukemia (2017) (14)
Application of the international scoring system for myelodysplasia to M.D. Anderson patients [3] (multiple letters) (1997) (14)
Thrombotic microangiopathy: a new dose-limiting toxicity of high-dose sequential chemotherapy (2001) (14)
Secondary acute lymphoblastic leukemia with t (4; 11): Report on two cases and review of the literature (1992) (14)
Trisenox (R) (arsenic trioxide) in patients with myelodysplastic syndromes (MDS): Preliminary results of a phase I/II study. (2004) (14)
Prognostic impact of DDX41 germline mutations in intensively treated acute myeloid leukemia patients: an ALFA-FILO study. (2022) (14)
Role of JAK 2 Mutation Detection in Budd-Chiari Syndrome (BCS) and Portal Vein Thrombosis (PVT) Associated to MPD. (2006) (14)
Abstract CT068: Phase Ib/II combination study of APR-246 and azacitidine (AZA) in patients withTP53mutant myelodysplastic syndromes (MDS) and acute myeloid leukemia (AML) (2018) (13)
Is ARAC Required in the Treatment of Newly Diagnosed APL? Results of a Randomized Trial (APL 2000). (2004) (13)
The Effect of Lenalidomide on Health‐Related Quality of Life in Patients With Lower‐Risk Non‐del(5q) Myelodysplastic Syndromes: Results From the MDS‐005 Study (2017) (13)
Hydroxyurea-induced apoptosis in an EBV-immortalized lymphoblastoid cell line. (2004) (13)
Evolving characteristics and outcome of secondary acute promyelocytic leukemia (APL): A prospective analysis by the French‐Belgian‐Swiss APL group (2015) (13)
Incidence of ATRX mutations in myelodysplastic syndromes, the value of microcytosis (2015) (13)
S837 TREATMENT WITH IMETELSTAT PROVIDES DURABLE TRANSFUSION INDEPENDENCE (TI) IN HEAVILY TRANSFUSED NON-DEL(5Q) LOWER RISK MDS (LR-MDS) RELAPSED/REFRACTORY (R/R) TO ERYTHROPOIESIS STIMULATING AGENTS (ESAS) (2019) (13)
Immunological detection of myeloperoxidase in poorly differentiated acute leukemia (1993) (13)
INTERFERON ALPHA‐2b THERAPY IN REFRACTORY ADULT CHRONIC THROMBOCYTOPENIC PURPURA (1991) (13)
Efficacy and Safety of Lenalidomide (LEN) Versus Placebo (PBO) in RBC-Transfusion Dependent (TD) Patients (Pts) with IPSS Low/Intermediate (Int-1)-Risk Myelodysplastic Syndromes (MDS) without Del(5q) and Unresponsive or Refractory to Erythropoiesis-Stimulating Agents (ESAs): Results from a Randomize (2014) (13)
PML–RARα ligand-binding domain deletion mutations associated with reduced disease control and outcome after first relapse of APL (2010) (13)
Inactivation of the p53 gene in leukemias and myelodysplastic syndrome (MDS) with 17p monosomy. (1994) (13)
Hepatosplenic candidiasis: an overlooked cause of prolonged fever during recovery from an episode of neutropenia. (1989) (13)
Persistence of AML1/ETO fusion mRNA in t(8;21) acute myeloid leukemia (AML) in prolonged remission: is there a consensus? (1996) (13)
Translocation (3;13)(q27;q14): a nonrandom and probably secondary structural change in non-Hodgkin lymphomas. (1998) (13)
Unlike AML1, CBFbeta gene is not deregulated by point mutations in acute myeloid leukemia and in myelodysplastic syndromes. (2002) (13)
Predicting outcome of patients with myelodysplastic syndromes after failure of azacitidine: validation of the North American MDS consortium scoring system (2016) (13)
Successful autologous bone marrow transplantation in second remission of malignant histiocytosis. (1990) (13)
Idasanutlin plus cytarabine in relapsed or refractory acute myeloid leukemia: results of the MIRROS trial (2022) (13)
P 53 Gene Mutations in Acute Myeloid Leukemia With 17 p Monosomy (2003) (13)
Recombinant human erythropoietin at high dose is effective for the treatment of the anemia of myelodysplastic syndromes. (1991) (13)
Cytomorphology review of 100 newly diagnosed lower-risk MDS patients in the European LeukemiaNet MDS (EUMDS) registry reveals a high inter-observer concordance (2017) (12)
Treatment of acute promyelocytic leukaemia. (2001) (12)
Eltrombopag for the Treatment of Thrombocytopenia of Low and Intermediate-1 IPSS Risk Myelodysplastic Syndromes: Interim Results on Efficacy, Safety and Quality of Life of an International, Multicenter Prospective, Randomized, Trial (2015) (12)
HIGH LEVELS OF SOLUBLE INTERLEUKIN‐2 RECEPTOR IN THE SERUM OF 30 PATIENTS WITH IDIOPATHIC HYPEREOSINOPHILIC SYNDROME (1990) (12)
Early Mortality in 1000 Newly Diagnosed MDS Patients with Low- and Intermediate-1 Risk MDS in the European Leukemianet MDS (EUMDS) Registry (2012) (12)
The effects of continued azacitidine treatment cycles on response in higher risk patients with myelodysplastic syndromes: an update (2008) (12)
Myelodysplastic syndrome (MDS) with isolated trisomy 8: a type of MDS frequently associated with myeloproliferative features? A report by the Groupe Francophone des Myélodysplasies (2018) (12)
Outcome of patients treated for myelodysplastic syndromes without deletion 5q after failure of lenalidomide therapy (2017) (12)
Bortezomib combined with low‐dose cytarabine in Intermediate‐2 and high risk myelodysplastic syndromes. A phase I/II Study by the GFM (2012) (12)
When can real-time quantitative RT-PCR effectively define molecular relapse in acute promyelocytic leukemia patients? (Results of the French Belgian Swiss APL Group). (2009) (12)
Absence of somatic mutations within the Runt domain of AML2/RUNX3 in acute myeloid leukaemia (2003) (12)
Long-Term Outcome in Polycythemia Vera (PV): Final Analysis of a Randomized Trial Comparing Hydroxyurea (HU) to Pipobroman (Pi). (2008) (12)
Cutaneous granulocytic sarcoma arising at the site of radiotherapy for breast carcinoma. (2001) (12)
Oral 9-cis retinoic acid (Alitretinoin) in the treatment of myelodysplastic syndromes: results from a pilot study (2000) (12)
Implications of TP53 allelic state for genome stability, clinical presentation and outcomes in myelodysplastic syndromes (2020) (12)
Giant-cell arteritis associated with myelodysplastic syndrome: French multicenter case control study and literature review. (2019) (12)
A European survey on the detection and management of iron overload in transfusion-dependent patients with MDS (2011) (12)
Influence of Karyotype On Overall Survival in Patients with Higher-Risk Myelodysplastic Syndrome Treated with Azacitidine or a Conventional Care Regimen. (2009) (12)
Azacitidine prolongs overall survival and reduces infections and hospitalizations in patients with WHO-defined acute myeloid leukaemia compared with conventional care regimens: an update (2008) (12)
Darbepoetin alfa in anemia of myelodysplastic syndromes: present and beyond (2010) (12)
Gamma-irradiation enhances transgene expression in leukemic cells. (2003) (12)
Enasidenib (ENA) Is Effective in Patients with IDH2 Mutated Myelodysplastic Syndrome (MDS) : The Ideal Phase 2 Study By the GFM Group (2021) (12)
Erythema elevatum diutinum and chronic lymphocytic leukaemia (1994) (12)
Rare occurrence of mutations of the FLR exon of the neurofibromatosis 1 (NF1) gene in myelodysplastic syndromes (MDS) and acute myeloid leukemia (AML) (1993) (12)
Myelodysplastic syndromes with single neutropenia or thrombocytopenia are rarely refractory cytopenias with unilineage dysplasia by World Health Organization 2008 criteria and have favourable prognosis (2016) (12)
Differentiating megakaryocytes in myelodysplastic syndromes succumb to mitochondrial derangement without caspase activation (2007) (12)
Update from an Open-Label Extension Study Evaluating the Long-Term Safety and Efficacy of Romiplostim In Thrombocytopenic Patients (Pts) with Myelodysplastic Syndromes (MDS) (2009) (12)
A Phase II prospective trial of azacitidine in steroid-dependent or refractory systemic autoimmune/inflammatory disorders and VEXAS syndrome associated with MDS and CMML (2022) (12)
Myelodysplasia syndromes during pregnancy (1991) (12)
Hypomethylating Agents as Bridging Therapy before Allogeneic Hematopoietic Stem Cell Transplantation in Patients with Chronic Myelomonocytic Leukemia? (2016) (11)
14 A PHASE 2, DOSE-FINDING STUDY OF SOTATERCEPT (ACE-011) IN PATIENTS WITH LOWER-RISK MYELODYSPLASTIC SYNDROMES (MDS) OR NON-PROLIFERATIVE CHRONIC MYELOMONOCYTIC LEUKEMIA (CMML) AND ANEMIA REQUIRING TRANSFUSION (2015) (11)
Frequent antibody production against RARα in both APL mice and patients (2006) (11)
Treatment of myelodysplastic syndrome with thrombomimetic drugs. (2015) (11)
Long-term follow-up of autologous stem cell transplantation after intensive chemotherapy in patients with myelodysplastic syndrome or secondary acute myeloid leukemia. (2006) (11)
Supportive care including growth factors in myelodysplastic syndromes. (2004) (11)
Time-dependent decision analysis: Stable disease in azacitidine (AZA)-treated patients (pts) with higher-risk MDS. (2010) (11)
Translocation (1;7) in a case of secondary chronic myelomonocytic leukemia. (1987) (11)
p 16 INK 4 a and p 15 INK 4 b gene methylations in plasma cells from monoclonal gammopathy of undetermined significance (2001) (11)
Cytokine-like protein 1-induced survival of monocytes suggests a combined strategy targeting MCL1 and MAPK in CMML. (2021) (11)
Translocation t(10;17)(p13;q12) in two cases of acute nonlymphocytic leukemia with phagocytic activity of blasts. A new cytogenetic entity? (1989) (11)
Interim Results of A Randomized Phase II Trial of Azacitidine (AZA) +/− Epo In Lower Risk Myelodysplastic Syndrome (MDS) Resistant to An Erythropoietic Stimulating Agent (ESA) Alone (2010) (11)
Personalized Medicine for TP53 Mutated Myelodysplastic Syndromes and Acute Myeloid Leukemia (2021) (11)
Results of a Phase II Study of Guadecitabine (SGI-110) in Higher Risk MDS, CMML or Low Blast Count AML Patients Refractory to or Relapsing after Azacitidine (AZA) Treatment (2016) (11)
Dyserythropoiesis evaluated by the RED score and hepcidin:ferritin ratio predicts response to erythropoietin in lower-risk myelodysplastic syndromes (2018) (11)
Long-term survivors in myelodysplastic syndromes: a report on 63 cases and comparison with short and intermediate survivors. (1993) (11)
Favourable outcome in an APL patient with PLZF/RARalpha fusion gene: quantitative real-time RT-PCR confirms molecular response. (2006) (11)
Relationship of different platelet response criteria and patient outcomes in a romiplostim myelodysplastic syndromes trial (2014) (11)
Cytogenetic abnormalities in Tunisian de novo myelodysplastic syndrome: a comparison with other populations. (2008) (11)
Present results of the treatment of myelodysplastic syndromes with low-dose cytosine arabinoside. Preliminary results of a cooperative protocol (38 patients) and review of the literature. (1987) (11)
Association between health literacy, communication and psychological distress among myelodysplastic syndromes patients. (2018) (10)
Effects of Azacitidine (AZA) Vs Conventional Care Regimens (CCR) in Elderly (≥75 years) Patients (Pts) with Myelodysplastic Syndromes (MDS) from the AZA-001 Survival Trial (2008) (10)
Toxic iron species in lower-risk myelodysplastic syndrome patients: course of disease and effects on outcome (2020) (10)
Characteristics and outcome of patients with low-/intermediate-risk acute promyelocytic leukemia treated with arsenic trioxide: an international collaborative study (2021) (10)
Phase II trial of CPT-11 in myelodysplastic syndromes with excess of marrow blasts (2003) (10)
A Phase II Study of Post–Remission Therapy with Azacitidine (AZA) in Patients with AML Post-MDS and High-Risk MDS: A GFM Group Study. (2009) (10)
Addition of suberoylanilide hydroxamic acid (Vorinostat) to azacitidine for patients with higher risk myelodysplastic syndromes and azacitidine failure: a phase II add‐on study from the Groupe Francophone des Myelodysplasies (2018) (10)
Guideline-based indicators for adult patients with myelodysplastic syndromes. (2020) (10)
Impact of somatic mutations on response to lenalidomide in lower-risk non-del(5q) myelodysplastic syndromes patients (2020) (10)
GEP analysis validates high risk MDS and acute myeloid leukemia post MDS mice models and highlights novel dysregulated pathways (2016) (10)
Detection of BCR-ABL transcripts in chronic myeloid leukemia (CML) using an in situ RT-PCR assay (1999) (10)
Imetelstat Treatment Leads to Durable Transfusion Independence (TI) in RBC Transfusion-Dependent (TD), Non-Del(5q) Lower Risk MDS Relapsed/Refractory to Erythropoiesis-Stimulating Agent (ESA) Who Are Lenalidomide (LEN) and HMA Naive (2018) (10)
Treatment of advanced myelodysplastic syndrome with demethylating agents: azacitidine. (2012) (10)
Absence of germline mutations of exons 5 to 8 of the P53 gene in 26 breast cancer families from the north of France. (1993) (10)
USAID Associated with Myeloid Neoplasm and VEXAS Syndrome: Two Differential Diagnoses of Suspected Adult Onset Still’s Disease in Elderly Patients (2021) (10)
Cytological and ultrastructural assessment of free crystals or precipitates associated with pseudoleukocytosis and pseudothrombocytosis in cryoglobulinemia. (1989) (10)
Toxic iron species in lower-risk myelodysplastic syndrome patients: course of disease and effects on outcome (2020) (10)
Impact of ATRA Duration during the Induction Treatment of Newly Diagnosed APL (2008) (10)
CPX 351 As First Line Treatment in Higher Risk MDS. a Phase II Trial By the GFM (2021) (10)
Allogeneic hematopoietic stem cell transplantation in elderly patients with acute myeloid leukemia or myelodysplastic syndromes: myth and reality (2020) (10)
Philadelphia negative, BCR-ABL positive adult acute lymphoblastic leukemia (ALL) in 2 of 39 patients with combined cytogenetic and molecular analysis. (1993) (10)
Evaluation of allogeneic hematopoietic SCT in younger adults with adverse karyotype AML (2012) (10)
Frequent antibody production against RARalpha in both APL mice and patients. (2006) (10)
A Randomized Phase II Study of Azacitidine (AZA) Alone or with Lenalidomide (LEN), Valproic Acid (VPA) or Idarubicin (IDA) in Higher-Risk MDS: Gfm's 'pick a Winner' Trial (2018) (10)
Panobinostat Plus Azacitidine in Adult Patients with MDS, CMML, or AML: Results of a Phase 2b Study (2015) (9)
Phase 3 VERONA study of venetoclax with azacitidine to assess change in complete remission and overall survival in treatment-naïve higher-risk myelodysplastic syndromes. (2021) (9)
Is there still a role for low-dose cytosine arabinoside in de novo acute myeloid leukemia in the elderly? (1993) (9)
Outcome Of Patients With IPSS Intermediate (int) Or High Risk Myelodysplastic Syndrome (MDS) According To Donor Availability: A Multicenter Prospective Non Interventional Study For The SFGM-TC and GFM (2013) (9)
Assessment of P-glycoprotein expression by immunocytochemistry and flow cytometry using two different monoclonal antibodies coupled with functional efflux analysis in 34 patients with acute myeloid leukemia. (1999) (9)
Time for Change? The Why, What and How of Promoting Innovation to Tackle Rare Diseases – Is It Time to Update the EU’s Orphan Regulation? And if so, What Should be Changed? (2020) (9)
p 16 Gene Homozygous Deletions in Acute Lymphoblastic Leukemia (2002) (9)
Optimal sequencing of treatments for patients with myelodysplastic syndromes (2009) (9)
Results of APL 91 European trial combining ATRA and chemotherapy: presentation of APL 1993 trial. (1994) (9)
The VIM3-AraC regimen followed by autologous stem cell transplantation in refractory or relapsing aggressive non-Hodgkin's lymphoma. A prospective study of 71 consecutive cases (1999) (9)
Treatment of myelodysplastic syndromes with excess of blasts by bevacizumab is well tolerated and is associated with a decrease of VEGF plasma level (2011) (9)
Azacitidine improves outcome in higher‐risk MDS patients with chromosome 7 abnormalities: a retrospective comparison of GESMD and GFM registries (2018) (9)
Treatment of newly diagnosed acute promyelocytic leukemia (APL) by a combination of all-trans retinoic acid (ATRA) and chemotherapy. French APL Group. (1994) (9)
Disease-Management of Low- and Intermediate-1 Risk Myelodysplastic Syndromes: Report on 800 Newly Diagnosed MDS Patients From the European LeukemiaNet MDS Registry (2010) (9)
Treatment of Acute Promyelocytic Leukemia with AIDA Based Regimen. Update of a Tunisian Single Center Study (2011) (9)
Predisposition to therapy-related acute leukemia with balanced chromosomal translocations does not result from a major constitutive defect in DNA double-strand break end joining. (2007) (9)
Results from a Global Randomized Phase 3 Study of Guadecitabine (G) Vs Treatment Choice (TC) in 815 Patients with Treatment Naïve (TN) AML Unfit for Intensive Chemotherapy (IC) ASTRAL-1 Study: Analysis By Number of Cycles (2019) (9)
Increased frequency of hematopoietic malignancies in relatives of patients with lymphoid neoplasms: A French case–control study (2009) (9)
The Commands Trial: A Phase 3 Study of the Efficacy and Safety of Luspatercept Versus Epoetin Alfa for the Treatment of Anemia Due to IPSS-R Very Low-, Low-, or Intermediate-Risk MDS in Erythropoiesis Stimulating Agent-Naive Patients Who Require RBC Transfusions (2020) (9)
7 Management of 1000 patients with low- and intermediate-1 risk myelodysplastic syndromes in the European LeukemiaNet MDS Registry (2011) (9)
S879 RESULTS OF ASTRAL-1 STUDY, A PHASE 3 RANDOMIZED TRIAL OF GUADECITABINE (G) VS TREATMENT CHOICE (TC) IN TREATMENT NAÏVE ACUTE MYELOID LEUKEMIA (TN-AML) NOT ELIGIBLE FOR INTENSIVE CHEMOTHERAPY (IC) (2019) (9)
Lenalidomide (LEN) Combined to Intensive Chemotherapy (IC) in AML and Higher Risk MDS with Del 5q. Interim Results of a Phase I/II Study. (2009) (9)
A randomized study of lenalidomide (LEN) with or without EPO in RBC transfusion dependent (TD) IPSS low and int-1 (lower risk) myelodysplastic syndromes (MDS) without del 5q resistant to EPO. (2013) (9)
Azacitidine Treatment for Lenalidomide (LEN)-Resistant Myelodysplastic Syndrome (MDS) with Del 5q (2012) (9)
Induction treatment of acute promyelocytic leukemia using all-trans retinoic acid. Controversies about dosage, advantages and side-effect management. (1994) (9)
[Congenital asplenia, a differential diagnosis of essential thrombocythemia]. (1993) (9)
[Iron overload and myelodysplastic syndromes]. (2001) (8)
Defects of immune surveillance offer new insights into the pathophysiology and therapy of myelodysplastic syndromes (2007) (8)
Azacitidine Prolongs Overall Survival (OS) and Reduces Infections and Hospitalizations in Patients (Pts) with WHO-Defined Acute Myeloid Leukemia (AML) Compared with Conventional Care Regimens (CCR) (2008) (8)
Iron overload of hematological origin: validation of a screening procedure for cardiac overload by MRI in routine clinical practice. (2013) (8)
Lenalidomide (LEN) in INT 2 and High Risk MDS with DEL 5q. Interim Results of a Phase II Trial by the GFM. (2007) (8)
BRIEF COMMUNICATION Good correlation between RT-PCR analysis and relapse in Philadelphia (Ph1)-positive acute lymphoblastic leukemia (ALL) (1997) (8)
Outcome of treatment after first relapse in younger adults with acute myeloid leukemia initially treated by the ALFA-9802 trial. (2012) (8)
Longer-term benefit of luspatercept in transfusion-dependent lower-risk myelodysplastic syndromes with ring sideroblasts. (2022) (8)
Targeting health-related quality of life in patients with myelodysplastic syndromes - Current knowledge and lessons to be learned. (2021) (8)
Clonal dominance is an adverse prognostic factor in acute myeloid leukemia treated with intensive chemotherapy (2020) (8)
Revised-IPSS (IPSS-R) Is a Powerful Tool to Evaluate the Outcome of MDS Patient Treated with Azacitidine (AZA): The Groupe Francophone Des Myelodysplasies (GFM) Experience (2012) (8)
Immunoglobulin and T-cell receptor delta gene rearrangements are rarely found in myelodysplastic syndromes in chronic phase. (1994) (8)
Unusual clonal evolution involving 5q in a case of myelodysplastic syndrome with deletion 5q 31 treated with lenalidomide (2008) (8)
Prospective Comparison of Outcomes with Azacitidine and Decitabine in AML Patients Ineligible for Intensive Chemotherapy. (2022) (8)
Response assessments in low-risk and high-risk myelodysplastic syndromes (MDS). (2005) (8)
A systematic review of higher-risk myelodysplastic syndromes clinical trials to determine the benchmark of azacitidine and explore alternative endpoints for overall survival. (2021) (8)
Subcutaneous or intravenous administration of romiplostim in thrombocytopenic patients with myelodysplastic syndrome (MDS). (2009) (8)
The Use of Hypomethylating Agents (HMAs) in Patients with Relapsed and Refractory Acute Myeloid Leukemia (RR-AML): Clinical Outcomes and Their Predictors in a Large International Patient Cohort (2016) (8)
Efficacy and Safety of Imetelstat in RBC Transfusion-Dependent (TD) IPSS Low/Int-1 MDS Relapsed/Refractory to Erythropoiesis-Stimulating Agents (ESA) (IMerge) (2017) (8)
Thrombopoietin (TPO) Receptor Agonist Eltrombopag in Combination with Azacitidine (AZA) for Primary Treatment of Myelodysplastic Syndromes (MDS) Patients with Thrombocytopenia: Outcomes from the Randomized, Placebo-Controlled, Phase III Support Study (2016) (8)
Sarcome granulocytique orbitaire révélant l’acutisation d’un syndrome myélodysplasique: À propos d’un cas (2004) (8)
Autologous or allogeneic stem cell transplantation as post-remission therapy in refractory or relapsed acute myeloid leukemia after highly intensive chemotherapy (2005) (8)
Phase 3 Study of Lenalidomide (LEN) Vs Placebo in Non-Transfusion Dependent (TD) Low Risk Del(5q) MDS Patients - Interim Analysis of the European Sintra-REV Trial (2020) (8)
Myelodysplasia during the course of myeloma. Restriction of 17p deletion and p53 overexpression to myeloid cells (1998) (8)
Determination of a Phase II Dose of Panobinostat in Combination with 5-Azacitidine in Patients with Myelodysplastic Syndromes, Chronic Myelomonocytic Leukemia, or Acute Myeloid Leukemia (2011) (8)
Bone marrow hypocellularity does not affect tolerance or efficacy of azacitidine in patients with higher‐risk myelodysplastic syndromes (2014) (8)
Clinical characteristics and outcomes according to age in lenalidomide-treated patients with RBC transfusion-dependent lower-risk MDS and del(5q) (2017) (8)
RNA for reverse PCR analysis can be obtained from bone marrow cells prepared for cytogenetic analysis and stored at -20 degrees C for several years. (1995) (8)
Treatment of high-risk MDS patients (pts) with -7/del(7q) with azacitidine (AZA) versus conventional care regimens (CCR): Effects on overall survival (OS) (2008) (8)
Azacytidine (AZA) in MDS (including RAEB-t and CMML) in Patients (pts) ≥ 80 Years: Results of the French ATU Program. (2009) (8)
Impact Of Cytogenetics and Cytogenetic Response On Outcome In Myelodysplastic Syndromes (MDS) treated With Azacitidine (AZA). A Collaborative Study In 878 Patients (2013) (8)
Treatment of Molecular and Clinical Relapse of Acute Promyelocytic Leukemia (APL) with Arsenic Trioxide: Results of the European Registry of Relapsed APL (2010) (8)
Hematologic Responses In Myelodysplastic Syndromes (MDS) Patients Treated with Deferasirox: An EPIC Post-Hoc Analysis Using International Working Group (IWG) 2006 Criteria (2010) (8)
Prognostic significance of p16INK4a immunocytochemistry in adult ALL with standard risk karyotype (2001) (8)
6 Treatment of acute promyelocytic leukaemia (1996) (7)
MIRROS: An ongoing randomized phase 3 trial of idasanutlin + ARA-C in patients with relapsed or refractory acute myeloid leukemia. (2019) (7)
Gene Homozygous Deletions in Acute Lymphoblastic Leukemia (2002) (7)
Allogeneic Hematopoietic Stem Cell Transplantation Following the Use of Hypomethylating Agents among Patients with Relapsed or Refractory AML: Findings from an International Retrospective Study. (2018) (7)
Prolonged Survival without Complete Remission (CR) In AML Patients (Pts) Treated with Azacitidine (AZA) (2010) (7)
Flt3 Receptor Inhibition Abolishes Constitutive NFκB Activation in High-Risk Myelodysplastic Syndrome and Acute Myeloid Leukemia. (2007) (7)
Translocation t(1;19)(q23;p13) in acute lymphoblastic leukemia. A report on six new cases and an unusual t(17;19)(q11;q13), with special reference to prognostic factors. (1989) (7)
Effect of Priming with Granulocyte-Macrophage Colony-Stimulating Factor (GM-CSF) in Younger Adults with Newly Diagnosed Acute Myeloid Leukemia (AML): A Trial by the Acute Leukemia French Association (ALFA) Group. (2005) (7)
Outcome of patients treated for myelodysplastic syndromes with 5q deletion after failure of lenalidomide therapy. (2017) (7)
SY-1425, a Potent and Selective RARα Agonist, in Combination with Azacitidine Demonstrates a High Complete Response Rate and a Rapid Onset of Response in RARA-Positive Newly Diagnosed Unfit Acute Myeloid Leukemia (2020) (7)
Response to Azacytidine (AZA) in MDS or AML with Del 5q : Current Results of the French ATU Program (2008) (7)
p16(INK4a) immunocytochemical analysis is an independent prognostic factor in childhood acute lymphoblastic leukemia. (2002) (7)
T-cell acute lymphoblastic leukemia occurring in the course of B cell chronic lymphocytic leukemia: a case report. (1995) (7)
The Use of Immunosuppressive Therapy (IST) in Patients with the Myelodysplastic Syndromes (MDS): Clinical Outcomes and Their Predictors in a Large International Patient Cohort (2017) (7)
Association of TET2 Alterations with NPM1 Mutations and Prognostic Value in De Novo Acute Myeloid Leukemia (AML). (2009) (7)
[Hemophagocytic syndrome associated with herpes simplex virus. Apropos of a case with a fatal outcome]. (1986) (7)
A phase II study of intensive chemotherapy with fludarabine, cytarabine, and mitoxantrone in P glycoprotein-negative high-risk myelodysplastic syndromes. (2004) (7)
Clinical Relevance of Clonal Hematopoiesis in the Oldest-Old Population (2020) (7)
Clinical spectrum, outcome and management of immune thrombocytopenia associated with myelodysplastic syndromes and chronic myelomonocytic leukemia (2021) (7)
Treatment With Decitabine (DAC) After Azacitidine (AZA) Failure In High Risk Myelodysplastic Syndrome (MDS) and Advanced Chronic Myelomonocytic Leukemia (CMML) (2013) (7)
An Association Between the Common Hereditary Hemochromatosis Mutation and the Factor V Leiden Allele in a Population With Thrombosis (1998) (7)
[Influence of pregnancy on the development of Hodgkin's disease]. (1988) (7)
Vasculitis associated with myelodysplastic syndrome and chronic myelomonocytic leukemia: French multicenter case-control study. (2020) (7)
Lenalidomide Treatment Is Not Related to AML Progression Risk but Is Associated with a Survival Benefit in RBC Transfusion-Dependent Patients with IPSS Low- or Int-1-Risk MDS with del5q: Results From a Comparative Study (2011) (7)
Prognostic impact of JAK2V617F mutation in myelodysplatic syndromes: A matched case control study☆ (2013) (7)
Outcome of patients treated for myelodysplastic syndromes with 5q deletion after failure of lenalidomide therapy (2017) (7)
Localization of the NRAS:BCL-2 complex determines anti-apoptotic features associated with progressive disease in myelodysplastic syndromes. (2013) (6)
Safety profile of lenalidomide in patients with lower-risk myelodysplastic syndromes without del(5q): results of a phase 3 trial (2018) (6)
Neutrophil and platelet increases with luspatercept in lower-risk MDS: secondary endpoints from the MEDALIST trial (2021) (6)
Clinical Relevance of Cardiac Iron Overload Estimated by MRI T2* in Regularly Transfused Low Risk MDS. (2006) (6)
Molecular Characterization of the Idiopathic Hypereosinophilic Syndrome (HES) in 35 French Patients with Normal Conventional Cytogenetics. (2004) (6)
Analysis of p 53 Antibodies in Patients with Various Cancers Define B-Cell Epitopes of Human p 53 : Distribution on Primary Structure and Exposure on Protein Surface 1 (2006) (6)
Romiplostim in Thrombocytopenic Patients (Pts) with Low-Risk or Intermediate-1 (Int-1)-Risk Myelodysplastic Syndrome (MDS) Results in Reduced Bleeding without Impacting Leukemic Progression: Updated Follow-up Results from a Randomized, Double-Blind, Placebo (PBO)-Controlled Study (2015) (6)
Early lenalidomide (LEN) dose intensity and durable RBC-transfusion independence (RBC-TI) in patients (pts) with low-/int-1-risk myelodysplastic syndromes (MDS) and del5q. (2011) (6)
Polymorphism of the proto-oncogene ETS-1 in hematological malignancies. (1990) (6)
Health-Related Quality of Life Outcomes in Patients with Myelodysplastic Syndromes with Ring Sideroblasts Treated with Luspatercept in the Medalist Study (2020) (6)
Azacytidine in refractory or relapsed AML after intensive chemotherapy (IC): results of the French ATU Program (2010) (6)
Lenalidomide-mediated erythroid improvement in non-del(5q) myelodysplastic syndromes is associated with bone marrow immuno-remodeling (2018) (6)
Arsenic Trioxide (ATO) In the Consolidation Treatment of Newly Diagnosed APL - First Interim Analysis of a Randomized Trial (APL 2006) by the French Belgian Swiss APL Group (2010) (6)
Autoantibodies in myelodysplastic syndromes and chronic myelomonocytic leukemia (2019) (6)
Very low incidence of p53 antibodies in adult non‐Hodgkin's lymphoma and multiple myeloma (1998) (6)
Efficacy and Safety of Luspatercept Treatment in Patients with Myelodysplastic Syndrome/Myeloproliferative Neoplasm with Ring Sideroblasts and Thrombocytosis (MDS/MPN-RS-T): A Retrospective Analysis from the Medalist Study (2020) (6)
Low-dose cytosine arabinoside in adult chronic myelomonocytic leukemia. (1987) (6)
Novel dynamic outcome indicators and clinical endpoints in myelodysplastic syndrome; the European LeukemiaNet MDS Registry and MDS-RIGHT project perspective (2020) (6)
Meeting report: myelodysplastic syndromes at ASH 2007 (2008) (6)
Eltrombopag for myelodysplastic syndromes or chronic myelomonocytic leukaemia with no excess blasts and thrombocytopenia: a French multicentre retrospective real‐life study (2021) (6)
Venetoclax and azacitidine combination in chemotherapy ineligible untreated patients with therapy-related myeloid neoplasms, antecedent myelodysplastic syndromes, or myelodysplastic/myeloproliferative neoplasms. (2021) (6)
Guadecitabine in myelodysplastic syndromes: promising but there is still progress to be made. (2019) (6)
Interleukin-3 plus low-dose cytosine arabinoside for advanced myelodysplasia: a pilot study. EORTC Leukemia Group. (1996) (6)
[p53 and hematologic malignancies]. (1997) (6)
Phase II Study of Oral Rigosertib Combined with Azacitidine (AZA) As First Line Therapy in Patients (Pts) with Higher-Risk Myelodysplastic Syndromes (HR-MDS) (2019) (6)
Challenges of phase III trial design for novel treatments in diseases with no standard treatment: the AZA-001 myelodysplasia study model. (2014) (6)
Cutaneous sclerosis, aplastic anemia, and antithymocyte globulin. (1989) (6)
Refractory Thrombocytopenia and Neutropenia: a Diagnostic Challenge (2015) (6)
Low-Dose Clofarabine Has Significant Activity in High-Risk Myelodysplastic Syndromes (MDS) and Acute Myeloid Leukemia Post-MDS (sAML) After Azacitidine (AZA) Failure: Interim Results of the GFM Clo08 Dose Escalating Phase I/II Study (NCT0106325) (2011) (6)
Frequency of molecular elimination of Ph1 clone in chronic myelogenous leukemia (CML) with interferon alpha. (1996) (6)
Primary Central Nervous System Lymphoma in Immunocompetent Adults: Poor Results Mainly Associated with High Treatment Related Toxicities (2002) (6)
Spontaneous conception after autologous hematopoietic stem cell transplantation: a case report. (2013) (6)
Eltrombopag In Combination With Azacitidine For First-Line Treatment Of Mds Patients With Thrombocytopenia : The Randomized, Placebo-Controlled, Phase Iii, Support Study (2017) (6)
Identification of clonal skin myeloid cells by next‐generation sequencing in myelodysplasia cutis (2020) (6)
Isolated pericardial and mediastinal relapse following allogeneic bone marrow transplantation for acute lymphoblastic leukemia. (1991) (6)
P135 Has treatment with EPO+/-G-CSF an impact on progression to AML and survival in low/int-1-risk MDS? A comparison between French-EPO patients and the IMRAW database (2007) (6)
Traitement des syndromes myélodysplasiques (1996) (6)
Cardiac failure in patients treated with azacitidine, a pyrimidine analogue: Case reports and disproportionality analyses in Vigibase (2020) (6)
Syndromes myélodysplasiques et délétion 5q (1995) (5)
Absence of BCR-ABL rearrangement (with m-bcr breakpoint) in chronic myelomonocytic leukemia. (1994) (5)
Health-Related Quality of Life Outcomes in Patients with Myelodysplastic Syndromes with Ring Sideroblasts Treated with Luspatercept in the MEDALIST Phase 3 Trial (2021) (5)
Development of a core outcome set for myelodysplastic syndromes – a Delphi study from the EUMDS Registry Group (2020) (5)
Which lower risk myelodysplastic syndromes should be treated with allogeneic hematopoietic stem cell transplantation? (2020) (5)
Effects of azacitidine in 93 patients with IDH1/2 mutated acute myeloid leukemia/myelodysplastic syndromes: a French retrospective multicenter study (2020) (5)
Development and Validation of a New Prognostic Model for Myelodysplastic Syndrome (MDS) That Accounts for Events Not Considered by the International Prognostic Scoring System (IPSS) (2008) (5)
Usefulness of electron microscopy in the diagnosis of congenital dyserythropoietic anemia type I: Report of a case (1991) (5)
Les agents hypométhylants dans le traitement des syndromes myélodysplasiques (2011) (5)
Treatment of Lower Risk MDS with Del 5q with Lenalidomide (LEN): Results of the French ATU Program. (2009) (5)
Non-del(5q) myelodysplastic syndromes-associated loci detected by SNP-array genome-wide association meta-analysis. (2019) (5)
Place de la double induction dans le traitement des leucémies aiguës myéloblastiques de l'adulte : résultats intermédiaires du protocole LAM90 (1994) (5)
[Orbital granulocytic sarcoma revealing acute myeloblastic syndrome: a case study]. (2004) (5)
Sequential Treatment with 5-Azacytidine, Valproic Acid (VPA), and All-Trans Retinoic Acid (ATRA) in Patients with High-Risk Acute Myeloid Leukemia (AML). (2005) (5)
Aggressive chemotherapy in adult primary myelodysplastic syndromes (1988) (5)
Treatment of myelodysplastic syndromes (MDS) and high leukaemic risk with low-dose cytosine arabinoside (LD-AraC) plus granulocyte-macrophage colony-stimulating factor (rh GM-CSF) (1992) (5)
Clonal hematopoiesis driven by chromosome 1q/MDM4 trisomy defines a canonical route toward leukemia in Fanconi anemia. (2023) (5)
Granulomonocytic progenitors are key target cells of azacytidine in higher risk myelodysplastic syndromes and acute myeloid leukemia (2018) (5)
A Phase I-II Study Of The Efficacy and Safety Of Lenalidomide (LEN) Combined To Azacitidine (AZA) In Higher Risk MDS and AML With Del 5q – A Study By The Groupe Francophone Des Myelodysplasies (GFM) (2013) (5)
Segmental Coecal Cytomegalovirus Colitis During Fludarabine, Cytarabine and Mitoxantrone Induction Chemotherapy for Myelodysplastic Syndrome (2002) (5)
A phase II study of the efficacy and safety of an intensified schedule of azacytidine in intermediate-2 and high-risk patients with myelodysplastic syndromes: a study by the Groupe Francophone des Myelodysplasies (GFM) (2018) (5)
A New Clinically-Based Subclassification Proposal in CMML with Significant Prognostic Implications to Overcome the MDS/MPN Categorizing Dilemma (2016) (5)
Romiplostim in Thrombocytopenic Patients with Low- or Int-1- Risk MDS Results in Reduced Bleeding without Impacting Leukemic Progression: Final Follow-up Results from a Randomized, Double-Blind, Placebo-Controlled Study (2016) (5)
Disclosure of myelodysplastic syndrome diagnosis: improving patients' understanding and experience (2013) (5)
Slow relapse in acute myeloid leukemia with inv(16) or t(16;16) (2009) (5)
Prognostic factors of acute non lymphoblastic leukemia in children and adults. Results from two multicentric trials (705 patients). (1990) (5)
Outcome of Treatment after First Relapse in Adults Patients with Acute Lymphoblastic Leukemia (ALL) Initially Treated by the LALA-94 Trial. (2006) (5)
Thiamine deficiency in a patient receiving chemotherapy for acute myeloblastic leukemia (1999) (5)
Azacytidine (AZA) In Relapsed MDS and AML After Allogeneic Stem Cell Transplantation (allo-HSCT): Results of the French ATU Program. (2010) (5)
BCL-2 Inhibitor Venetoclax (ABT-199) and MEK Inhibitor GDC-0973 Synergise to Target AML Progenitors and Overcome Drug Resistance with the Use of PET Scanning in a Mouse Model of HR-MDS to Monitor Response to Treatment (2018) (5)
Prognostic Factors and Response Duration in 419 MDS Treated with Erythropoietin±GCSF: The GFM Experience. (2006) (5)
Treatment of Newly Diagnosed Acute Promyelocytic Leukemia (APL) in the Elderly: A Joint Analysis of the French -Belgian-Swiss and PETHEMA Groups. (2009) (5)
Effect of olutasidenib (FT-2102) on complete remissions in patients with relapsed/refractory (R/R) mIDH1 acute myeloid leukemia (AML): Results from a planned interim analysis of a phase 2 clinical trial. (2021) (5)
Prognostic Value of TP53 Gene Mutations in Higher Risk MDS Treated with Azacitidine (2012) (5)
A Phase II Study of the Combination of Oral Rigosertib and Azacitidine in Patients with Myelodysplastic Syndromes (MDS) (2015) (5)
Chronic myelogenous leukemia with t(9;22) and t(8;11): a new chromosome anomaly. (1987) (5)
In vitro stimulation of erythropoiesis by stem cell factor alone in myelodysplastic syndrome patients with elevated endogenous erythropoietin serum levels. (1996) (5)
Long Term Effects of Eltrombopag Treatment Versus Placebo for Low-Risk Myelodysplastic Syndromes with Thrombocytopenia (EQoL-MDS): Interim Results of a Single-Blind, Randomised, Controlled, Phase 2 Superiority Trial (2019) (5)
Acadesine Circumvents Azacitidine Resistance in Myelodysplastic Syndrome and Acute Myeloid Leukemia (2019) (5)
Risk of AML Evolution In Lower Risk MDS with Del 5q Treated with or without Lenalidomide. A Report by the Groupe Francophone Des Myelodysplasies (GFM) (2010) (5)
How I Treat TP53-Mutated Acute Myeloid Leukemia and Myelodysplastic Syndromes (2022) (5)
Congenital diserythropoietic anemia type I (1990) (5)
Targeting NF-jB in hematologic malignancies (2006) (5)
Treatment of High Risk MDS and AML Post-MDS with Azacytidine (AZA): Preliminary Results of the French ATU Program. (2006) (5)
Proposal for a new risk model in myelodysplastic syndrome (MDS) that accounts for events not considered in the original International Prognostic Scoring System (IPSS) (2008) (5)
P-104 Outcomes by IPSS-R in lenalidomide-treated patients with IPSS low-/Int-1-risk MDS With del(5q) in MDS-003 and MDS-004: A retrospective analysis (2013) (4)
Core set of patient-reported outcomes for myelodysplastic syndromes: an EUMDS Delphi study involving patients and hematologists (2021) (4)
Which AML Subsets Benefit from Leukemic Cell Priming during Chemotherapy? Long-Term Analysis of the ALFA-9802 GM-CSF Study (2008) (4)
Safety of Lenalidomide (LEN) 10mg in Non-Del(5q) Versus Del(5q) in the Treatment of Patients (Pts) with Lower-Risk Myelodysplastic Syndromes (MDS): Pooled Analysis of Treatment-Emergent Adverse Events (TEAEs) (2015) (4)
Absence of rearrangement of proto‐oncogene MET in 88 cases of myelodysplastic syndromes (MDS) (1989) (4)
195 Autologous bone marrow (ABMT) or peripheral blood stem cell (ABSCT) transplantation after intensive chemotherapy in myelodysplastic syndromes (MDS) (1997) (4)
The first international meeting on V617F JAK2 mutation and its relevance in Philadelphia-negative myeloproliferative disorders. (2007) (4)
Prise en charge des myélodysplasies (2015) (4)
Early paternity and relapse after bone marrow transplantation (1993) (4)
DNA-mediated adjuvant immunotherapy extends survival in two different mouse models of myeloid malignancies (2015) (4)
Achievement of Red Blood Cell (RBC) Transfusion Independence with Azacitidine (AZA) Leads to Improved Survival In Patients with Higher-Risk Myelodysplasias Regardless of Baseline Transfusion Needs (2010) (4)
Dual pyroptotic biomarkers predict erythroid response in lower-risk non-del(5q) myelodysplastic syndromes treated with lenalidomide and recombinant erythropoietin (2021) (4)
Effect of Lenalidomide (LEN) Exposure on AML-Free Survival and Overall Survival in LEN-Treated Patients (Pts) with IPSS Low- or Intermediate-1-Risk Myelodysplastic Syndromes (MDS) with Del(5q) (2015) (4)
Myelodysplastic Syndrome (MDS) in France: Results of a One-Week Cross-Sectional Survey on Daily Practice Management in 919 Patients by the GFM (2008) (4)
Predicting the outcome of patients with higher-risk myelodysplastic syndrome treated with hypomethylating agents (2012) (4)
del(17p) in myeloid malignancies (2011) (4)
Finding consistency in classifications of myeloid neoplasms: a perspective on behalf of the International Workshop for Myelodysplastic Syndromes (2022) (4)
Venetoclax and idasanutlin in relapsed/refractory AML: a non-randomized, open-label phase 1b trial. (2022) (4)
A predictive algorithm using clinical and laboratory parameters may assist in ruling out and in diagnosing MDS. (2021) (4)
Outcome of patients less than 55 years of age with high-risk acute leukemia who did not have an human leukocyte antigen-identical related donor: a long-term study of 97 consecutive patients (2005) (4)
Cardiac iron overload assessed by T2* magnetic resonance imaging and cardiac function in regularly transfused myelodysplastic syndrome patients, the GFM experience: response to Bowen et al (2014) (4)
recommendations from an international expert panel, on behalf of the Diagnosis and management of acute myeloid leukemia in adults: (2010) (4)
VIM3‐ARA C: An effective salvage regimen in refractory or recurrent aggressive non hodgkin's lymphoma. A report on 18 cases (2006) (4)
Arsenic Trioxide (ATO) Or ATRA For Consolidation Treatment Of Standard Risk Non Elderly Newly Diagnosed APL– Second Interim Analysis Of a Randomized Trial (APL 2006) By The French Belgian Swiss APL Group (2013) (4)
Personalized medicine in myelodysplastic syndromes: wishful thinking or already clinical reality? (2015) (4)
Treatment With Romiplostim, a Thrombopoietin-Receptor Agonist, In Thrombocytopenic Patients With Low Or Intermediate-1 Risk Myelodysplastic Syndrome: Updated Follow-Up Results For Acute Myeloid Leukemia and Survival From a Randomized, Double-Blind, Placebo-Controlled Study (2013) (4)
Central Nervous System (CNS) at First Relapse In APL. A Report on 2 Multicenter Trials. (2010) (4)
[Hypomethylating agents for the treatment of myelodysplastic syndromes]. (2011) (4)
Lenalidomide with or without Erythropoietin in transfusion dependent erythropoiesis-stimulating agent-refractory lower risk MDS without 5 q deletion Running title : Lenalidomide in transfused non del 5 q low risk MDS (2015) (4)
Combination of Oral Rigosertib and Injectable Azacitidine in Patients with Myelodysplastic Syndromes (MDS): Results from a Phase II Study (2016) (4)
Association Of Cytogenetic Response (CyR) With RBC Transfusion-Independence (RBC-TI) and AML-Free Survival In Lenalidomide (LEN)-Treated Patients (Pts) With IPSS Low-/Int-1-Risk Myelodysplastic Syndromes (MDS) With Del(5q) (2013) (4)
Thalidomide for the Treatment of Low Risk Myelodysplasia. (2004) (4)
Late Relapses in APL Treated with ATRA and Anthracycline Based Chemotherapy: The European APL Group Experience (APL 91 and APL 93 Trials). (2005) (4)
A Randomized, Double-Blind, Placebo-Controlled, Phase II Study of MBG453 Added to Hypomethylating Agents (HMAs) in Patients (pts) with Intermediate, High, or Very High Risk Myelodysplastic Syndrome (MDS): Stimulus-MDS1 (2019) (4)
Acute colonic pseudo‐obstruction (ogilvie's syndrome) during induction treatment with chemotherapy and all‐trans‐Retinoic Acid for acute promyelocytic leukemia (1995) (4)
diagnosed acute promyelocytic leukemia: a pilot study on 26 cases complete remission rate and may prolong remissions in newly All-transretinoic acid followed by intensive chemotherapy gives a high (2011) (4)
Low dose IL-2 in patients with steroid-dependent dysimmune manifestations associated with myelodysplastic syndromes: a three-case report. (2020) (4)
Correlation Between Decreased Serum Ferritin and Improved Liver Transaminases During Deferasirox (Exjade®) Treatment in Iron-Overloaded Patients with Myelodysplastic Syndromes. (2009) (4)
Erythropoietin for the anemia of low-risk myelodysplastic syndromes (2005) (4)
Phase 3, Multi-Center, International, Randomized, Double-Blind, Placebo Controlled Study of Oral Rigosertib + Injectable Azacitidine (AZA) Versus Injectable Azacitidine in Treatment-Naive Patients with Higher-Risk Myelodysplastic Syndrome (HR-MDS) (2019) (4)
Prognostic Relevance of the Kinetics of Worsening of Cytopenias in Lower-Risk MDS: A Substudy From the European Leukemianet Low Risk MDS (EUMDS) Registry (2012) (4)
P140 Reduction in serum ferritin (SF) is associated with improvement in liver transaminase levels during treatment with deferasirox (Exjade®) in ironoverloaded patients with myelodysplastic syndromes (MDS) (2009) (4)
Outcome of Patients (pts) Treated for Myelodysplastic Syndrome (MDS) and Secondary Acute Myeloid Leukemia (s AML) After Azacitidine (AZA) Failure (2010) (4)
A randomised phase II study of azacitidine (AZA) alone or with Lenalidomide (LEN), Valproic acid (VPA) or Idarubicin (IDA) in higher‐Risk MDS or low blast AML: GFM's “pick a winner” trial, with the impact of somatic mutations (2022) (4)
Primary Results of Stimulus-MDS1: A Randomized, Double-Blind, Placebo-Controlled Phase II Study of TIM-3 Inhibition with Sabatolimab Added to Hypomethylating Agents (HMAs) in Adult Patients with Higher-Risk Myelodysplastic Syndromes (MDS) (2022) (4)
P-113 Revised International Prognostic Scoring System (IPSS-R) for primary treated myelodysplastic syndromes (MDS) patients: A report from the IWG-PM (2013) (4)
Imerge: A Phase 3 Study to Evaluate Imetelstat in Transfusion-Dependent Subjects with IPSS Low or Intermediate-1 Risk Myelodysplastic Syndromes (MDS) That Is Relapsed/Refractory to Erythropoiesis-Stimulating Agent (ESA) Treatment (2020) (4)
A NEW CASE OF THERAPY‐RELATED ACUTE MYELOID LEUKAEMIA WITH t(8;16)(p11;p13) (1998) (4)
Efficacy of lenalidomide in an sAML patient with del 5q relapsing after reduced-intensity allogeneic stem cell transplantation performed in complete remission (2010) (4)
Phase 1b study of venetoclax in combination with azacitidine in patients with treatment-naïve higher-risk myelodysplastic syndromes. (2018) (4)
Investigation of minimal residual disease in adult Ph1 positive acute lymphoblastic leukemia by a combination of cell sorting and fluorescence in situ hybridization: a preliminary study on 6 cases. (2000) (4)
Molecular Prognostic Factors in Acute Myeloid Leukemia (AML) Patients Receiving First Line Therapy with Azacytidine (AZA) (2014) (4)
Myeloid-Derived Suppressive Cells Belonging to the Leukemic Clone Account for Immunosuppression In CMML (2010) (4)
Arsenic Trioxide-Based Therapy Of Relapsed Acute Promyelocytic Leukemia: Updated Results Of The European Registry Of Relapsed APL (PROMYSE) (2013) (3)
Systemic injection of GM-CSF increases survival in a murine model of acute leukemia. (2002) (3)
Azacitidine (AZA) After Failure of Lenalidomide (LEN) in Low/Int-1 Risk MDS with Del 5q (2011) (3)
Outcome of Patients Treated for Myelodysplastic Syndromes after Failure of Lenalidomide Therapy (2015) (3)
Clinical, Pathological and Molecular Features of Myelodysplasia Cutis. (2021) (3)
Acute myeloblastic leukemia (AML) with inv (16)(p13;q22) and the rare I type CBFbeta-MYH11 transcript: report of two new cases. (2002) (3)
Imerge: A Study to Evaluate Imetelstat (GRN163L) in Transfusion-Dependent Subjects with IPSS Low or Intermediate-1 Risk Myelodysplastic Syndromes (MDS) That Is Relapsed/Refractory to Erythropoiesis-Stimulating Agent (ESA) Treatment (2019) (3)
Consensus proposal for revised International Working Group response criteria for higher risk myelodysplastic syndromes. (2023) (3)
Genetic analysis of therapy-related myeloid neoplasms occurring after intensive treatment for acute promyelocytic leukemia (2018) (3)
Olutasidenib (FT-2102) in Combination with Azacitidine Induces Durable Complete Remissions in Patients with mIDH1 Acute Myeloid Leukemia (2021) (3)
Outcome of lower-risk myelodysplastic syndrome with ring sideroblasts (MDS-RS) after failure of erythropoiesis- stimulating agents. (2020) (3)
Model Heterogeneity in Predicting Outcomes in Patients with Chronic Myelomonocytic Leukemia (CMML): An Overestimation of Survival in Lower-Risk Group (2017) (3)
Analysis of Second Primary Malignancies in Lenalidomide-Treated Patients with IPSS Low- or Int-1-Risk Myelodysplastic Syndromes (2011) (3)
Outcome of Relapsed AML Patients Aged between 50 and 70: The ALFA Group Experience (ALFA 9801 Study). (2007) (3)
Arsenic Trioxide (AS2O3) Therapy for Relapsed Acute Promyelocytic Leukemia (APL): Comparison with a Historic Control Combining All-Trans Retinoic Acid (ATRA) Plus Intensive Chemotherapy. (2005) (3)
Azacytidine in Refractory or Relapsed AML After Intensive Chemotherapy (IC): Results of the French ATU Program. (2009) (3)
Treatment of Newly Diagnosed Acute Promyelocytic Leukemia (APL): A Comparison between French -Belgian-Swiss and Spanish Results. (2005) (3)
An agenda to advance research in MDS: A TOP 10 Priority List from the first international workshop in MDS (iwMDS). (2022) (3)
Phase Ib Study of Oral Panobinostat In Combination with 5-Azacitidine (5-aza) In Patients with Myelodysplastic Syndromes (MDS), Chronic Myelomonocytic Leukemia (CMML), or Acute Myeloid Leukemia (AML) (2010) (3)
Outcomes for Patients (Pts) with Low-/Int-1-Risk Myelodysplastic Syndromes (MDS) with del5q Aged < 65 Years Treated with Lenalidomide (LEN) in MDS-003 and MDS-004: A Retrospective Combined Analysis (2011) (3)
Is Arsenic Trioxide (ATO) Required in the Treatment of Standard Risk Newly Diagnosed APL? Analysis of a Randomized Trial (APL 2006) By the French Belgian Swiss APL Group (2015) (3)
Luspatercept Significantly Reduces Red Blood Cell (RBC) Transfusion Burden, Regardless of Gene Mutation Frequency, Spectrum, and Prognostic Significance, Among Patients (Pts) with LR-MDS Enrolled in the MEDALIST Trial (2019) (3)
Achievement of red blood cell transfusion independence in red blood cell transfusion-dependent patients with lower-risk non-del(5q) myelodysplastic syndromes correlates with serum erythropoietin levels (2020) (3)
Treatment of Acute Promyelocytic Leukemia a Tunisian Single Center Study (2011) (3)
Time Changes In Predictive Power Of MDS Prognostic Scores – Effects On Revised Scores Such As The IPSS-R, Impact Of Age (2013) (3)
Facteurs pronostiques des leucmies aigus et des lymphomes (2002) (3)
The IPSS-R has prognostic impact in untreated patients with MDS del(5q). (2015) (3)
Inflammatory and Immune Disorders Associated with Myelodysplastic Syndromes (2021) (3)
MDS and AML with 17p deletion are associated to specific dysgranulopoiesis and a high incidence of p53 mutations (1994) (3)
Luspatercept for myelodysplastic syndromes/myeloproliferative neoplasm with ring sideroblasts and thrombocytosis (2022) (3)
Mutation Profiles Identify Distinct Clusters of Lower Risk Myelodysplastic Syndromes with Unique Clinical and Biological Features and Clinical Endpoints (2020) (3)
Chronic myeloid leukemia with unusual variant Ph translocation (22;22)(q11;q13). Two cases with chimeric BCR-ABL transcripts. (1990) (3)
Acute Promyelocytic Leukemia in Children: a Report on Eleven Cases. (1990) (3)
Prise en charge des syndromes myélodysplasiques en 2019 : mise au point (2019) (3)
Comparison of TP53 mutations screening by functional assay of separated allele in yeast and next-generation sequencing in myelodysplastic syndromes. (2015) (3)
Incidence and Prognostic Value of TP53 Mutations in Lower Risk MDS with Del 5q. (2012) (3)
Is There a Role for ATRA in Combination to EPO in Lower Risk Myelodysplastic Syndrome? Preliminary Results of a Phase II Study. (2005) (3)
Prognostic Factors of Response and Survival in CMML Patients Treated with Azacitidine (AZA) (2011) (3)
Role of Allogeneic Transplantation In Chronic Myelomonocytic Leukemia: An International Collaborative Analysis. (2022) (3)
Two Distinct Mechanisms Contribute to Granulomonocytic Hyperplasia in Chronic Myelomonocytic Leukemias (CMML) (2012) (3)
279 FREQUENCY OF AUTOANTIBODIES (AAB) IN MDS WITH AND WITHOUT CLINICAL AUTOIMMUNE DISORDERS (AID) (2015) (3)
115 MDS-005 STUDY: EFFECT OF BASELINE ENDOGENOUS EPO ON RBC TRANSFUSION INDEPENDENCE (RBC-TI) IN LENALIDOMIDE-TREATED PATIENTS WITH LOW/INTERMEDIATE-1-RISK MDS WITHOUT DEL(5Q) (2015) (3)
Outcomes and mutational analysis of patients with lower-risk non-del5q myelodysplastic syndrome treated with antithymocyte globulin with or without ciclosporine A. (2018) (3)
Management and Supportive Care Measures of Adverse Events (AEs) in Higher-Risk MDS Patients (Pts) Treated with Azacitidine (AZA) (2008) (3)
[Autologous bone marrow graft in the initial treatment of follicular lymphomas in young high risk subjects. A new therapeutic approach]. (1991) (3)
Prognostic Factors of Long-Term Outcomes In Low- or Int-1-Risk MDS with del5q Treated with Lenalidomide (LEN): Results From a Randomized Phase 3 Trial (MDS-004) (2010) (3)
[Systemic diseases in myelodysplastic syndromes]. (1995) (3)
Machine learning identifies the independent role of dysplasia in the prediction of response to chemotherapy in AML (2021) (3)
Clinical Benefit‐Risk Profile of Lenalidomide in Patients With Lower‐risk Myelodysplastic Syndromes Without del(5q): Results of a Phase III Trial (2019) (3)
On-Target Activity of Imetelstat Correlates with Clinical Benefits, Including Overall Survival (OS), in Heavily Transfused Non-Del(5q) Lower Risk MDS (LR-MDS) Relapsed/Refractory (R/R) to Erythropoiesis Stimulating Agents (ESAs) (2021) (3)
Evolving trends in the treatment of low‐risk myelodysplastic syndromes: immunomodulation and beyond—9th European Hematology Association Congress Geneva, Switzerland, 10–13 June 2004 (2007) (3)
1721P Prolonged positive SARS-CoV-2 RT-PCR in cancer outpatients requires specific reorganization of cancer centres (2020) (3)
Le traitement des lymphomes malins non hodgkiniens (1990) (3)
Potentiation of Apoptosis in MDS/AML by Combination of Azacitidine and the EGFR-Tyrosine Kinase Inhibitor (TKI) erlotinib (2011) (3)
The impact of lenalidomide exposure on response and outcomes in patients with lower-risk myelodysplastic syndromes and del(5q) (2018) (3)
Assessment of PML-RARa Real-Time Quantitative PCR for Definition of Molecular Relapse in APL Patients (Results of the APL Study Group). (2005) (3)
Délétion chromosomique 17p, mutation de P53, anomalie de Pelger-Huët et vacuolisation des granulocytes : une nouvelle entité dans les pathologies myéloïdes ? (1995) (3)
Erythema elevatum diutinum and chronic lymphocytic leukemia. (1994) (3)
Auer rods and differentiation in acute promyelocytic leukemia (2008) (3)
Frontline azacitidine (AZA) or intensive chemotherapy (ICTx) in older AML patients. (2010) (3)
Outcome of APL In Young Children and Adolescents In Two Consecutive Trials of the European APL Group (2010) (3)
[Primary cardiac lymphoma. A new case]. (1990) (3)
Total peroxidase deficiency in eosinophils: A report on twin sisters, one with a refractory anaemia (1987) (3)
Fièvre prolongée au cours d’un syndrome 5q– révélant une transformation blastique extramédullaire (2009) (3)
11 Glutathione S transferase theta 1 (GSTT1) gene defects in myelodysplastic syndromes (MDS) and their correlation with Kryotype and exposure to potential carcinogens (1997) (3)
Azacitidine in patients older than 80 years with acute myeloid leukaemia or myelodysplastic syndromes: a report on 115 patients (2020) (3)
pVAX14DNA-mediated add-on immunotherapy combined with arsenic trioxide and all-trans retinoic acid targeted therapy effectively increases the survival of acute promyelocytic leukemia mice (2015) (2)
A Phase I-II Study of Vorinostat and Low Dose Cytarabine for Patients Treated for High Risk Myelodysplastic with Azacytidine Failure: The GFM-VOR2007 Study (2010) (2)
Multicentric Validation of the Monocyte Assay for Chronic Myelomonocytic Leukemia Diagnosis By Flow Cytometry (2017) (2)
Prognostic Factors Of Response and Survival To Azacitidine (AZA) +/- EPO In RBC Transfusion Dependent (TD) IPSS Low and Int-1 (LR) MDS Resistant To EPO, With Particular Emphasis Of Genetic Lesions: A Study By The GFM (2013) (2)
p53 Mutant Independently Impacts Risk: Analysis of Deletion 5q, Lower-Risk Myelodysplastic Syndromes (MDS) Patients Treated with Lenalidomide (LEN) in the MDS-004 Study (2014) (2)
99 Expression of LRP and its correlation with other drug resistance proteins and outcome in myelodysplastic syndromes (MDS) (1997) (2)
Author Correction: Implications of TP53 allelic state for genome stability, clinical presentation and outcomes in myelodysplastic syndromes (2021) (2)
Validation Of The Revised International Prognostic Scoring System (IPSS-R) In 1000 Newly Diagnosed MDS Patients With Low- and Intermediate-1 Risk MDS In The European Leukemianet MDS (EUMDS) Registry (2013) (2)
Outcomes In RBC Transfusion-Dependent Patients (Pts) With Low-/Intermediate (Int)-1-Risk Myelodysplastic Syndromes (MDS) With Isolated Deletion 5q Treated With Lenalidomide (LEN): A Subset Analysis From The MDS-004 Study (2013) (2)
Olutasidenib (FT-2102) induces durable complete remissions in patients with relapsed or refractory IDH1-mutated AML. (2023) (2)
Health-Related Quality of Life In Newly Diagnosed Low Risk and Intermediate-1 Risk MDS: Report on the First 683 Patients From the European LeukemiaNet Registry (2010) (2)
P-309 Low/intermerdiate-1 risk MDS treated with high-dose rHu-EPO: Hematological responses and impact on quality of life, a prospective GFM study (2013) (2)
Comparative Cost-Effectiveness of Azacitidine Versus Decitabine for the Treatment of Myelodysplastic Syndromes (MDS). (2009) (2)
Should Immunosuppressive Therapy (IST) Be Used More Often In Lower Risk MDS (2010) (2)
Reducing mortality in newly diagnosed standard-risk acute promyelocytic leukemia in elderly patients treated with arsenic trioxide requires major reduction of chemotherapy: a report by the French Belgian Swiss APL group (APL 2006 trial) (2018) (2)
Therapy-related acute promyelocytic leukaemia. (1994) (2)
The EHA Research Roadmap: Malignant Myeloid Diseases (2021) (2)
Lenalidomide (LEN) In Lower-Risk Myelodysplastic Syndromes (MDS) with Karyotypes Other Than Deletion 5q and Refractory to Erythropoiesis-Stimulating Agents (ESAs) (2010) (2)
BCL2L10 (Bcl-B) Is Associated with Resistance to Azacitidine (AZA) in MDS and AML, and Is a Possible Therapeutic Target in AZA Resistant Patients (2012) (2)
RBC Transfusions and Iron Chelation Therapy in Clinical Practice in MDS: A One Month Survey by the GFM. (2006) (2)
Early Deaths (ED) in Acute Promyelocytic Leukemia (APL) in France: A Retrospective Multicenter Study in 355 Patients (pts) (2012) (2)
Evaluation of Salvage Induction Chemotherapy Regimens in Higher Risk Myelodysplastic Syndrome and Acute Myeloid Leukemia after Hypomethylating Agent Treatment Failure (2016) (2)
Impact of Post-Remission Therapy on Survival of Older Patients with AML Treated with Intensive Chemotherapy: Results of the Multicenter ALFA-9803 Trial. (2006) (2)
[Role of double induction in the treatment of acute myeloblastic leukemia in the adult: intermediate results of protocol LAM90]. (1994) (2)
The Safety and Tolerability of Azacitidine (AZA) Are Comparable in Patients with Acute Myeloid Leukemia (AML) or Higher-Risk Myelodysplastic Syndromes (MDS) (2015) (2)
Development and Validation of a Model to Predict Response to Romiplostim in Patients with Lower-Risk Myelodysplastic Syndromes (MDS). (2012) (2)
Timing for Allogeneic Hematopoietic Stem Cell Transplantation (HSCT) in Chronic Myelomonocytic Leukemia (CMML): A Joint Study from the International MDS/MPN Working Group and the Chronic Malignancies Working Party of the EBMT (2019) (2)
Erlotinib Antagonizes Efflux Via ABC Transporters and Decreases P-Gp Cell Surface Expression by Inhibiting SRC Kinase and mTOR Pathways in Acute Myeloid Leukemia (AML) (2011) (2)
Idarubicin and Ifosfamide in the Treatment of Refractory and Relapsed Acute Lymphoblastic Leukemia (1998) (2)
Olutasidenib (FT-2102) Induces Durable Complete Remissions in Patients with Relapsed/Refractory mIDH1 Acute Myeloid Leukemia. Results from a Planned Interim Analysis of a Phase 2 Pivotal Clinical Trial (2022) (2)
Prognostic value of monocyte subset distribution in chronic myelomonocytic leukemia: results of a multicenter study (2020) (2)
Prognostic value of monocyte subset distribution in chronic myelomonocytic leukemia: results of a multicenter study (2020) (2)
Patient outcome measures during prolonged survival in patients (Pts) with high-risk myelodysplastic syndromes (MDS) treated with azacitidine (AZA) (2008) (2)
Effect of Luspatercept on Biomarkers of Erythropoiesis in Patients (Pts) with Lower-Risk Myelodysplastic Syndromes (LR-MDS) in the Medalist Trial (2020) (2)
[Relapsing polychondritis and chronic myelomonocytic leukemia]. (2009) (2)
Prognostic impact of a suboptimal number of analyzed metaphases in normal karyotype lower-risk MDS. (2018) (2)
Treatment of Progression of Myeloproliferative Disorders(MPD) to MDS/AML by Azacytidine (AZA) : A Preliminary Report on 17 Patients (pts) (2008) (2)
Can Peg-Interferon (IFN) α-2a Eradicate JAK2V617F-Positive Bone Marrow Progenitors in Polycythemia Vera (PV)? (2008) (2)
Cause of death and excess mortality in patients with lower‐risk myelodysplastic syndromes (MDS): A report from the European MDS registry (2022) (2)
Deferoxamine Stability in Intravenous Solution (1998) (2)
IMerge: A phase 3 study to evaluate imetelstat in transfusion-dependent subjects with IPSS low or intermediate-1 risk myelodysplastic syndromes that are relapsed/refractory to erythropoiesis-stimulating agent treatment. (2021) (2)
Correction for Cassinat et al., “New Role for Granulocyte Colony-Stimulating Factor-Induced Extracellular Signal-Regulated Kinase 1/2 in Histone Modification and Retinoic Acid Receptor α Recruitment to Gene Promoters: Relevance to Acute Promyelocytic Leukemia Cell Differentiation” (2017) (2)
Treatment of Myelodysplastic Syndromes with del 5q before the Lenalidomide Era: The GFM Experience. (2006) (2)
[Transient ischemic colitis complicating sickle cell crisis]. (1991) (2)
Expression of the interleukin 6 gene in acute myeloid leukemia and myelodysplastic syndromes: a report on 49 cases. (1990) (2)
Treatment of severe aplastic anemia with antilymphocyte globulin and androgens: A report on 33 patients (1991) (2)
A randomized, open-label, phase II study of azacitidine (AZA) in combination with durvalumab in patients (pts) with previously untreated higher-risk myelodysplastic syndromes (MDS) or acute myeloid leukemia (AML) ineligible for hematopoietic stem cell transplantation (HSCT). (2017) (2)
A Phase II Trial of Eltrombopag in Chronic Myelomonocytic Leukemia (CMML) with Thrombocytopenia (2017) (2)
Impact of Somatic Gene Mutations on Response to Lenalidomide (LEN) in IPSS Lower-Risk Myelodysplastic Syndromes (MDS) Patients (Pts) without Del(5q) and Ineligible for or Refractory to Erythropoiesis-Stimulating Agents (ESAs) (2016) (2)
The complex genetic landscape of familial MDS and AML reveals pathogenic germline variants (2020) (2)
The Proinflammatory Protein S100A9 Suppresses Erythropoietin Elaboration in Patients with Myelodysplastic Syndromes (2015) (2)
Meeting report: the 11th International Conference on Differentiation Therapy and Innovative Therapeutics in Oncology. (2007) (2)
Highly Transfused MDS Patients Often Have Cardiac Iron Overload, as Shown by MRI Assessment (2010) (2)
Low Doses of Thalidomide (Thal) in Low Risk MDS with Transfusion-Dependant Anemia: The GFM THAL-SMD-200 Trial. (2006) (2)
A randomized, double-blind, placebo-controlled study of tamibarotene/azacitidine versus placebo/azacitidine in newly diagnosed adult patients selected for RARA+ HR-MDS (SELECT-MDS-1). (2022) (2)
[Management of myelodysplastic syndromes in 2019: An update]. (2019) (2)
C6) Mutations of the P53 gene in myelodysplastic syndromes (MDS). A report on 152 cases (1991) (2)
Is cytarabine required in the treatment of acute promyelocytic leukemia? (2006) (2)
Azacitidine (AZA) for Patients with Vexas and Myelodysplastic Syndrome (MDS): Data from the French Vexas Registry (2021) (2)
Azacitidine (AZA) Combined with Idarubicin in Untreated Patients with High Risk MDS – Results of a Phase I/II Study of the Groupe Francophone Des Myelodysplasies (2012) (2)
Prognostic Impact of Cytogenetic Abnormalities in Elderly Patients with Acute Myeloid Leukemia (AML) Enrolled in the ALFA-9803 Trial. (2007) (2)
Peg IFNα-2a in Polycythemia Vera (PV). Results of a Phase 2 Study by the French “PV-NORD” Group. (2006) (2)
EFFECT OF AZACITIDINE (AZA) vs LOW-DOSE ARA-C (LDAC) ON OVERALL SURVIVAL (OS), HEMATOLOGIC RESPONSE, TRANSFUSION INDEPENDENCE, AND SAFETY IN PATIENTS (PTS) WITH HIGHER-RISK MYELODYSPLASTIC SYNDROMES (MDS) (2008) (2)
Comprehensive Analysis of Safety: Rigosertib in 557 Patients with Myelodysplastic Syndromes (MDS) and Acute Myeloid Leukemia (AML) (2016) (2)
Therapy related myeloid neoplasms following PARP inhibitors: real-life experience. (2022) (2)
Distinct mutational pattern of myelodysplastic syndromes with and without 5q– treated with lenalidomide (2020) (2)
Abnl Marro: An International Cooperative Trial for Patients with MDS/MPN Overlap Syndromes (2019) (2)
P122 Value of transfusion-free living in myelodysplastic syndromes (MDS): results of health utility interviews with patients (2007) (2)
Blinatumomab retreatment after relapse in patients with relapsed/refractory B-precursor acute lymphoblastic leukemia (2)
Myeloid Clonal Infiltrate Identified With Next-Generation Sequencing in Skin Lesions Associated With Myelodysplastic Syndromes and Chronic Myelomonocytic Leukemia: A Case Series (2021) (2)
ABT 737 BCL-2 INHIBITOR TARGETS LEUKEMIC STEM CELLS IN MOUSE MODELS OF MYELOID (PRE)LEUKAEMIA (2009) (2)
Eltrombopag in Chronic Myelomonocytic Leukemia (CMML) with Severe Thrombocytopenia: Final Results of a Multicenter Phase II Study (2020) (2)
Final Report of GFM-VOR2007 Study: a Phase I/II Study of Vorinostat and Low Dose Cytarabine (LDAC) for MDS Patients with Azacitidine (AZA) Failure (2012) (2)
An International Data Set for the Study of Chronic Myelomonocytic Leukemia (CMML) Validates Modern Prognostic Scoring Systems and Demonstrates a Critical Need for Novel Prognostication Strategies (2014) (2)
[Acute lymphoblastic leukemia, Burkitt-cell type, after Hodgkin's disease. Study of 2 cases]. (1987) (2)
Analysis of JAK2 Mutation in Essential Thrombocythemia (ET) Patients with Monoclonal and Polyclonal X-Chromosome Inactivation Patterns (XCIPs). (2005) (2)
A sex-informed approach to improve the personalised decision making process in myelodysplastic syndromes: a multicentre, observational cohort study (2022) (2)
Results of an international phase 2study of the oral farnesyl transferase inhibitor (FTI) tipifarnib (ZARNESTRA®) in patients with high-risk myelodysplastic syndrome (MDS) (2005) (2)
MDS/CMML with TET2 or IDH mutation Are Associated with Systemic Inflammatory and Autoimmune Diseases (SIAD) and T Cell Dysregulation (2020) (2)
Impact of the Provisional Revised-IPSS (R-IPSS) in 265 MDS Patients Treated with Azacitidine (AZA): The Groupe Francophone Des Myelodysplasies (GFM) Experience (2011) (2)
Detection and Treatment of Iron Overload in Red Blood Cell (RBC) Transfusion-Dependent Myelodysplastic Syndromes (MDS): A European Survey. (2009) (2)
A Phase II Study of the Efficacy and Tolerance of Azacytidine (AZA) in Steroid Dependent/Refractory Systemic Autoimmune and Inflammatory Disorders (SAID) Associated with MDS or CMML (GFM- AZA-SAID -trial) (2021) (2)
BCL-2 Inhibitor ABT-737 Effectively Targets Leukemia-Initiating Cells with Differential Regulation of Relevant Genes Leading to Extended Survival in a NRAS/BCL-2 Mouse Model of High Risk-Myelodysplastic Syndrome (2021) (2)
[Assessment of P glycoprotein expression by immunocytochemistry and flow cytometry coupled with functional efflux analysis: application to acute myeloid leukemia]. (1999) (2)
215 Update of open-label extension study evaluating the long-term safety and efficacy of romiplostim in thrombocytopenic patients with myelodysplastic syndromes (MDS) (2011) (2)
Azacitidine in Older Patients with Acute Myeloid Leukemia (AML). Results from the Expanded International E-Alma Series (E-ALMA+) According to the MRC Risk Index Score (2015) (2)
[Molecular abnormalities and clonality in myelodysplastic syndromes]. (1997) (2)
Treatment of AML with Azacytidine (AZA): Current Results of the French ATU Program. (2007) (2)
Are myelodysplastic syndromes and acute myeloid leukaemia occurring during the course of lymphoma always therapy related? (2018) (2)
Treatment of Advanced CMML by Azacitidine (AZA) In a Compassionate Program. the GFM Experience In 38 Patients (pts) (2010) (2)
Relationship of progression to acute myeloid leukemia (AML) from myelodysplastic syndrome (MDS) and cytogenetic status (2008) (2)
Arsenic Trioxide Treatment during Pregnancy for Acute Promyelocytic Leukemia in a 22-Year-Old Woman (2020) (2)
Effect of Lenalidomide (LEN) Exposure on Response and Outcomes in Patients (Pts) with Lower-Risk Non-Del(5q) Myelodysplastic Syndromes (MDS) (2016) (2)
Romiplostim in Low/INT-1-Risk MDS Results in Reduced Bleeding without Impacting Leukemic Progression: Final Results from a Randomized, Double-Blind, Placebo-Controlled Study (2017) (2)
AN EVALUATION OF THE ASSOCIATION OF CDKN2B (P15) DNA METHYLATION WITH RESPONSE AND SURVIVAL IN PATIENTS WITH HIGHER-RISK MYELODYSPLASTIC SYNDROMES (MDS) TREATED IN THE AZA-001 TRIAL (2010) (2)
112 RANDOMIZED PHASE III STUDY OF IV RIGOSERTIB VERSUS BEST SUPPORTIVE CARE (BSC) IN PATIENTS WITH HIGHER-RISK MDS (HR-MDS) AFTER FAILURE OF HYPOMETHYLATING AGENTS (HMAS) (2015) (2)
58 Interaction of karyotype complexity and response on overall survival and AML progression in lenalidomide-treated Low/INT-1 risk del (5q) MDS patients (2011) (2)
Phase 3 Study of Lenalidomide (LEN) Vs Placebo in Non-Transfusion Dependent (TD) Low Risk Del(5q) MDS Patients with Del(5q) — Preliminary Blinded Analysis of the European Sintra-REV Trial (2018) (2)
Red blood cell transfusion burden in myelodysplastic syndromes (MDS) with ring Sideroblasts (RS): A retrospective multicenter study by the Groupe Francophone des Myélodysplasies (GFM) (2020) (2)
AZA In the Treatment of Therapy Related MDS and AML (tMDS/AML): a Report on 60 Patients by the Groupe Francophone Des Syndromes Myelodysplasiques (GFM) (2010) (2)
In vitro assessment of the sensitivity to APR‐246 + azacitidine combination predicts response to this combination in myelodysplastic/acute myeloid leukaemia patients (2021) (2)
Prognostic Value of Early Drop in Platelets in Lower-Risk MDS. A Sub-Study from the European Leukemianet Lower-Risk MDS (EUMDS) Registry (2017) (2)
Long-Term Evolution of Somatic Mutations in Patients with Del(5q) MDS Early Treated with Lenalidomide in the Sintra-Rev Clinical Trial: Safe and Effecitive Approach? (2022) (2)
34 Health-related quality of life in low-risk MDS patients from the European LeukemiaNet Registry: Correlation with age, gender and decreased survival (2011) (2)
Recent frustration and innovation in myelodysplastic syndrome (2016) (2)
Prognostic Factors of Response and Overall Survival (OS) in Higher-Risk MDS (including RAEB-t) Treated with Azacytidine (AZA): Results of the French ATU Program. (2009) (2)
Allogeneic Hematopoietic Stem Cell Transplantation (allo HSCT) in Patients with IPSS Low or Intermediate-1 Myelodysplastic Syndrome (MDS): A Prospective Multicenter Phase II Study Based on Donor Availability By the GFM & SFGM-TC "MDS-ALLO-Risk" (2021) (2)
Impact of Lenalidomide Treatment on Overall Survival in Patients With Lower-Risk, Transfusion-Dependent Myelodysplastic Syndromes. (2022) (2)
Comparison of 5-Azacytidine Versus Allogeneic Hematopoietic Cell Transplantation In Elderly (≥ 60 years) Patients with De Novo High-Risk MDS - a Retrospective Matched Pair Analysis (2010) (2)
Surcharge en fer d’origine hématologique : validation d’une procédure de dépistage de la surcharge cardiaque par IRM en routine clinique (2013) (2)
Nouveaux outils et traitements pour les syndromes myélodysplasiques (2013) (2)
Epidémiologie et facteurs étiologiques des syndromes myélodysplasiques (1997) (2)
Le traitement des leucémies aiguës à promyélocytes par l'acide tout-trans rétinoïque. (1991) (2)
Prospective validation of a biomarker-driven response prediction model to romiplostim in lower-risk myelodysplastic neoplasms – results of the EUROPE trial by EMSCO (2022) (1)
Detection of TP53 Mutations in Myelodysplastic Syndromes (MDS) and Acute Myeloid Leukemia (AML). a Comparison Between a Functional Method (FASAY) and Next Generation Sequencing (NGS) (2014) (1)
The ABNL-MARRO 001 study: a phase 1–2 study of randomly allocated active myeloid target compound combinations in MDS/MPN overlap syndromes (2022) (1)
172 Azacytidine in relapsed MDS and AML after allogeneic stem cell transplantation: Results of the French ATU Program (2011) (1)
Impact of Gene Mutations on Response to Lenalidomide and OS in Lower-Risk Non-Del(5Q) MDS Patients Ineligible/Refractory to Erythropoiesis-Stimulating Agents (ESAS) (2017) (1)
Correlation of overall survival (OS) with bone marrow blast (BMBL) response in patients (pts) with myelodysplastic syndrome. (2015) (1)
P768: GUADECITABINE (SGI-110) VS. TREATMENT CHOICE (TC) IN RELAPSED/REFRACTORY(R/R) MYELODYSPLASTIC SYNDROME (MDS), RESULTS OF A GLOBAL, RANDOMIZED, PHASE 3 STUDY. (2022) (1)
A phase I /II Trial of Erlotinib in Higher Risk MDS After Azacitidine (AZA) Failure (2012) (1)
[Cytogenetics and myelodysplastic syndromes (MDS)]. (1991) (1)
The transfusion of non‐prophylactically RH‐KEL1 antigen‐matched red blood cells is feasible in selected myelodysplastic syndrome and acute myeloid leukaemia patients (2022) (1)
P53 mutations are a strong prognostic factor of response to chemotherapy and survival in myelodysplastic syndromes (MDS) (1994) (1)
[Behçet's-like syndrome and other dysimmunitary manifestations related to myelodysplastic syndromes with trisomy 8]. (2020) (1)
Results of All-Trans Retinoic Acid Treatment in Acute Promyelocytic Leukemia (European Experience) (1997) (1)
P147 Management of haematological adverse events in MDS patients treated with lenalidomide (2007) (1)
Myelodysplastic syndromes: state of the art pathology, diagnosis and management. (2013) (1)
P-121 BCL2L10 is associated with resistance to azacitidine (AZA) in MDS and AML, and is a possible target in resistant patients (2013) (1)
Azacitidine (AZA) Combined with Idarubicin in Higher Risk MDS - Results of a Phase I/II Study By the Groupe Francophone Des Myelodysplasies (GFM) (2015) (1)
Author Correction: Implications of TP53 allelic state for genome stability, clinical presentation and outcomes in myelodysplastic syndromes (2021) (1)
P149 Treatment of high risk MDS and AML post-MDS with azacytidine (AZA): current results of the French ATU program (2007) (1)
Prognostic Impact of Clonal Diversity in Acute Myeloid Leukemia (AML) Treated with Intensive Chemotherapy (IC) (2019) (1)
Long-term outcome after fludarabine in 133 patients with advanced B-cell chronic lymphoid malignancies (1995) (1)
Results from a Global Randomized Phase 3 Study of Guadecitabine (G) Vs Treatment Choice (TC) in 302 Patients with Relapsed or Refractory (r/r) Acute Myeloid Leukemia after Intensive Chemotherapy (ASTRAL-2 Study) (2021) (1)
Randomized phase II study LD-ARAC plus rhGM-CSF in advanced myelodysplasia (1993) (1)
A Two-Gene Classifier for Chronic Myelomonocytic Leukemia (CMML) Patients Treated with Hypomethylating Agents (HMA): A Report By the GFM (2015) (1)
Treatment of MDS with Excess Blasts by Bevacizumab Is Well Tolerated and Is Associated with a Decrease of VEGF Plasma Level. (2009) (1)
S168: ERYTHROPOIETIN STIMULATION AGENTS SIGNIFICANTLY IMPROVES OUTCOME IN LOWER RISK MDS. (2022) (1)
Arsenic Trioxide (ATO) and ATRA with Limited Chemotherapy (CT) in Newly Diagnosed Standard Risk APL in the Elderly. a Report By the French Belgian Swiss APL Group (APL 2006 trial) (2016) (1)
Azacitidine Treatment For Patients With Myelodysplastic Syndromes and Acute Myeloid Leukemia Harboring Chromosome 3q Abnormalities (2013) (1)
Leucémies et lymphomes d'origine lymphocytaire T (1987) (1)
Impact of Cytogenetics and Cytogenetic Response On Outcome in MDS Treated with Azacitidine (AZA). (2012) (1)
Disruption of Bcl-2 Heterodimerization by the BH3 Mimetic ABT-737 Restores Spontaneous Apoptosis and Induces Differentiation in High Risk MDS and AML. (2007) (1)
Outcome of Acute Promyelocytic Leukemia (APL) with Very High WBC Counts Treated with ATRA and Chemotherapy (CT): The European Group Experience. (2007) (1)
Long-Term Outcome of Anemic Non Del 5q Lower-Risk MDS Refractory to or Relapsing After Erythropoiesis Stimulating Agents (ESAs) (2010) (1)
Genomic Landscape and Clinical Features of Myeloproliferative Neoplasm (MPN) Patients with Auto-Immune and Inflammatory Diseases (AID) (2021) (1)
Prognostic Factors of Response to Erythropoiesis Stimulating Agents (ESA) Treatment in Non RBC Transfusion Dependent Lower Risk MDS. Preliminary Results of a French and Italian Study (on behalf of the GFM and FISM). (2012) (1)
AML with 11q23/MLL Abnormalities: A Survey of 146 Cases from French AML Intergroup. (2006) (1)
Overall survival (OS) and baseline disease characteristics in MDS patients with primary HMA failure in a randomized, controlled, phase III study of rigosertib. (2015) (1)
Long-Term Survival Analysis in Older Patients with AML Treated Intensively: Positive Impact of Idarubicin in a Cure Fraction Estimation Model. (2008) (1)
P-023 Incidence and prognostic value of TP53 mutations in IPSS low and INT 1 (lower risk) MDS with del 5q (2013) (1)
Results of a phase II trial of azacitidine (AZA) with or without epoetin beta (EPO) in lower-risk MDS. (2012) (1)
116 THE EFFECT OF LENALIDOMIDE ON HEALTH-RELATED QUALITY OF LIFE (HRQOL) IN PATIENTS WITH MDS: RESULTS FROM THE MDS-005 TRIAL (2015) (1)
Equivalent Outcome Between Reduced Intensity Versus Conventional Myeloablative Conditioning Hematopoietic Stem Cell Transplantation for Patients Older Than 35 Years with Acute Myeloid Leukemia. (2012) (1)
[ Myelodysplastic syndrome]. (2002) (1)
Impact of Red Blood Cell Transfusions on Survival in Lower-Risk MDS Patients Included in the European Leukemianet MDS (EUMDS) Registry (2017) (1)
A randomized, open-label, phase II study of CC-486 (oral azacitidine), alone or in combination with durvalumab (MEDI4736), in patients (pts) with myelodysplastic syndromes (MDS) unresponsive to prior parenteral azacitidine or decitabine. (2016) (1)
Efficacy of Azacitidine (AZA) in Autoimmune and Inflammatory Disorders (AID) Associated with Myelodysplastic Syndromes (MDS) and Chronic Myelomonocytic Leukemia (CMML) (2015) (1)
A Phase 2a/2b Multicenter Study of AG-946 in Patients with Anemia Due to Lower-Risk Myelodysplastic Syndromes (2022) (1)
Molecular Characteristics of Response to Olutasidenib (FT-2102) in Patients with Relapsed/Refractory mIDH1 Acute Myeloid Leukemia (2021) (1)
Is cytarabine required in the treatment of acute promyelocytic leukemia? Updated experience and review of the literature. (2006) (1)
Targeting RARA Overexpression with Tamibarotene, a Potent and Selective RARα Agonist, is a Novel Approach in AML. (2022) (1)
Haematological and cytogenetic responses after only 7 days of Lenalidomide in a patient with myelodysplastic syndrome and chromosome 5q deletion. (2011) (1)
Evaluation of Lenalidomide (LEN) Vs Placebo in Non-Transfusion Dependent Low Risk Del(5q) MDS Patients. Final Results of Sintra-REV Phase III International Multicenter Clinical Trial (2022) (1)
Treatment of newly diagnosed APL. The best choice is not ATRA or chemotherapy ... but a combination of both. European APL Group. (1994) (1)
Clinical and Molecular Characteristics of DDX41-Mutated Patients in a Large Cohort of Sporadic MDS/AML (2018) (1)
Association between Vasculitides and Myelodysplastic Syndrome (MDS): A Report on 21 Cases. (2004) (1)
European Registry for Low Risk and Intermediate-1 Risk MDS: Base Line Report On First 400 Registered Patients. (2009) (1)
Syndromes Revised International Prognostic Scoring System for Myelodysplastic (2012) (1)
Comprehensive Genetic Screening of Chronic Myelomonocytic Leukemias (CMML) (2012) (1)
Efficacy and tolerability of lenalidomide (LEN) in patients (pts) 75 and older versus those younger than 75 with RBC transfusion-dependent low/int-1-risk MDS and del 5q. (2012) (1)
Effects of erythropoietin (rHuEpo) plus granulocyte colony stimulating factor (rHuG-CSF) for the treatment of myelodysplastic syndromes (MDS) on anemia, costs and quality of life: a randomized controlled trial. (2004) (1)
ALL Transretinoic Acid Followed by Intensive Chemotherapy in Newly Diagnosed Acute Promyelocytic Leukemia: A Pilot Study on 27 Cases (1994) (1)
Prognostic Impact of Rare Single Abnormalities in Myelodysplastic Syndromes (2015) (1)
[Management of myelodysplastic syndromes]. (2015) (1)
P-006 Prognostic value of TP53 gene mutations in higher-risk MDS treated with azacitidine (AZA) (2013) (1)
High Response Rate and Improved Exercise Capacity and Quality of Life with a New Regimen of Darbepoetin Alfa (DAR) +/−G-CSF in Lower-Risk MDS : a Phase II Study. (2009) (1)
Awareness of acute myeloid leukaemia risk induced by diagnosis of a myelodysplastic syndrome. (2016) (1)
MDS-171: Effects of Luspatercept on Serum Ferritin in Patients with Lower-Risk Myelodysplastic Syndromes (LR-MDS) with Ring Sideroblasts (RS) in the Phase 3 MEDALIST Trial (2020) (1)
Therapeutic Strategies in Patients with Atypical CML (aCML) and Unclassified MDS/MPN (MDS/MPN-U). a Single Center Report (2014) (1)
105 Outcome of high risk myelodysplastic syndrome after azacytidine failure (2011) (1)
p 53 protein expression independently predicts outcome in patients with lowerrisk lowerrisk lowerrisk myelodysplastic syndromes with del ( 5 q ) (1)
Recombinant human erythropoietin (rh Epo): A possible treatment for the anemia of myelodysplastic syndromes (MDS) (1991) (1)
Multicenter next-generation sequencing studies between theory and practice: harmonization of data analysis using real world myelodysplastic syndrome data. (2020) (1)
Hypomethylating Agents Correct Subcellular Localization of FOXO3a and (re)Establish Expression of Its Transcriptional Targets In AML and MDS- Cells (2010) (1)
The Revised IPSS (IPSS-R) Predicts Response To Erythropoietic Stimulating agents (ESA) In Pts With Classical IPSS Low Or Intermediate-1 (int 1)- MDS: A Joint Retrospective Study Of The GFM, Düsseldorf Registry and Fism (2013) (1)
Long-Term Outcome Associated with Current Allogeneic Stem Cell Transplantation Procedures In Younger Adults with Adverse-Risk AML In First CR – A Real-Life Transplant Versus No-Transplant Analysis of the Acute Leukemia French Association (ALFA) (2010) (1)
Is life expectancy of polycythemia vera patients clearly different from that of the general population? (2005) (1)
Bortezomib + Low Dose Cytarabine in Int-2 and High Risk MDS. Interim Results of a Phase I/II Trial by the GFM. (2007) (1)
[(9;11) (p21;q23) translocation: apropos of 2 new cases seen in acute undifferentiated monoblastic AML5a leukemia]. (1987) (1)
Retinoic Acid in Acute Myeloid Leukemias (2015) (1)
Myelodysplastic Syndrome associated TET2 mutations affect NK cell function and genome methylation (2023) (1)
MDS Diagnosis: Many Patients May Not Require Bone Marrow Examination (2018) (1)
[Extramedullary blastic transformation revealed by a prolonged fever during the course of a 5q- syndrome]. (2009) (1)
Practical recommendations on the management of non-haematological adverse events in MDS patients treated with lenalidomide (2007) (1)
97 CHARACTERISTICS OF ROMIPLOSTIM-TREATED MDS PATIENTS WITH HEMATOLOGIC IMPROVEMENT IN PLATELETS (HI-P) (2015) (1)
Aseptic muscular abscesses associated with myelodysplastic syndrome (2014) (1)
59 Myelodysplastic syndromes with isolated neutropenia or thrombocytopenia: Are they refractory cytopenias with unilineage dysplasia? A GFM registry study (2011) (1)
P128 Transfusion independence (TI) in patients with myelodysplastic syndromes (MDS) treated with azacitidine (AZA) (2009) (1)
P033 Isolated del 20q defines a subgroup of MDS patients with lower blast counts and more frequent thrombocytopenia (2009) (1)
Prognostic and predictive value of IPSS-R in assessing overall survival (OS) in a phase III study of rigosertib in second-line higher-risk (HR) MDS patients. (2015) (1)
[Large B cell lymphoma of the mediastinum. 6 cases]. (1989) (1)
A Prognostic Score for Overall Survival (OS) with Azacitidine (AZA) In Higher Risk MDS Based on 282 Patients (pts), and Validated In 175 Pts From the AZA 001 Trial (2010) (1)
O-014 Azacitidine versus best supportive care before non-myeloablative allogeneic stem cell transplantation for MDS: A study by the SFGM-TC (2013) (1)
A Prognostic Classifier Based on Early Platelet Drop in Lower-Risk MDS. a Study from the European Leukemianet Lower-Risk MDS (EUMDS) Registry (2017) (1)
The Impact of the Administration Schedule and Mutational Profile on Outcomes of Patients with Relapsed and Refractory Acute Myeloid Leukemia Treated with Hypomethylating Agents: A Large, International, Multi-Center Analysis (2017) (1)
Reduced murine double minute 2 and 4 protein, but not messenger RNA, expression is associated with more severe disease in myelodysplastic syndromes and acute myeloblastic leukaemia (2022) (1)
Myelodysplastic Syndromes (2018) (1)
Prognostic Impact of JAK2V617F Mutation In MDS: a Matched Case Control Study (2010) (1)
15 Occupational and environmental risk factors of MDS = a case control study (1997) (1)
tipifarnib in intermediate- to high-risk myelodysplastic syndrome A multicenter phase 2 study of the farnesyltransferase inhibitor (2012) (1)
Correction to: Allogeneic hematopoietic stem cell transplantation in elderly patients with acute myeloid leukemia or myelodysplastic syndromes: myth and reality (2021) (1)
Niclas mouse model of AML by targeting primitive LSK and progenitor cells BCL-2 inhibition with ABT-737 prolongs survival in an NRAS / BCL-2 (2013) (1)
A new case of dic(9;12)(p13;p11) in acute lymphocytic leukemia. (1989) (1)
BCL-2 Inhibition with ABT-737 Prolongs Survival in an NRAS/BCL2-Mediated MOUSE MODEL of Myelodyspastic Syndrome (MDS) Progressing to ACUTE Myelogenous Leukemia (AML) by Targeting Leukemia Initiating CELLS (2012) (1)
Bone Marrow Hypocellularity Does Not Impair the Tolerability or Efficacy of Azacitidine (AZA) in Patients with Higher-Risk Myelodysplastic Syndromes Treated in the AZA-001 Study (2012) (1)
Analysis of Duration of Response, Exposure-Adjusted Safety and Progression to Acute Myeloid Leukemia (AML) for Patients with Lower-Risk Myelodysplastic Syndromes (LR-MDS) Receiving Luspatercept in the MEDALIST Study (2021) (1)
The Impact of Diabetes Mellitus As Comorbid Condition, in Patients with Lower-Risk Myelodysplastic Syndromes (MDS)— a Study of the European Leukemianet-Based MDS (EUMDS) Registry (2017) (1)
Le lymphome à grandes cellules B du médiastin : six observations (1990) (1)
340 Improvement in haematologic parameters in patients with MDS treated with the iron chelator deferasirox (Exjade®): An EPIC study post-hoc analysis (2011) (1)
Whole Exome Analysis of Relapsing Patients with Acute Promyelocytic Leukemia (2016) (1)
Increased Proliferation Induced by Constitutive Activation of the Src-Kinase Lyn and Aberrant mTOR Signaling in AML Is Abrogated by the EGFR-Inhibitor Erlotinib. (2009) (1)
Intra-Tumor Heterogeneity in Acute Myeloid Leukemia (AML): Results from a Real Life Cohort (2018) (1)
Continue rare cancers collaboration with European Reference Networks after Brexit (2021) (1)
Efficacy and Safety of Bemcentinib in Patients with Myelodysplastic Syndromes or Acute Myeloid Leukemia Failing Hypomethylating Agents (2020) (1)
O-3 Risk factors for myelodysplastic syndrome and leukemia after breast cancer: Results of a French multicenter case-control study (2005) (1)
Erratum to: High response rate and improved exercise capacity and quality of life with a new regimen of darbepoetin alfa with or without filgrastim in lower-risk myelodysplastic syndromes: a phase II study by the GFM (2013) (1)
213 AZACITIDINE (AZA) IN HIGHER RISK MDS PATIENTS WITH CHROMOSOME 7 ABNORMALITIES (ABN 7): RESULTS OF A RETROSPECTIVE STUDY FROM THE GFM AND GESMD REGISTRIES (2015) (1)
Prognostic Factors of Infections and Effect of Primary Anti-Infectious Prophylaxis in MDS Patients Treated with Azacitidine (AZA): A Prospective Study (2014) (1)
A Phase II Study Of The Efficacy and Safety Of An Intensified Schedule Of Azacitidine (AZA) In Intermediate-2 and High Risk MDS Patients (2013) (1)
Evaluation of Minimal Residual Disease Based on NPM1 Mutations in AML with Intermediate Risk Cytogenetics: A Prospective Study of 36 Patients. (2007) (1)
AML-187: The STIMULUS Clinical Trial Program: Evaluating Combination Therapy with MBG453 in Patients with Higher-Risk Myelodysplastic Syndrome (HR-MDS) or Acute Myeloid Leukemia (2020) (1)
NPM1 Expression Level and a CRBN Polymorphism Are Able to Predict the Rate of Response to Lenalidomide in Non Del(5q) Lower Risk MDS Patients Resistant to Erythropoiesis-Stimulating Agents: The GFM Experience (2014) (1)
A randomized trial of hydroxyuea (HY) versus VP16 in advanced adult chronic myelomonocytic leukemia (1994) (1)
This is a repository copy of Health-related quality of life in lower-risk MDS patients compared with age- and sex-matched reference populations: a European LeukemiaNet (2018) (1)
Overall Survival and Progression-Free Survival of Patients Following Luspatercept Treatment in the MEDALIST Trial (2022) (1)
35 SYSTEMIC INFLAMMATORY AND AUTOIMMUNE DISEASES (SAID) ASSOCIATED WITH MDS: A FRENCH MULTICENTER RETROSPECTIVE STUDY (2015) (1)
Treatment of the 5 q – Syndrome Pierre Fenaux and Charikleia Kelaidi Myelodysplastic Syndromes (2006) (1)
A Phase II Study of the Efficacy and Safety of an Intensified Schedule of Azacitidine (AZA) in Intermediate-2 and High Risk MDS Patients: A Study By the Groupe Francophone Des Myelodysplasies (GFM) (2015) (1)
Facteurs pronostiques dans les syndromes myélodysplasiques (2002) (1)
Lymphome primitif du foie: deux observations traitées par polychimiothérapie (1987) (1)
Syndromes myélodysplasiques: Mise au point (2006) (1)
Maladies systémiques et manifestations auto-immunes au cours des hémopathies myéloïdes (2007) (1)
Les facteurs de croissance hématopoïétiques dans le traitement des hémopathies malignes (1997) (1)
Une nouvelle classification des syndromes myélodysplasiques (2002) (1)
Syndrome 5q- : caractéristiques hématologiques, physiopathologie et traitement (2008) (1)
Actualités des syndromes myélodysplasiques Société française d’hématologie (Paris, 2011), MDS Foundation (Edimbourg, 2011) (2011) (1)
Progrès dans les syndromes myélodysplasiques (2006) (1)
Maladie de hodgkin révélée par une myélofibrose en apparence primitive (1988) (1)
Impact of Azacitidine (AZA) Prior to Allogeneic Stem Cell Transplantation (allo-SCT) for Myelodysplastic Syndromes (MDS): A Large-Scale Study on Behalf of the SFGM-TC and GFM Groups (2011) (1)
The Capacity of the Hypomethylating Agents Azacytidine and Decitabine to Induce Apoptosis and Cell Cycle Arrest Depends on the Activation of the DNA-Damage Response Pathway. (2008) (1)
Reduced peripheral blood dendritic cell and monocyte subsets in MDS patients with systemic inflammatory or dysimmune diseases (2022) (1)
Re-Evaluation of the Efficacy of Azacitidine (AZA) In Patients From the AZA-001 Study with Higher-Risk Myelodysplastic Syndromes (MDS) Classified by WHO Criteria and WPSS Risk (2010) (1)
Hodgkin Lymphoma (HL) in Tunisia Results of a 5 Year Prospective Multicenter Trial in 251 Pts (2008) (1)
Outcome of Lower Risk Non Del 5q MDS after Failure of Erythropoiesis Stimulating Agents (ESA), and Impact of Post-ESA Treatment on Survival: A Retrospective European Study (2015) (1)
Myelodysplastic Syndromes: The End of the Beginning? (2008) (1)
Should all CMV infections after bone marrow transplantation be treated? (1991) (1)
Challenging IWG2006 Response Criteria: Results of a Randomized Study of Epoetin Alfaversus Placebo in Anemic Lower Risk MDS Patients (2017) (1)
Machine learning-based improvement of MDS-CBC score brings platelets into the limelight to optimize smear review in the hematology laboratory (2022) (0)
La prise en charge précoce des autistes (2000) (0)
[New tools and treatments in myelodysplastic syndromes]. (2013) (0)
Diverse Genetic Lesions In Myelodysplastic Syndromes Originate Exclusively In Rare MDS Stem Cells (2013) (0)
Dermatose par infiltrat à cellules dendritiques plasmacytoïdes ou indéterminées matures chez des patients atteints d’hémopathie myéloïde, une étude de 14 cas (2022) (0)
A Phase II Add-on Study of Vorinostat (VOR) in Higher Risk Myelodysplastic Syndrome with Failure of Hypomethylating Agents (HMA): The GFM Azavor Study (2015) (0)
Prognostic Value of Minimal Residual Disease by Real-Time Quantitative PCR in AML with CBFB-MYH11 Rearrangement: The French Experience. (2007) (0)
Fish and “Fiction” analysis of chromosome 7 in MDS : a study on 99 cases (1994) (0)
P-80 Improved predictive factors ofresponse for myelodysplastic syndrome patients treated by the combination of erythropoietin and G-CSF (2005) (0)
La paix en questions (1994) (0)
Compte rendu du IVe symposium international sur les syndromes myélodysplasiques, Barcelone, 24-27avril 1997 (1997) (0)
159 CSNK1A1 IS NORMALLY EXPRESSED AND UNMUTATED IN MDS PATIENTS WITHOUT DEL(5Q) BEFORE AND UNDER TREATMENT WITH LENALIDOMIDE (2015) (0)
P068 Suppression of the DNA damage response in acute myeloid leukemia versus myelodysplastic syndrome (2009) (0)
Topic: AS04-MDS Biology and Pathogenesis/AS04i-Microenvironment and stem cell niche: MESENCHYMAL STROMAL CELLS OF THE BONE MARROW NICHE CONTRIBUTE TO THE PROINFLAMMATORY PHENOTYPE OF CMML MONOCYTES THROUGH IGFBP2 (2023) (0)
291 Prognostic impact of JAK2V617F mutation in MDS: a matched case control study (2011) (0)
117 A PHASE 3 STUDY OF LENALIDOMIDE VERSUS PLACEBO IN RBC TRANSFUSION-DEPENDENT (TD) PATIENTS WITH LOWER-RISK MDS WITHOUT DEL(5Q) UNRESPONSIVE OR REFRACTORY TO ERYTHROPOIESIS-STIMULATING AGENTS (ESAS) (2015) (0)
Lymphomes agressifs à localisations cardiaques révélatrices (1990) (0)
The Bottom Line Hypomethylating Agents as Bridging Therapy before Allogeneic Hematopoietic Stem Cell Transplantation in Patients with Chronic Myelomonocytic Leukemia ? (2015) (0)
Manifestations auto-immunes au cours de syndromes myélodysplasiques (2013) (0)
Characteristics and Outcome of Older Patients with Acute Promyelocytic Leukemia Front-Line Treated with or without Arsenic Trioxide — an International Collaborative Study (2018) (0)
Les lymphomes lymphoblastiques de l'adulte : problèmes diagnostiques et pronostiques. À propos de 80 observations (1990) (0)
Sequential Chemotherapy with Mitoxantrone, Etoposide and Cytarabine for Previously Treated Acute Myeloid Leukemia: EMA 86 Regimen (1996) (0)
Characteristics of Germline CHEK2 Mutated Patients in a Large Cohort of 2322 Myeloid Malignancies (2022) (0)
Early Treatment of Anemia of Lower Risk MDS by Erythropoiesis-Stimulating Agents (ESAs): A Report On 112 Cases. (2009) (0)
High Body Mass Index (BMI) as a predictor of Differentiation Syndrome (DS) In Acute Promyelocytic Leukemia (APL) (2010) (0)
p16INK4a andp15INK4b gene methylations in plasma cells from monoclonal gammopathy of undetermined significance (2001) (0)
A Molecular-Based Response Prediction Model to Romiplostim in Patients with Lower-Risk Myelodysplastic Syndrome and Severe Thrombocytopenia (2020) (0)
Lymphome hépatique simulant une glycogénose (1986) (0)
Arbres décisionnels de l'article : Syndromes myélodysplasiques et leucémies secondaires. Traitement (2014) (0)
L'ASPLENIE CONGENITALE, UN DIAGNOSTIC DIFFERENTIEL DE THROMBOCYTEMIE ESSENTIELLE (1993) (0)
FRI0211 VASCULITIS ASSOCIATED WITH MYELODYSPLASTIC SYNDROME AND CHRONIC MYELOMONOCYTIC LEUKEMIA: FRENCH MULTICENTER CASE CONTROL STUDY (2020) (0)
210 Should immunosuppressive therapy (1ST) be used more often in lower risk MDS (2011) (0)
P099 Comparison of IWG 2006 and IWG 2000 response criteria for anemia of MDS in 419 patients: the GFM experience (2007) (0)
184 Intensive chemotherapy in de novo MDS. Outcome of patients who achieved partial remission (PR) (1997) (0)
Stratégie thérapeutique dans les syndromes myélodysplasiques : Les syndromes myélodysplasiques (1997) (0)
Mitoxantrone induces DNA topoisomerase II cleavage at translocation breakpoint hotspot in PML gene in acute promyelocytic leukemia (2003) (0)
Sequential Study By RNA-Seq Shows a Reduction in Inflammation and a Cell Cycle Activation in T-Lymphocytes from Myelodysplastic Syndrome with Del(5q) after Lenalidomide Treatment in Patients Included in the "Sintra-REV" Clinical Trial (2020) (0)
S169: CLINICAL AND MOLECULAR MARKERS FOR PREDICTING RESPONSE TO ROMIPLOSTIM TREATMENT IN LOWER-RISK MYELODYSPLASTIC SYNDROMES (2022) (0)
57 A PHASE 2 MULTICENTER STUDY OF CC-486 (ORAL AZACITIDINE) IN PATIENTS WITH MYELODYSPLASTIC SYNDROMES (MDS) WHO FAIL TO ACHIEVE RESPONSE WITH INJECTABLE AZACITIDINE OR DECITABINE (2015) (0)
MDS-029: Prevalence of VEXAS Syndrome in MDS/CMML Patients with Systemic Inflammatory and Auto-Immune Disease (2021) (0)
Maladie de Still et PseudoStill associés aux SMD et LMMC : Étude nationale Française (2021) (0)
156 Lenograstim associated or not to ARA-C (3mg/m 2 X2) as therapy for poor prognosis refractory anemia with excess of blasts (RAEB) (1997) (0)
P. glycoprotein (PGP) expression and response to intensive chemotherapy and low dose AraC in myelodysplastic syndromes (MDS). A report on 66 cases (1994) (0)
Treatment with Hypomethylating Agents (HMA) (2018) (0)
Syndromes myélodysplasiques (SMD) (2003) (0)
[Cytosine-arabinoside in high doses in refractory acute granulocytic leukemia. Apropos of 17 cases]. (1985) (0)
Reassessment of an apparent t(12;17)(p11;p11) as an unbalanced t(17;21)(p11;q11) in a case of B-cell chronic lymphocytic leukemia by fluorescence in situ hybridization. (1994) (0)
Clinics and pathology Disease Acute non lymphocytic leuemia / myelodysplastic syndromes (2011) (0)
PB2352: CONSOLIDATION OF ERN-EUROBLOODNET: THE EUROPEAN REFERENCE NETWORK ON RARE HEMATOLOGICAL DISEASES FIRST 5 YEARS OF IMPLEMENTATION (2022) (0)
Topic: AS08-Treatment/AS08f-Clinical trials – Phase II-III: SELECT-MDS-1 TRIAL IN PROGRESS: A PHASE 3 RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED TRIAL OF TAMIBAROTENE/AZACITIDINE VS PLACEBO/AZACITIDINE IN NEWLY DIAGNOSED (ND) ADULT PATIENTS SELECTED FOR RARA-POSITIVE HR-MDS (2023) (0)
Les lésions cutanées sweetoïdes du syndrome VEXAS sont dues à une infiltration myéloïde de cellules clonales mutées UBA1 (2021) (0)
La leucémie myéloïde chronique: progrès biologiques et thérapeutiques (1989) (0)
MDS-280: Longer-Term RBC Transfusion Reduction in the Phase 3 MEDALIST Study of Luspatercept in Patients with Lower-Risk MDS (LR-MDS) with Ring Sideroblasts (RS) (2020) (0)
P126 Treatment of progression of myeloproliferative neoplasm (MPN) to MDS/AML by azacytidine (AZA): a report on 44 patients (pts) (2009) (0)
Burkitt’s Acute Lymphoblastic Leukemia (L3ALL) in Adults (2008) (0)
Familial AML With Germline CEBPA Mutations: Extended Clinical Outcomes and Analysis Of Secondary Mutations Using Whole Exome Sequencing (2013) (0)
Performance of the Medical Research Council (MRC) and the Leukemia Research Foundation (LRF) score in predicting survival benefit with hypomethylating agent use in patients with relapsed or refractory acute myeloid leukemia (2018) (0)
Intensive treatment of myelodysplastic syndromes and secondary leukemias (1995) (0)
Clinical benefit of luspatercept in patients (pts) with lower-risk MDS (LR-MDS) and high transfusion burden in the phase III MEDALIST study. (2020) (0)
Tracking the Extramedullary PML-RARα-Positive Cell Reservoirs in a Preclinical Model of APL: Biomarker of Long-Term Drug Efficacy (2012) (0)
Les lymphomes à localisation testiculaire : analyse de 12 observations (1990) (0)
C020 Prevalence of TET2 mutations in MDS (2009) (0)
Poor Prognosis of Adult Acute Myeloid Leukemia (AML) with High Level of Evi1 and BAALC Transcript. (2004) (0)
P-45 NF-κB is a potential therapeutictarget in high risk MDS: Induction of apoptosis by bortezomib and BAY 11-7082 (2005) (0)
Erratum to Myelodysplastic syndromes are propagated by rare and distinct human cancer stem cells in vivo, [Cancer Cell, 25, 2014, 794-808] (2014) (0)
Les syndromes myélodysplasiques ou états préleucémiques (2004) (0)
P107 Treatment of MDS with moderate anemia, not requiring RBC transfusions, by erythropoiesis stimulating agents (ESAs) (2009) (0)
Impact Of The Proportion Of Metaphases With Isolated Del(5q) On Clinical Outcomes In Lenalidomide (LEN)-Treated Patients With IPSS Low-/Int-1-Risk Myelodysplastic Syndromes (MDS) In MDS-003 and MDS-004 (2013) (0)
Les facteurs pronostiques des syndromes myélodysplasiques: analyse critique de l'influence de l'âge et du sexe et impossibilité d'identifier un groupe à très faible risque en utilisant les techniques de ratio standard de mortalité (1996) (0)
Few Genes Expression Predicts Outcome in Adult Acute Myeloid Leukemia (AML) with Normal Karyotype. (2005) (0)
P728: GENE EXPRESSION PROFILE REVELS T-LYMPHOCYTES ACTIVATION THROUGH CELL CYCLE PROGRESSION AND MITOCHONDRIAL METABOLISM REGULATION IN MYELODYSPLASTIC SYNDROMES WITH DEL(5Q) AFTER LENALIDOMIDE TREATMENT (2022) (0)
Associations entre maladies systémiques et syndromes myélodysplasiques (1998) (0)
Efficacité de l’azacytidine dans les manifestations auto immunes associées aux syndromes myélodysplasiques : 23 observations (2014) (0)
[Sequential chemotherapy with or without GM-CSF in acute myeloid leukemia (AML) in the advanced phase: current status of protocols EMA 86 and EMA 91]. (1994) (0)
PHM20 VALUE OF TRANSFUSION-FREE LIVING IN MDS: RESULTS OF HEALTH UTILITY INTERVIEWS WITH MDS PATIENTS (2007) (0)
Iconographies supplémentaires de l'article : Iron overload of hematological origin: Validation of a screening procedure for cardiac overload by MRI in routine clinical practice (2013) (0)
Prognosis of Patients with AML Carrying 11Q23/MLL Reciprocal Translocations : A Retrospective Study of 191 Cases from the French AML-Intergroup (2008) (0)
[T-cell leukemia and lymphoma]. (1987) (0)
Imetelstat Achieved Prolonged, Continuous Transfusion Independence (TI) in Patients with Heavily Transfused Non-Del(5q) Lower-Risk Myelodysplastic Syndrome (LR-MDS) Relapsed/Refractory (R/R) to Erythropoiesis Stimulating Agents (ESAs) within the IMerge Phase 2 Study (2022) (0)
Les lymphomes primitifs du sein : à propos de 9 observations (1991) (0)
Azacitidine Improves Outcome in High Risk MDS Patients with Chromosome 7 Abnormalities: Retrospective Comparison of GESMD and GFM Registries (2017) (0)
122 PROGNOSTIC FACTORS OF INFECTIONS AND EFFECT OF PRIMARY ANTI-INFECTIOUS PROPHYLAXIS IN MDS PATIENTS TREATED WITH AZACITIDINE (AZA): A PROSPECTIVE STUDY (2015) (0)
Further Evidence That MDS and AML Cells Exhibit a Differential Capacity To Activate the DNA-Damage Response (DDR) Pathways. (2007) (0)
Caractéristiques phénotypiques et mutationnelles des maladies auto-immunes et inflammatoires (MAI) associées aux néoplasies myéloprolifératives (NMP) (2021) (0)
口服9—顺式视黄酸（Alitretinoin）治疗骨髓增生异常综合征：实验性研究结果 (2001) (0)
Les hyperplaquettoses... ou à propos de l'intérêt de la numération plaquettaire (1989) (0)
Les anémies sidéroblastiques (1989) (0)
Traitement des leucémies aigües non lymphoblastiques par la cytosine arabinoside à faibles doses: a propos de soixante-quatre cas (1989) (0)
Syndrome hemophagocytaire lié au virus d'Epstein Barr et anticoagulant circulant au cours d'une polyarthrite rhumatoïde (1987) (0)
Leucémie aiguë promyélocytaire (1997) (0)
Prognostic Factors of Severe Infections, and Effect of Primary Anti-Infectious Prophylaxis in MDS Patients Treated with Azacitidine (AZA). A Single Center Study On 144 Patients (2012) (0)
P015 European LeukemiaNet registry programme for low/INT-1 IPSS score myelodysplastic syndromes (2009) (0)
Excess Mortality in Low-Risk MDS Can be Explained By MDS and AML Related Causes of Death (2018) (0)
Publisher Correction: Outcome of older (≥70 years) APL patients frontline treated with or without arsenic trioxide—an International Collaborative Study (2021) (0)
Syndromes myélodysplasiques et leucémies secondaires. Traitement (2014) (0)
P727: NK-CELL IMMUNOEDITING BY MESENCHYMAL STROMAL CELLS IN MDS (2022) (0)
Aberrant Repertoire and Deficient Proliferation of TCR γδ T Cells in Myelodysplastic Syndromes (MDS). (2006) (0)
106 Treatment of advanced CMML by azacitidine (AZA) in a compassionate program. The GFM experience in 38 patients (pts) (2011) (0)
Treatment Algorithms for Lower-Risk Myelodysplastic Syndrome (2020) (0)
Clinical benefit among lenalidomide (LEN)-treated patients (pts) with RBC transfusion-dependent (RBC-TD) low-/int-1-risk myelodysplastic syndromes (MDS) without del(5q). (2016) (0)
O-027 European distribution of usage and impact on outcome for treatment with erythropoietic stimulating agents within the EUMDS lower-risk registry programme (2013) (0)
Erratum to: Flt3 receptor inhibition reduces constitutive NFκB activation in high-risk myelodysplastic syndrome and acute myeloid leukemia (2015) (0)
OP0053 Inflammatory disorders associated with trisomy 8 myelodysplastic syndromes : french retrospective case control study (2018) (0)
Expérience de douze ans de chimiothérapie des leucémies aiguës myéloblastiques (1985) (0)
Acute Promyelocytic Leukemia: Manifestations and Therapy (2011) (0)
P-245 Effector CD4+CD45RA-CD25brightFoxp3bright regulatory T cells (eTregs) are significantly increased in chronic myelomonocytic leukemia (CMML) with TET2 mutations (2013) (0)
[Treatment of malignant hemopathies with all transretinoic acid]. (1997) (0)
Cas cliniques de l'article : Syndromes myélodysplasiques et leucémies secondaires. Traitement (2014) (0)
Application of a Validated Composite Comorbidity Score Measuring Both Fitness and Cytogenetic Risk to Assess Outcomes in 1L AML Patients Who Received Venetoclax Plus Azacitidine in Viale-A (2022) (0)
I-Care for MDS: Development of Guidelines-Based Indicators for Appropriate Care in Adult Patients with Myelodysplastic Syndromes (2019) (0)
[Primary lymphomas of the breast. 9 case reports]. (1991) (0)
Very low dose GM-CSF (0.5 or 0.25 μg/kg/d) in MDS. A report on 35 cases (1994) (0)
Infiltrat myéloïde clonal identifié par next generation sequencing dans les lésions cutanées associées aux syndromes myélodysplasiques et leucémies myélomonocytaires chroniques (2021) (0)
50 BCL2L10-POSITIVE CELL (BPC) QUANTIFICATION IS A PREDICTIVE FACTOR OF SURVIVAL IN AZA-TREATED HIGHER RISK MDS (HR-MDS) AND AML (2015) (0)
Abcès musculaires aseptiques associés à un syndrome myélodysplasique (2013) (0)
Les agranulocytoses aiguës médicamenteuses: ètude clinique, biologique et évolutive ― A propos de soixante et une observations (1986) (0)
A phase 3, randomized, double-blind study of luspatercept (ACE-536) in patients (pts) with Revised International Prognostic Scoring System (IPSS-R) very low- to intermediate-risk myelodysplastic syndromes (MDS) with ring sideroblasts (RS) who require red blood cell (RBC) transfusions: The MEDALIST t (2016) (0)
Efficacité du tocilizumab dans une vascularite cryoglobulinémique réfractaire au rituximab (2011) (0)
Prevalence and Impact on Outcomes of Additional Karyotypic Abnormalities in Patients (Pts) with Myelodysplastic Syndromes (MDS) and Del(5q) from the MDS-003 and MDS-004 Studies (2015) (0)
9-cis-retinoic acid treatment for myelodysplasia [Abstract] (1998) (0)
P-180 Final report of an open-label extension (OLE) study of romiplostim in MDS with a focus on patients with prolonged treatment (2013) (0)
Manifestations auto-immunes et inflammatoires associées aux syndromes myélodysplasiques avec trisomie 8 : étude cas-contrôles française rétrospective (2018) (0)
[Hematopoietic growth factors in the treatment of malignant hemopathies]. (1997) (0)
166 Safety of panobinostat plus 5-azacitidine in myelodysplastic syndrome, chronic myelomonocytic leukemia, or acute myeloid leukemia patients: a phase Ib study (2011) (0)
Facteurs pronostiques des leucémies aiguës et des lymphomesPrognosis factors for acute leukemias and lymphomas. (2002) (0)
Différenciation de la cellule blastique. Une nouvelle approche thérapeutique dans les leucémies aiguës et les anémies réfractaires (1987) (0)
Longer-term RBC transfusion reduction in the phase III MEDALIST study of luspatercept in patients (pts) with lower-risk MDS with ring sideroblasts (RS). (2020) (0)
Evidence for Pulmonary Vascular Disease Despite Absence of Overt Pulmonary Arterial Hypertension (PAH) in Myeloproliferative Disorders (MPD) (PV and ET). (2005) (0)
Determinants of low health-related quality of life in patients with myelodysplastic syndromes: EUMDS registry study. (2023) (0)
188 The EGFR-inhibitor erlotinib sensitizes MDS derived cells to chemotherapeutic agents by increasing their intracellular retention via modulation of ABC-transporters (2011) (0)
O-017 A Phase I/II trial of erlotinib (ERLO) in higher-risk MDS after azacitidine (AZA) failure (2013) (0)
Biopsies ganglionnaires à l’aiguille : contribution dans le diagnostic des adénopathies périphériques (2011) (0)
Apoptose et syndromes myélodysplasíques (1998) (0)
Efficacité du pipobroman dans le traitement de la thrombocythémie essentielle (1988) (0)
Efficacité et tolérance de azacitidine dans les manifestations dysimmunes associées aux SMD/LMMC : essai prospectif de phase II (2022) (0)
[Difficulty in diagnosing an orbital non-Hodgkin's lymphoma]. (1989) (0)
Autologous Stem Cell Transplantation in Acute Promyelocytic Leukemia Patients Achieving a Second Complete Remission (2000) (0)
46 Recent developments in the prognostic classification for MDS: Results of The International Risk Analysis Workshop (1997) (0)
Leucémie Myéloïde Chronique: de la cytogénétique à la biologie moléculaire (1990) (0)
Effector CD4+CD45RA−CD25brightFoxp3bright Regulatory T Cell (eTreg) Distribution Is Significantly Impaired in Chronic Myelomonocytic Leukemia (CMML) and Correlates with TET 2 Mutational Status. (2012) (0)
51 Transcription Intermediary Factor 1 gamma (TIF1γ) is an epigenetically-regulated tumor suppressor gene in human chronic myelomonocytic leukemia (2011) (0)
Délétion du bras long du chromosome 5 dans les hémopathies malignes : à propos de 37 cas (1992) (0)
Iconographies supplémentaires de l'article : Prise en charge des syndromes myélodysplasiques en 2019 : mise au point (2019) (0)
Mutations du gene codant pour la proteine p53 dans les hemopathies malignes (1992) (0)
Defining The Translocation Mechanism In Therapy-Related Acute Promyelocytic Leukaemia (2009) (0)
Facteurs de croissance hématopoïétiques. Une place dans le traitement des syndromes myélodysplasiques (1997) (0)
P111 Long-term outcome of MDS with del 5q before the lenalidomide era. The GFM experience (2009) (0)
Un traitement décoiffant qui marche sur un foie pas sain (2004) (0)
Chimiothérapiue séquentielle avec ou sans GM-CSF dans les leucémies aiguës myéloïdes (LAM) en phase avancée : état actuel des protocoles EMA 86 et EMA 91 (1994) (0)
[Chronic myeloid leukemia: from cytogenetics to molecular biology]. (1990) (0)
142 MOLECULAR PROGNOSTIC FACTORS IN HIGHER RISK MDS RECEIVING FIRST LINE AZACYTIDINE (AZA) (2015) (0)
A Phase II Study of Decitabine In Advanced Chronic Myelomonocytic Leukemia (CMML) (2010) (0)
O-71 High response rate to darbopoetin alpha and sustained response in low risk MDS (2005) (0)
Real-World Validation of Molecular International Prognostic Scoring System (IPSS-M) for Myelodysplastic Syndromes (2022) (0)
Devenir à long terme des échecs de la splénectomie dans le purpura thrombopénique auto-immun chronique (2001) (0)
Very Long Term Follow up a Phase II Study of Post-Remission Subcutaneous (SC) Azacitidine (AZA) in Patients with AML Post-MDS or Higher-Risk (HR) MDS (2020) (0)
Transfusion des patients avec syndrome myélodysplasique (SMD) : indication en CGR phénotypés (2019) (0)
Effect of PEG-rHu MGDF in the induction treatment of acute myeloid leukemia (1997) (0)
Manifestations auto-immunes et maladies inflammatoires associées aux leucémies myélomonocytaires chroniques : étude rétrospective française (2014) (0)
Traitement de l’anémie dans les syndromes myélodysplasiques (2006) (0)
Outcome of Lower-Risk Patients with Myelodysplastic Syndromes without 5Q Deletion after Failure of Erythropoiesis Stimulating Agents (2017) (0)
P039 The EGFR-inhibitor erlotinib exhibits various off-target effects in MDS and AML (2007) (0)
MDS with Isolated Neutropenia or Thrombocytopenia. Incidence and Characteristics in the Groupe Francophone des Myélodysplasies (GFM) Registry. (2007) (0)
Cytogénétique Hématologique (GFCH) d'Hématologie Cellulaire (GFHC) and the Groupe Français de gene mutations: a report of 59 cases by the Groupe Français M0 AML, clinical and biologic features of the disease, includingAML1 (2013) (0)
189 Hypomethylating agents induce apoptosis and cell cycle arrest with a concomitant activation of p53-dependent signalling pathways and Foxo3a activation (2011) (0)
Traitement intensif des syndromes myélodysplasiques et des leucémies secondaires (1995) (0)
Characteristics and Outcome of MDS with Isolated Del 20q: The GFM Experience in 64 Cases. (2008) (0)
myelodysplastic syndrome B constitutes a potential therapeutic target in high-risk κ NF- (2011) (0)
Erlotinib Increases Efficacy of 5-Azacitidine (AZA) by Inhibiting Drug Efflux Via ABC-Transporters (2010) (0)
173 Intensive chemotherapy with quinine in myelodysplastic syndromes (MDS) (1997) (0)
Clinical Implications of p53 Dysfunction in Patients with Myelodysplastic Syndromes (2022) (0)
PF257 GEMTUZUMAB OZOGAMICIN COMBINED WITH CYTARABINE FOR ACUTE MYELOID LEUKEMIA PATIENTS IN FIRST RELAPSE (2019) (0)
NPM Mutations in Adult AML with Normal Karyotype: A Retrospective Study of the Acute Leukemia French Association (ALFA). (2005) (0)
Non-allogeneic immunotherapy in acute myeloid leukaemia. (2019) (0)
DNA and All-Trans Retinoic Acid as Immunotherapy or Add-on Adjuvants to 5-Azacytidine In Myelodysplastic Syndromes (2010) (0)
Epidemiology and etiologic factors of myelodysplastic syndromes (1997) (0)
Impact of treatment prior to allogeneic stem cell transplantation for myelodysplastic syndromes: A study on behalf of the SFGM-TC and the GFM groups. (2017) (0)
Results with ATRA and Anthracycline Based Chemotherapy (CT) in Acute Promyelocytic Leukemia (APL) in a Developing Country. Should Dose Intensity Be Reduced to Obtain Acceptable Results (2011) (0)
174 Does addition of erythropoietic stimulating agents (ESAs) improve the outcome of higher-risk MDS patients treated with azacitidine (AZA)? (2011) (0)
Comparative trial of aazacitidine versus conventional care in high risk MDS patients: Methodologic challenges in designing an international survival trial. (2003) (0)
Allogeneic Hematopoietic Stem Cell Transplantation for Acute Myeloblastic Leukemia (AML) or Myelodysplastic Syndrome (MDS) in Patients (pts) Older Than 50 Years: a Retrospective Single Center Study (2008) (0)
MDS-175: Assessment of Dose-Dependent Response to Luspatercept in Patients with Lower-Risk Myelodysplastic Syndromes (LR-MDS) with Ring Sideroblasts (RS) in the Phase 3 MEDALIST Trial (2020) (0)
280 EFFICACY OF AZACITIDINE (AZA) IN AUTOIMMUNE DISORDERS (AID) ASSOCIATED WITH MDS (2015) (0)
Traitement des leucémies myéloïdes de l'adulte (1999) (0)
Therapy Related APL (tAPL). Prospective Analysis of Etiological Factors In Recent Cases, and Comparison with De Novo Cases (2010) (0)
Decitabine Versus Hydroxyurea for Advanced Proliferative Chronic Myelomonocytic Leukemia: Results of a Randomized Phase III Trial Within the EMSCO Network (2022) (0)
Exome analysis of treatment‐related AML after APL suggests secondary evolution (2018) (0)
Abstract 6168: Implementation and adoption of a web tool to support precision diagnostic and treatment decisions for patient with myelodysplastic syndromes (2023) (0)
Differences in classification schemata for myelodysplastic/myeloproliferative overlap neoplasms (2022) (0)
P-133 A single nucleotide polymorphism in CRBN gene as a biomarker of response to treatment with lenalidomide in MDS without del5q (2013) (0)
Caractéristiques cliniques, pathologiques et moléculaires des myelodysplasia cutis (2021) (0)
162 A phase II study of decitabine in advanced chronic myelomonocytic leukemia (CMML) (2011) (0)
MDS-110 SELECT-MDS-1 Trial in Progress: A Phase 3 Randomized, Double-Blind, Placebo-Controlled Study of Tamibarotene/Azacitidine Versus Placebo/Azacitidine in Newly Diagnosed Adult Patients Selected for RARA-Positive Higher-Risk MDS. (2022) (0)
Myelodysplastic syndromes and 5q deletion (1995) (0)
Impact Of Myelofibrosis (MF) In MDS Treated With Azacitidine (AZA). A Single Center Study (2013) (0)
Traitement des leucémies aiguës promyélocytaires de l’adulte (2008) (0)
Allogeneic Stem Cell Transplantation (allo-SCT) for Chronic Myelomonocytic Leukemia (CMML): Prognostic Factors for Survival. A Report From the Societe Francaise De Greffe De Moelle Et De Therapie Cellulaire (SFGM-TC), (2011) (0)
Relationship of Bone Marrow Blast (BMBL) Response to Overall Survival (OS) in Patients with Higher-Risk Myelodysplastic Syndrome (HR-MDS) Treated with Rigosertib after Failure of Hypomethylating Agents (HMAs) (2014) (0)
Outcome of patients less than 55 years of age with high-risk acute leukemia who did not have an HLA-identical related donor: A long-term study of 97 consecutive patients. (2004) (0)
adults : recommendations from the European LeukemiaNet Diagnosis and treatment of primary myelodysplastic syndromes in (2013) (0)
O-011 Azacitidine (AZA) + idarubicin (IDA) in untreated high-risk MDS – A GFM phase I/II study (2013) (0)
P-26 Structural parameters provided by blood analysis with Sysmex XE 2100N analyzer are helpful for the diagnosis of MDS (2005) (0)
Myelodysplastic syndromes. (1996) (0)
Les syndromes myélodysplasiques (2006) (0)
Les néo-écologistes: des boy-scouts en recherche d'ascension sociale ? : Ecolo, complètement parti (1999) (0)
Acknowledgement to Referees (2005) (0)
Sintra-Rev Clinical Trial: Preliminary Analysis of Efficacy and Safety at Week 12 of Treatment in MDS Del(5Q) and Transfusion Independence (2017) (0)
NRAS:BCL-2 Complex Localization Determines Anti-Apoptotic Features Associated with Progressive Disease in Myelodysplastic Syndromes (MDS) (2012) (0)
Correlation Between Bone Marrow Dysplasia and Genomic Profile in De Novo Acute Myeloid Leukemia (AML): A Study By the ALFA Group (2015) (0)
Psychological Distress Among MDS Patients: Prevalence and Correlates (2017) (0)
Des colonies aux comptoirs marchands (1994) (0)
PB1921: A RANDOMIZED, DOUBLE-BLIND, PHASE 3 STUDY OF TAMIBAROTENE/AZACITIDINE VERSUS PLACEBO/AZACITIDINE IN NEWLY DIAGNOSED ADULT PATIENTS SELECTED FOR RARA-POSITIVE HR-MDS (SELECT-MDS-1) (2022) (0)
High Body Mass Index (BMI) as a Predictor of Differentiation Syndrome (DS) In Acute Promyelocytic Leukemia (APL). (2010) (0)
ALFA-9000 Trial - An Analysis of Cytogenetic Subsets: Significant Long-Term Benefit of Early Induction Reinforcement Is Observed in CBF-AML Only. (2005) (0)
Groupe neoplasms to myelodysplastic syndrome or acute myeloid leukemia by Treatment of progression of Philadelphia-negative myeloproliferative (2010) (0)
Prognostic Role of Gene Mutations in Chronic Myelomonocytic Leukemia (CMML) Patients Treated with Hypomethylating Agents. a Report on 183 Patients (2017) (0)
Caractéristiques cliniques, évolution et prise en charge des thrombopénies immunologiques associées aux syndromes myélodysplasiques et leucémies myélomonocytaires chroniques : une étude multicentrique rétrospective comparative (2019) (0)
[Amyloidosis AL and chronic myelo-monocytic leukemia]. (1994) (0)
The EGFR-Inhibitor Erlotinib Induces Differentiation, Cell Cycle Arrest and Apoptosis in EGFR-Negative Cells of MDS and AML. (2007) (0)
ADULT B‐CELL ALL, BURKITT TYPE (1989) (0)
Venous thromboembolism during systemic inflammatory and autoimmune diseases associated with myelodysplastic syndromes, chronic myelomonocytic leukaemia and myelodysplastic/myeloproliferative neoplasms: a French multicentre retrospective case-control study. (2021) (0)
81 LONG-TERM OUTCOME OF LOWER RISK MDS PATIENTS RECEIVING ESA, AND IMPACT OF POST-ESA TREATMENTS ON SURVIVAL: A RETROSPECTIVE STUDY FROM THE GFM, DÜSSELDORF, AND GESMD REGISTRIES (2015) (0)
Investigations into the Mechanisms and Clinical Implications of Modulation of Hepcidin Levels By Luspatercept in TD MDS and TD b-Thalassemia (2022) (0)
DNA Replication Stress Due to Loss of R-Loops in Myelodysplastic Syndromes with SF3B1 Mutation (2022) (0)
Abnormal Expression and Function of the Lnk Adaptor Protein in Myeloproliferative Neoplasms (MPN). (2009) (0)
Identification de mutations clonales identiques dans les xanthélasma palpébraux de maladie d’Erdheim-Chester associés à des leucémies myélomonocytaires chroniques: à propos de 3 cas (2019) (0)
MDS with Isolated Trisomy 8: A type of MDS Frequently Associated with Myeloproliferative Features? A Report by the GFM (2017) (0)
[Cytological diagnosis of myelodysplastic syndromes. Apropos of 200 cases]. (1987) (0)
Dynamics of Mortality and Transformation Risk within Different Risk Groups of Patients with Myelodysplastic Syndromes Stratified According to the IPSS-R - Comparison of Treated and Untreated Patients and Consequences for the Description of Risk Categories (2022) (0)
‘Corrigendum to “Chronic myelomonocytic leukemia: Myelodysplastic or myeloproliferative?” [Best Pract Res Clin Haematol (2013) 387–400]’ (2014) (0)
BCL2L10 Quantification Is a Predictive Factor of Response to Azacitidine in Myelodysplastic Syndromes (MDS) and Acute Myeloid Leukemia (AML) (2014) (0)
PCN3 Changes in Transfusion Burden (TB), Hemoglobin (Hb), Serum Ferritin (SF), and Iron Chelation Therapy (ICT) Use in Patients With Lower-Risk Myelodysplastic Syndromes With Ring Sideroblasts Treated With Luspatercept From the MEDALIST Study (2021) (0)
Syndrome hyperéosinophilique idiopathique «sous-groupe myéloprolifératif révélateur d'un lymphome non hodgkinien (1989) (0)
Iconographies supplémentaires de l'article : Syndromes myélodysplasiques et leucémies secondaires. Traitement (2014) (0)
15 HLA-MATCHED ALLOGENEIC STEM CELL TRANSPLANTATION IMPROVES OVERALL SURVIVAL OF HIGHER RISK MYELODYSPLASTIC SYNDROME (2015) (0)
GERMLINE CHEK2 MUTATED MDS PATIENTS (2023) (0)
Mutational Analysis of MDS and AML Occurring after Treatment for Acute Promyelocytic Leukemia (APL). a Report of 9 Cases (2016) (0)
Sequential Conditioning Regimen with Thiotepa in Allogeneic Hematopoietic Cell Transplantation for the Treatment of Refractory Myeloid Malignancies (2021) (0)
Evaluation Of Acadesine, a Drug Stimulating Cell Autophagy, In Azacitidine(AZA)-Resistant Myelodysplastic Syndromes (MDS) (2013) (0)
Reply to S. Nagai et al (2010) (0)
[Therapeutic strategy in myeloblastic syndromes]. (1997) (0)
Topic: AS04-MDS Biology and Pathogenesis/AS04h-Immune deregulation/inflammation: CXCL8 SECRETED BY IMMATURE GRANULOCYTES INHIBITS WILD-TYPE STEM AND PROGENITOR CELL EXPANSION IN CHRONIC MYELOMONOCYTIC LEUKEMIA (2023) (0)
Effect of Lenalidomide Exposure on Response and Outcomes in Patients with Lower-Risk Non-Del(5Q) Myelodysplastic Syndromes (MDS) (2017) (0)
88 BONE MARROW BLAST (BMBL) RESPONSE CORRELATES WITH OVERALL SURVIVAL IN RIGOSERTIB-TREATED PATIENTS WITH HIGHER-RISK MDS AFTER FAILURE OF HYPOMETHYLATING AGENTS (HMAS): A NEW RESPONSE CRITERION? (2015) (0)
Diagnostic Techniques in Hematological Malignancies: Myelodysplastic syndromes and myelodysplastic/myeloproliferative neoplasms (2010) (0)
Compte rendu de l’ASCO 2006 : Hémopathies myéloïdes (2006) (0)
109 CLINICAL AND MOLECULAR PREDICTORS OF RESPONSE TO ERYTHROPOIESIS STIMULATING AGENTS (ESA) IN LOWER RISK MDS PATIENTS (2015) (0)
23 DOWN-REGULATION OF MIR150 PROMOTES THE ACCUMULATION OF CLASSICAL MONOCYTES, A CHARACTERISTIC FEATURE OF CHRONIC MYELOMONOCYTIC LEUKEMIA (2015) (0)
P-284 Impact of cytogenetics and cytogeneticresponse on outcome in MDS treated with azacitidine (AZA) (2013) (0)
Multi-Modal Analysis and Federated Learning Approach for Classification and Personalized Prognostic Assessment in Myeloid Neoplasms (2022) (0)
21 Association between myelodysplastic syndromes and inflammatory bowel diseases: report of 4 new cases and review of previously reported cases (1997) (0)
Current landscape of translational and clinical research in myelodysplastic syndromes/neoplasms (MDS): Proceedings from the 1st International Workshop on MDS (iwMDS) Of the International Consortium for MDS (icMDS). (2023) (0)
Improved benefit of continuing luspatercept therapy: sub-analysis of patients with lower-risk MDS in the MEDALIST study (2023) (0)
Treatment of Lower Risk MDS with Del 5q by Lenalidomide, with or without G-CSF: Current Results of the French Patient Named Program (ATU) (2008) (0)
Multicenter validation of the flow measurement of classical monocyte fraction for chronic myelomonocytic leukemia diagnosis (2018) (0)
Incidence, Clinical Associations, and Co-Mutation Patterns of UBA1 Mutations in MDS (2022) (0)
pVAX14 DNA, a Non-Specific DNA Vaccine, Improves Survival In An Acute Promyelocytic Leukemia (APL) Mouse Model Treated With All-Trans Retinoic Acid (ATRA) and Arsenic Trioxide (ATO) and Targets Leukemia Initiating Cells (LICs) (2013) (0)
P-283 Efficacy of salvage with decitabine (DAC) for high-risk (HR)-MDS and advanced CMML after azacitidine (AZA) treatment failure (2013) (0)
P118 The capacity of the hypomethylating agents azacytidine and decitabine to induce apoptosis and cell cycle arrest depends on the activation of the DNA-damage response pathway (2009) (0)
Intensive Therapy of Myelodysplastic Syndromes and Secondary Leukemias: Preliminary Findings of the French Experience (1997) (0)
Myelodysplasia cutis (2020) (0)
Disease Characteristics and International Prognostic Scoring Systems (IPSS, IPSS-R, IPSS-M) in Adult Patients with Higher-Risk Myelodysplastic Syndromes (MDS) Participating in Two Randomized, Double-Blind, Placebo-Controlled Studies with Intravenous Sabatolimab Added to Hypomethylating Agents (HMA) (2022) (0)
Molecular Response Analysis By High Throughput Sequencing in Higher Risk Myelodysplastic Syndrome (HR-MDS) Treated Intensively with CPX-351 (2022) (0)
217 DEFINING LIKELIHOOD OF FUTURE RESPONSE IN PATIENTS WITH DEL(5Q) MYELODYSPLASTIC SYNDROMES (MDS) TREATED WITH LENALIDOMIDE (2015) (0)
Prevalence and Clinical Impact of Additional Cytogenetic Abnormalities in Patients (Pts) with Myelodysplastic Syndromes (MDS) and Deletion 5q from the MDS-003 and MDS-004 Studies (2014) (0)
Original article A cost-effectiveness analysis of using azacitidine vs. decitabine in treating patients with myelodysplastic syndromes (2012) (0)
Topic: AS06-Prognosis/AS06a-Prognostic factors of outcome and risk assessment (2021) (0)
172 Chemotherapy of adult chronic myelomonocytic leukemia (CMML) (1997) (0)
Is There a Role for Red Cell Mass (RCM) Assessment To Classify Myeloproliferative Disorders (MPD) in the JAK2 Era (2007) (0)
The Population-Based ‘real world’ of Low Risk Myelodysplastic Syndromes; Second Interim Analysis of the European LeukemiaNet MDS Registry at 800 Registered New Patients (2010) (0)
in MDS patients treated with AZA. Its prognostic value may be further improved by specific scoring systems established for AZA treatment such as the one we described previously.3 (2017) (0)
Corrigendum to "A systematic review of higher-risk myelodysplastic syndromes clinical trials to determine the benchmark of azacitidine and explore alternative endpoints for overall survival" [Leukemia Res. 104 March (2021)]. (2021) (0)
ABT-737 Targets Leukemic Stem Cells In Mouse Models of Mutant NRASD12/hBCL-2- Mediated Acute Myeloid Leukemia Progression with Increased Survival (2010) (0)
Recommandations pourl'utilisation de l'azacitidine dans le traitement des syndromes myélodysplasiques de risque intermédiaire-2 ou élevé (2010) (0)
MEETING REPORT Meeting report: myelodysplastic syndromes at ASH 2007 (2008) (0)
ORAL RIGOSERTIB COMBINED WITH AZACITIDINE IN PATIENTS WITH ACUTE MYELOID LEUKEMIA (AML) AND MYELODYSPLASTIC SYNDROMES (MDS): EFFECTS IN TREATMENT NAÏVE AND RELAPSED/REFRACTORY PATIENTS Author(s): (2017) (0)
Disappearance of Slan-Positive Non-Classical Monocytes As a New Parameter for the Diagnosis of Chronic Myelomonocytic Leukemia with Associated Inflammatory State (2018) (0)
Reduced MDM2 and MDM4 Protein, but Not mRNA, Expression Is Associated with More Severe Disease in Acute Myeloid Leukemia (AML), Myelodysplastic Syndromes (MDS), and Chronic Myelomoncytic Leukemia (CMML) (2022) (0)
Results of a Phase II Study of Guadecitabine in Higher Risk MDS Patients Refractory to or Relapsing after Azacitidine Treatment (2017) (0)
185 Long term survival after intensive chemotherapy in de novo MDS: Lille's experience (1997) (0)
[Myelodysplastic syndromes or refractory anemias]. (1993) (0)
P-281 Escalating doses of clofarabine (CLO) for high-risk myelodysplastic syndrome (HR-MDS) and acute myeloid leukemia post-MDS (sAML) failing azacitidine (AZA) (2013) (0)
TP53 Alterations in Myelodysplastic Syndromes and Acute Myeloid Leukemia (2023) (0)
Correlation Between serum ferritin Level at diagnosis and Survival In Lower Risk, Non-Transfusion Dependent, MDS Patients.A Report by the Groupe Francophone Des Myelodysplasies (GFM) (2010) (0)
inflammatory Arthritis in Patients with Myelodysplastic Syndrome: French Multicenter Retrospective Study. : 195 (2012) (0)
Manifestations auto-immunes et inflammatoires associées aux syndromes myélodysplasiques : effet de l’azacitidine sur les différentes populations immunitaires (2019) (0)
Management of MDS with Isolated Del(5q) Patients in the European MDS (EUMDS) Registry: A Report on 197 Cases (2022) (0)
Perspective: Pivotal translational hematology and therapeutic insights in chronic myeloid hematopoietic stem cell malignancies (2022) (0)
pVAX14DNA-mediated add-on immunotherapy combined with arsenic trioxide and all-trans retinoic acid (ATO+ATRA) targeted therapy effectively increases survival of APL mice (2015) (0)
[Acquired idiopathic sideroblastic anemia. Apropos of 39 cases]. (1989) (0)
Progression Free Survival (PFS), and Event Free Survival (EFS) from a Global Randomized Phase 3 Study of Guadecitabine (G) Vs Treatment Choice (TC) in 815 Patients with Treatment Naïve (TN) AML Unfit for Intensive Chemotherapy (IC): ASTRAL-1 Study (2019) (0)
Allogeneic transplantation in acute myelogenous leukemia: a comprehensive single institution's experience. (2023) (0)
Allogeneic Hematopoietic Peripheral Blood Stem-Cell Transplantation From HLA-Identical Siblings Versus Allelic-Matched Unrelated Donors (10/10 high resolution) in Patients with Acute Myeloid Leukemia and Myelodyplasic Syndrome After Reduced Intensity Conditioning, (2011) (0)
Author ' s Accepted Manuscript Treatment of MDS With Thrombomimetic Drugs (2014) (0)
Combination of Oral Rigosertib and Injectable Azacitidine in Patients with Myelodysplastic Syndromes (MDS) (2017) (0)
99 Correlation between serum ferritin level at diagnosis and survival in lower risk, non-transfusion dependent, MDS patients (2011) (0)
Intra-Tumor Heterogeneity (ITH) in Acute Myeloid Leukemia (AML) (2019) (0)
A phase Ib study of oral panobinostat (LBH589) administered with 5-azacitidine (5-Aza) in patients with myelodysplastic syndromes (MDS), chronic myelomonocytic leukemia (CMML), or acute myeloid leukemia (AML). (2010) (0)
Luspatercept significantly reduces red blood cell transfusion burden, regardless of gene mutation frequency, spectrum, and prognostic significance, among patients with lower-risk myelodysplastic syndromes enrolled in the MEDALIST trial (2020) (0)
[A treatment that messes one's hair up and works on an unhealthy liver...]. (2004) (0)
Validation of the Medical Research Council (MRC) and the Leukemia Research Foundation (LRF) Score for Hypomethylating Agents (HMAs) Use in Patients with Relapsed and Refractory Acute Myeloid Leukemia (RR-AML) (2017) (0)
Prognostic Impact of Response According to International Consortium for MDS/MPN Criteria in CMML Treated with Hypomethylating Agents (HMA) (2015) (0)
Management of MDS with Isolated Del(5q) Patients in the European MDS (EUMDS) Registry, a Unique Prospective Real-World Dataset (2021) (0)
Dual origin of relapses in retinoic-acid resistant acute promyelocytic leukemia (2018) (0)
TP, NV, ST, CG, PF and SG received research support from Celgene. SG owns stock in Celgene. (2012) (0)
Assessment of longer-term efficacy, safety, and haematological improvement in the phase 3, randomised, double-blind, placebo-controlled MEDALIST trial of luspatercept to treat anaemia in patients with lower-risk myelodysplastic syndromes with ring sideroblasts who require red blood cell transfusions (2020) (0)
Systemic Inflammatory and Autoimmune Diseases (SAID) Associated with MDS: A French Multicenter Retrospective Study (2014) (0)
MIR150 Is Involved in the Monocyte Subset Differentiation and Its Down-Regulation Leads to Classical Monocyte Accumulation in Chronic Myelomonocytic Leukemia (2016) (0)
In vitro studies of stem cell factor (SCF) and interleukin-11 (IL-11) in normal and “preleukemic” haematopoiesis (1993) (0)
306 Impact of TET2 mutations on response rate to azacitidine in myelodysplastic syndromes and low blast count acute myeloid leukemias (2011) (0)
ERN-EurobloodNet: A European Reference Network for Rare Blood Diseases and a Model for Emulation (2019) (0)
Favorable evolution of lung interstitial disease in a patient with chronic myelomonocytic leukemia treated with azacitidine (2018) (0)
POLYCHONDRITE ATROPHIANTE ET LEUCÉMIE MYÉLOMONOCYTAIRE CHRONIQUE (2009) (0)
Granulomonocytic Progenitors (GMPs) Are Key Target Cells of Azacitidine in MDS and AML (2017) (0)
Pan-Stakeholder Core Outcome Set (COS) Definition for Selected Hematological Malignancies - Results of the Harmony Alliance (2021) (0)
The Absolute Count of Circulating, Classical, CD14++/CD16- Monocytes Is a Poor Prognosis Marker in Chronic Myelomonocytic Leukemia (CMML) (2019) (0)
Multiple myeloma. A model of nature. (1999) (0)
Synthetic Data Generation By Artificial Intelligence to Accelerate Translational Research and Precision Medicine in Hematological Malignancies (2022) (0)
Iconographies supplémentaires de l'article : Syndromes myélodysplasiques et leucémies secondaires. Généralités, diagnostic et classification (2014) (0)
A Validation of a Post-Hypomethylating Agent Failure (HMAF) Prognostic Model in MDS Patients Treated with Rigosertib Versus Best Supportive Care (BSC) (2017) (0)
O-016 Relationship of different platelet response criteria and patient outcomes in a Romiplostim MDS trial (2013) (0)
Comparison between the FAB system and three prognostic scoring systems in 245 untreated patients with de novo MDS. The lille experience (1994) (0)
P778: LONG-TERM UTILIZATION AND BENEFIT OF LUSPATERCEPT IN PATIENTS (PTS) WITH LOWER-RISK MYELODYSPLASTIC SYNDROMES (LR-MDS) FROM THE MEDALIST TRIAL (2022) (0)
Study of the Rearrangement of Proto-oncogene MET in 88 Cases of Myelodysplastic Syndromes (1992) (0)
Biomarkers of Response to Romiplostim in Patients with Lower-Risk Myelodysplastic Syndrome (MDS) and Thrombocytopenia - Results of the Europe Trial By the Emsco Network (2019) (0)
Health-Related Quality of Life is Substantially Impaired in Lower-Risk MDS when Compared with Reference Populations and Significantly Affects Overall Survival (2017) (0)
[Ineffective erythropoiesis of immunologic origin with free bilirubin jaundice in an elderly subject]. (1987) (0)
Book Review Postgraduate Haematology Fifth edition. Edited by A. Victor Hoffbrand, Daniel Catovsky, and Edward G.D. Tuddenham. 1073 pp., illustrated. Malden, Mass., Blackwell, 2005. $250. 1-405-10821-5 (2005) (0)
[Dosage and efficacy of antilymphocyte serum in severe bone marrow aplasia]. (1986) (0)
SNP-Array Genome Wide Association Study Meta-Analysis Identifies Innate Immune Susceptibility Loci Associated with Non-Del(5q) Myelodysplastic Syndromes Predisposition (2018) (0)
223 WHICH QUESTIONS MDS PATIENTS WOULD LIKE TO ASK THEIR DOCTORS (2015) (0)
Syndrome de pseudo-Behçet et autres manifestations dysimmunitaires associées aux syndromes myélodysplasiques avec trisomie 8 (2020) (0)
Abstract 2570: Identification of genetic polymorphisms associated with myelodysplastic syndromes by genome-wide association study (2016) (0)
Topic: AS08-Treatment/AS08g-Clinical trials - Phase II-III (2021) (0)
P127 Rates of infection and bleeding are not increased in patients (Pts) with MDS treated with azacitidine (AZA) compared with best supportive care (BSC) (2009) (0)
[Hepatic lymphoma simulating glycogenosis]. (1986) (0)
Deriving Core Patient-Reported Outcomes in Patients with Myelodysplastic Syndromes — a Delphi Survey from the European-MDS Registry (2018) (0)
Validation of a post-hypomethylating agent failure prognostic model in myelodysplastic syndromes patients treated in a randomized controlled phase III trial of rigosertib vs. best supportive care (2017) (0)
148 CLONAL EVOLUTION OF HEMATOPOIETIC STEM CELL UNDER TREATMENT BY LENALIDOMIDE IN NON DEL(5Q) MDS (2015) (0)
Abrogation of the DNA-Damage Response in De Novo AML Versus MDS Cell Lines. (2006) (0)
P098 Detection and management of iron overload in MDS: a European survey (2009) (0)
Job offer (2007) (0)
Incidence of Atrx Mutations in Myelodysplastic Syndromes (MDS) (2014) (0)
Hypervitaminémie B12 dans les syndromes myélodysplasiques : facteur de mauvais pronostic ? (2015) (0)
Machine learning-based improvement of MDS-CBC score brings platelets into the limelight to optimize smear review in the hematology laboratory (2022) (0)
Selective Suppression of the DNA Damage Response in Acute Myeloid Leukemia Versus Myelodysplastic Syndrome. (2008) (0)
MDS-179: Clinical Benefit of Luspatercept in Patients with Lower-Risk Myelodysplastic Syndromes (LR-MDS) and High Transfusion Burden (HTB) in the Phase 3 MEDALIST Study (2020) (0)
LES LIMITES DE BARAK (1999) (0)
P088 Evaluation of cardiac iron overload by cardiac MRI T2 in regularly transfused MDS (2009) (0)
Diagnosis and outcome prediction for childhood acute leukaemia by gene expression profiling (2004) (0)
P-273 Azacitidine treatment for patients with myelodysplastic syndrom and acute myeloid leukemia harboring chromosome 3q abnormalities (2013) (0)
P35 Impact sur la survie et la probabilité de rechute de la radio- I thérapie effectuée après autogreffe de cellules souches hématopoïétiques chez des patients atteints d'un lymphome malin non hodgkinien. Expérience de l'hôpital Saint-Antoine (1997) (0)
Is Azacitidine (AZA) Really Effective in High Risk MDS Patients with Chromosome 7 Abnormalities (Abn 7)? Results of a Retrospective Study From the GFM and GESMD Registries (2012) (0)
Management of APL in the Elderly (2018) (0)
Clinical Results of All Trans Retinoic Acid (1995) (0)
Author Correction: Implications of TP53 allelic state for genome stability, clinical presentation and outcomes in myelodysplastic syndromes (2021) (0)
Markers of Oxidative Stress Do Not Correlate with Labile Plasma Iron Blood in Patients with Myelodysplastic Syndromes (2015) (0)
Treatment-emergent adverse events (TEAEs) in lenalidomide (LEN)-treated Low-/Int-1-risk myelodysplastic syndromes (MDS) patients (pts) without del(5q) ineligible for or refractory to erythropoiesis-stimulating agents (ESAs). (2016) (0)
Conditional Survival in Patients with Del(5q) Myelodysplastic Syndromes Treated with Lenalidomide (2015) (0)
Erlotinib Inhibits ABC Transporters of AML Progenitors with Stem Cell Features and Increases Chemosensitivity to Current AML Drugs (2010) (0)
51 PROGNOSTIC IMPACT OF TRANSFUSION INTENSITY ON SURVIVAL AND THROMBOCYTOPENIA IN NEWLY DIAGNOSED LOWER-RISK MDS PATIENTS PARTICIPATING IN THE EUROPEAN LEUKEMIANET MDS (EUMDS) REGISTRY (2015) (0)
The impact of lenalidomide exposure on response and outcomes in patients with lower-risk myelodysplastic syndromes and del(5q) (2018) (0)
P-098 p53 protein expression predicts outcome and cytogenetic response in patients with low-/INT-1-risk myelodysplastic syndromes treated with lenalidomide (2013) (0)
100 Expression of FAS/APO-1/CD95 antigen and its function in myelodysplastic syndromes (1997) (0)
PSY31 CLINICAL-ECONOMIC EVALUATION OF AZACITIDINE VERSUS DECITABINE FOR TREATING PATIENTS WITH MYELODYSPLASTIC SYNDROMES (MDS) (2010) (0)
Group leukemia. Results of a multicenter randomized trial. European APL 91 Effect of all transretinoic acid in newly diagnosed acute promyelocytic (2013) (0)
Efficacy and Safety of Darbepoetin Alfa (DA) in Patients with Myelodysplastic Syndromes (MDS): A Systematic Review and Meta-Analysis (2015) (0)
Prognostic Impact of Transfusions Intensity on Survival and Development of Thrombocytopenia in Newly Diagnosed Lower-Risk MDS Patients Participating in the European Leukemianet EU-MDS Registry (2015) (0)
145 Mutations of the MSH2 gene in myelodysplastic syndrome (MDS) (1997) (0)
[Efficacy of pipobroman in the treatment of essential thrombocythemia]. (1988) (0)
Comparison of In vivo [18F]Fluoro-desoxyglucose and [18F]Fluoro-thymidine Positron Emission Tomography for Disease Monitoring in a Mouse Model of Higher-Risk Myelodysplastic Syndrome (2021) (0)
Characterization of Patients with Lower-Risk Myelodysplastic Syndromes Experiencing Long-Term Responses with Luspatercept in the MEDALIST Study (2022) (0)
[Hodgkin's disease disclosed by myelofibrosis of primary appearance. Apropos of 2 cases]. (1988) (0)
205 a Single Center Report of Therapeutic Strategies in Patients With Atypical Cml (Acml) and Unclassified Mds/Mpn (Mds/Mpn-U) (2015) (0)
Le rituximab est-il une alternative à la splénectomie chez les adultes atteints d'un purpura thrombopénique immunologique chronique ? Résultats d'une étude prospective multicentrique de phase 2 (2006) (0)
Multiple Episodes of Transfusion Independence with Luspatercept Treatment and the Impact of Dose Escalation in Patients with Lower-Risk Myelodysplastic Syndromes from the MEDALIST Study (2022) (0)
INSPIRE: A randomized phase III trial of intravenous rigosertib in patients with higher-risk myelodysplastic syndromes (HR-MDS) after failure of hypomethylating agents (HMAs)—Study design informed by subgroup analyses of ONTIME. (2016) (0)
International Working Group (IWG) Response Criteria and Association with Overall Survival in Patients with Myelodysplastic Syndromes Treated with Hypomethylating Agents - a Systematic Review and Meta-Analysis (2022) (0)
P-110 Thalidomide for the treatmentof low risk myelodysplasia: The ThaI-SMD-200 trial (2005) (0)
191 Vorinostat and low dose cytarabine for high risk myelodysplastic syndromes with azacytidine failure: the GFM-VOR2007 study (2011) (0)
113 Morphological, cytogenetic, molecular and etiological features of the ⪡ 17p syndrome ⪢ in MDS (1997) (0)
Brief report M0 AML, clinical and biologic features of the disease, including AML1 gene mutations: a report of 59 cases by the Groupe Franc¸ais d’He´matologie Cellulaire (GFHC) and the Groupe Franc¸ais de Cytoge´ne´tique He´matologique (GFCH) (2003) (0)
[Prognostic factors in myelodysplasia syndromes]. (2002) (0)
Mutations in the Exon 12 of the JAK2 Gene Appeared To Be a Rare Event Essentially Clustered in V617F JAK2 Negative PV Patients. (2007) (0)
AB0044 REDUCED PERIPHERAL BLOOD MYELOID CELLS IN PATIENTS WITH VEXAS SYNDROME (2022) (0)
P114 Treatment of lower risk MDS with del 5q by lenalidomide (LEN), with or without G-CSF: current results of the French Patient Named Program (ATU) (2009) (0)
MDS with Isolated Trisomy 8. a Type of MDS Frequently Associated with Myeloproliferative Features? A Report from the GFM (2015) (0)
Long-Term Outcome of Lower-Risk MDS Patients after Immunosuppressive Therapy (IST) with Anti-Thymocyte Globulin (ATG)+/- Cyclosporin A (CsA) (2014) (0)
myelodysplastic syndromes: a randomized, controlled trial granulocyte colony-stimulating factor for the treatment of Health, economic, and quality-of-life effects of erythropoietin and (2013) (0)
Hematopoietic growth factors. Do they have a role in the management of myelodysplastic syndromes (1997) (0)
A Retrospective Validation of International Consortium for MDS/MPN Response Criteria in CMML Treated with Hypomethylating Agents (2017) (0)
Pr Michel Boiron (2019) (0)
Fréquence des auto-anticorps dans les syndromes myélodysplasiques avec et sans manifestations auto-immunes cliniques (2015) (0)
Association entre syndrome myélodysplasique et entérocolopathies inflammatoires (1997) (0)
Caractéristiques des manifestations articulaires inflammatoires au cours des syndromes myélodysplasiques (2012) (0)
The EGFR-Inhibitor Erlotinib Induces Apoptosis in Neoplastic Cells of Myelodysplastic Syndrome (MDS) and Acute Myeloid Leukemia (AML), an Effect Determined by the Expression Level of Nucleophosmin (NPM). (2006) (0)
Topic: AS04-MDS Biology and Pathogenesis/AS04f-Gene expression profiling: CMML PATIENTS WITH LOW EXPRESSION OF TP53 POINT TO AML TRANSFORMATION (2023) (0)
Older Patients with Acute Myeloid Leukemia (AML) in First Relapse: Impact of Genetics and of Salvage Therapy. A Study of the Acute Leukemia French Association (ALFA) (2011) (0)
phase 2 study immune thrombocytopenic purpura - results of a prospective multicenter Rituximab efficacy and safety in adult splenectomy candidates with chronic (2013) (0)
Evaluation of Salvage Induction Chemotherapy Regimens in Myelodysplastic Syndrome and Acute Myeloid Leukemia after Hypomethylating Agent Treatment Failure (2017) (0)
All-Trans Retinoic Acid a s a Differentiation Therapy for Acute Promyelocytic Leukemia (1990) (0)
PVN1: A Phase 2 Study of Pegylated Interferon-α2a in Polycythemia Vera (PV) by the “PV-Nord” Group. Preliminary Report of Efficacy and Safety. (2005) (0)
NF- (cid:1) B constitutes a potential therapeutic target in high-risk myelodysplastic syndrome (2006) (0)
(MDS) on anemia, costs and quality of life: a randomized controlled trial factor (rHuG-CSF) for the treatment of myelodysplastic syndromes Effects of erythropoietin (rHuEpo) plus granulocyte colony stimulating (2013) (0)
promyelocytic leukemia. I. Clinical results (see comments) All-trans retinoic acid as a differentiation therapy for acute (2011) (0)
model of AML by targeting primitive LSK and progenitor cells BCL-2 inhibition with ABT-737 prolongs survival in an NRAS / BCL-2 mouse (2013) (0)
Myelodysplastic Syndrome and Giant Cell Arteritis: A Nonfortuitous Association that Geriatricians Should Know About (2017) (0)
Utilisation de l’azacitidine dans le VEXAS chez des patients porteurs d’un syndrome myélodysplasique : données du registre Français VEXAS (2021) (0)
Are Myelodysplastic Syndrome (MDS) and Acute Myeloid Leukemia (AML) Occurring during the Course of Lymphoma (Ly) Always Therapy Related (2015) (0)
The JAK2 V617F Mutation Identifies Specific Subgroups of Myelodysplastic Syndrome (MDS). (2006) (0)
Syndrome de lyse tumorale au cours d'une leucémie lymphoïde chronique traitée par polychimiothérapie (1987) (0)
Soumission Congres MDS 2015 English immuno (2015) (0)
Autoévaluations de l'article : Syndromes myélodysplasiques et leucémies secondaires. Généralités, diagnostic et classification (2014) (0)
Uncommon Mutations in PML-RARα Associated with Poor Outcome after First Relapse in APL. (2007) (0)
Diagnosis and management of inflammatory and autoimmune manifestations associated with myelodysplastic syndromes (2016) (0)
Presence of inv (16) May Be One of the Only “Favorable” Prognostic Factors in AML: A Report on 16 Cases (1994) (0)
P057 Abrogation of the DNA-damage response in AML versus MDS cell lines (2007) (0)
Additional prognostic impact of the percentage of erythroid cells in the bone marrow of patients with myelodysplastic syndromes. (2019) (0)
Les syndromes myélodysplasiques acquis ou anémies réfractaires (1985) (0)
Acute Promyelocytic Leukemia (2011) (0)
Physiopathologie de l'angiogenèse dans les myélodysplasies (2007) (0)
Exposure to occupational and environmental factors in MDS. Preliminary results of a case control study (1994) (0)
Localisation thyroïdienne spécifique de la maladie de Hodgkin : revue de la littérature a propos de trois observations (1991) (0)
Amylose AL et leucémie myélo-monocytaire chronique (1994) (0)
Leucémie myélomonocytaire chronique et microangiopathie thrombotique (2011) (0)
Échos de l’ASH 2008 (2009) (0)
Cases With 17p Deletion Essential Thrombocythemia Treated With Hydroxyurea: High Proportion of Acute Myeloid Leukemia and Myelodysplastic Syndromes Following (2013) (0)
Efficacy of ABT-737, a BCL-2 Inhibitor, in an NRAS/BCL2 Mouse Model of High Risk Myelodysplasia (HR-MDS) By Targeting Pathways Identified By Gene Expression Profiling (2014) (0)
Decreased Expression of Anti-DNMT1 Tumor-Suppressor microRNAs in Azacitidine (AZA)-Resistant Cells Independently Predicts Survival in Patients Treated with AZA for Higher Risk Myelodysplastic Syndrome (HRMDS) and Oligoblastic Acute Myeloid Leukemia (AML) (2015) (0)
30 Which myelodysplastic syndromes patients are candidates for treatment with hematopoietic growth factors (2007) (0)
Hyperlymphocytose à cellules T suppressives avec anémie et neutropénie d'évolution favorable sous cyclophosphamide (1988) (0)
P-19 French registry of GFM group (2005) (0)
Efficacité des biothérapies dans les manifestations auto-immunes et systémiques des syndromes myélodysplasiques : étude multicentrique rétrospective de 29 patients (2016) (0)
Une association exceptionnelle maladie de Still de l'adulte et myélodysplasie (2001) (0)
PS1329 IN VIVO 18F-FLUORO-THYMIDINE POSITRON EMISSION TOMOGRAPHY IMAGING FOR DISEASE MONITORING IN A MOUSE MODEL OF HIGH-RISK MYELODYSPLASTIC SYNDROME (2019) (0)
Quoi de neuf dans la leucémie lymphoïde chronique (1991) (0)
Human Mutation (2019) (0)
P108 Long-term outcome of low-risk MDS patients treated with ESAs: an update of the GFM cohort (2009) (0)
Mutations of the P53 Gene in Acute Leukemias: A Report on 207 Cases (1994) (0)
Prévalence et pronostic des manifestations thrombotiques dans les maladies inflammatoires et auto-immunes associées aux syndromes myélodysplasiques : étude cas-témoins rétrospective multicentrique française (2020) (0)
Observatoire français de 116 patients avec un syndrome VEXAS : corrélation phénotype–génotype et prise en charge (2021) (0)
Expression and Function of the P-Glycoprotein (P-gp) In Myelodysplastic Syndromes (MDS) Treated with Azacytidine (AZA) (2011) (0)
219 Long-term outcome of anemic non del 5q lower-risk MDS refractory to or relapsing after erythropoiesis stimulating agents (ESAs) (2011) (0)
Le lymphome à cellules à noyau multilobé: une entité bien individualisée? A propos de quatre observations (1987) (0)
Very low dose GM-CSF in MDS A report on 35 cases (1994) (0)
Abnormal Numbers Of Regulatory T Cell (Tregs) Subsets Are Sigificantly Associated With Adverse Disease Outcome In Lower Risk Myelodysplastic Syndromes (MDS) and Chronic Myelomonocytic Leukemia (CMML) (2013) (0)
123 AZACITIDINE (AZA) COMBINED WITH IDARUBICIN (IDA) IN HIGHER RISK MDS (HRMDS) – RESULTS OF A PHASE I/II STUDY BY THE GFM (2015) (0)
175 ADJUVANT, PVAX14 DNA, AS AN IMMUNOTHERAPY FOR A MOUSE MODEL OF HIGH RISK MYELODYSPLASTIC SYNDROME (HR-MDS) EXTENDS SURVIVAL AS ADD-ON TREATMENT TO AZACITIDINE (AZA) (2015) (0)
Longitudinal Changes of Impairments in Health-Related Quality of Life in Lower-Risk MDS Patients: A European Leukemianet Study (2018) (0)
Yeast Assay Highlights the Intrinsic Genomic Instability of Human PML Intron 6 over Intron 3 and the Role of Replication Fork Proteins (2015) (0)
165 Synergistic effects on apoptosis in higher risk MDS by combining azacitidine (AZA) and the EGFR-tyrosine kinase inhibitor erlotinib (2011) (0)
87 A PHASE II STUDY OF THE EFFICACY AND SAFETY OF AN INTENSIFIED SCHEDULE OF AZACITIDINE IN HIGHER RISK MDS PATIENTS: A STUDY BY THE GFM (2015) (0)
Les anmies sidroblastiques acquises idiopathiques propos de 39 cas (1989) (0)
Le traitement du purpura thrombopénique auto-immun (1992) (0)
Analysis of BCR-ABL Rearrangement by PCR in Adult Acute Lymphoblastic Leukemia (ALL): A Report on 28 Cases (1994) (0)
Lithium Treatment Potentiates Both in Vitro and in Vivo Retinoic Acid Efficacy in APL. (2012) (0)
Polychondrite chronique atrophiante et syndrome myélodysplasique. À propos de deux observations (1991) (0)
Comparison of the Molecular Spectrum of Lenalidomide-Treated Myelodysplastic Syndrome with and without Del(5q) (2016) (0)
Agents déméthylants dans les syndromes myélodysplasiques (2008) (0)
What role for somatic mutations in systemic inflammatory and autoimmune diseases associated with myelodysplastic neoplasms and chronic myelomonocytic leukemias? (2023) (0)
O-010 Prognostic factors of response to azacitidine (AZA) in low-risk MDS resistant to erythroid stimulating agents (ESA). The GFM Azaepo 08 study (2013) (0)
Allogeneic hematopoietic cell transplantation in patients 60 to 70 years of age with de novo high-risk MDS or secondary AML – a comparison with patients lacking donors who received azacitidine Biol Blood Marrow Transplant (2015) (0)

This paper list is powered by the following services:

What Schools Are Affiliated With Pierre Fenaux?

Pierre Fenaux is affiliated with the following schools: